CN101080404B - 嘧啶基异噁唑衍生物 - Google Patents
嘧啶基异噁唑衍生物 Download PDFInfo
- Publication number
- CN101080404B CN101080404B CN2005800435089A CN200580043508A CN101080404B CN 101080404 B CN101080404 B CN 101080404B CN 2005800435089 A CN2005800435089 A CN 2005800435089A CN 200580043508 A CN200580043508 A CN 200580043508A CN 101080404 B CN101080404 B CN 101080404B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- pyrimidyl
- isoxazole
- kharophen
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NGJCUJZBSJGQPY-UHFFFAOYSA-N 3-pyrimidin-2-yl-1,2-oxazole Chemical class O1C=CC(C=2N=CC=CN=2)=N1 NGJCUJZBSJGQPY-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 28
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 20
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 claims description 305
- -1 4-chloro-phenyl- Chemical group 0.000 claims description 206
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 20
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 9
- 108010002352 Interleukin-1 Proteins 0.000 claims description 9
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims description 9
- 102000004890 Interleukin-8 Human genes 0.000 claims description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims description 9
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 208000030507 AIDS Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000005024 Castleman disease Diseases 0.000 claims description 4
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 4
- 229940096397 interleukin-8 Drugs 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 201000000023 Osteosclerosis Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 3
- 206010036600 Premature labour Diseases 0.000 claims description 3
- 206010036631 Presenile dementia Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 208000038016 acute inflammation Diseases 0.000 claims description 3
- 230000006022 acute inflammation Effects 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000026500 emaciation Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 210000000629 knee joint Anatomy 0.000 claims description 3
- 210000003584 mesangial cell Anatomy 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 208000014081 polyp of colon Diseases 0.000 claims description 3
- 208000026440 premature labor Diseases 0.000 claims description 3
- 230000001185 psoriatic effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 150000003851 azoles Chemical class 0.000 claims 13
- 150000007978 oxazole derivatives Chemical class 0.000 claims 9
- 239000000470 constituent Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 31
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 10
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 150000002545 isoxazoles Chemical class 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000002585 base Substances 0.000 description 501
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 501
- 238000005160 1H NMR spectroscopy Methods 0.000 description 421
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 92
- 150000001875 compounds Chemical class 0.000 description 78
- 239000000243 solution Substances 0.000 description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 230000006837 decompression Effects 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 45
- 239000002904 solvent Substances 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 37
- 125000000714 pyrimidinyl group Chemical group 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- 238000001035 drying Methods 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
- 230000002194 synthesizing effect Effects 0.000 description 25
- 238000000605 extraction Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000010898 silica gel chromatography Methods 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 238000003810 ethyl acetate extraction Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 14
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 13
- 239000002024 ethyl acetate extract Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002386 leaching Methods 0.000 description 10
- 241000790917 Dioxys <bee> Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 6
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 150000002460 imidazoles Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- FMCLLAVOTPKADJ-UHFFFAOYSA-N 3-(4-fluorophenyl)-4-pyrimidin-2-yl-1,2-oxazol-5-amine Chemical compound NC=1ON=C(C=2C=CC(F)=CC=2)C=1C1=NC=CC=N1 FMCLLAVOTPKADJ-UHFFFAOYSA-N 0.000 description 3
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000047918 Myelin Basic Human genes 0.000 description 3
- 101710107068 Myelin basic protein Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- DNBIDYXUQOSGDT-UHFFFAOYSA-N 2-(2-chlorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1Cl DNBIDYXUQOSGDT-UHFFFAOYSA-N 0.000 description 2
- GHCFWKFREBNSPC-UHFFFAOYSA-N 2-Amino-4-methylpyrimidine Chemical compound CC1=CC=NC(N)=N1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UCERVHYBSTYCQS-UHFFFAOYSA-N 4-methyl-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC(C)=N1 UCERVHYBSTYCQS-UHFFFAOYSA-N 0.000 description 2
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 2
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- VFSFCYAQBIPUSL-UHFFFAOYSA-N cyclopropylbenzene Chemical compound C1CC1C1=CC=CC=C1 VFSFCYAQBIPUSL-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- PZEHLGURHZERFE-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;heptane Chemical compound [Li+].CCCCCCC.CC(C)[N-]C(C)C PZEHLGURHZERFE-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IUJAAIZKRJJZGQ-UHFFFAOYSA-N 2-(2-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Cl IUJAAIZKRJJZGQ-UHFFFAOYSA-N 0.000 description 1
- SKILLEHGFMDIJB-UHFFFAOYSA-N 2-(4-aminophenyl)ethyl acetate Chemical compound CC(=O)OCCC1=CC=C(N)C=C1 SKILLEHGFMDIJB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 description 1
- SHHGMESNVFQZIV-UHFFFAOYSA-N 2-pyrimidin-4-ylacetonitrile Chemical compound N#CCC1=CC=NC=N1 SHHGMESNVFQZIV-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 0 CCC(CC=N)C(C)(*)C(C)N(C)C Chemical compound CCC(CC=N)C(C)(*)C(C)N(C)C 0.000 description 1
- DZAHXNNEQCZPGJ-UHFFFAOYSA-N CCCCOC(OC)=O.COC(O)=O Chemical class CCCCOC(OC)=O.COC(O)=O DZAHXNNEQCZPGJ-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-IMJSIDKUSA-N L-1,4-dithiothreitol Chemical compound SC[C@H](O)[C@@H](O)CS VHJLVAABSRFDPM-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- HVPWKVXLGDNZBV-UHFFFAOYSA-N [2-(methoxymethoxy)phenyl] acetate Chemical compound C(C)(=O)OC1=C(C=CC=C1)OCOC HVPWKVXLGDNZBV-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- XPDSSIYNQBGBRZ-UHFFFAOYSA-N n-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-methyl-2-phenylpropanamide Chemical compound C=1C=CC=CC=1C(C)(C)C(=O)NC=1ON=C(C=2C=CC(F)=CC=2)C=1C1=CC=NC=N1 XPDSSIYNQBGBRZ-UHFFFAOYSA-N 0.000 description 1
- YHPAQNDMQXEWAS-UHFFFAOYSA-N n-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-phenylpropanamide Chemical compound C=1C=CC=CC=1C(C)C(=O)NC=1ON=C(C=2C=CC(F)=CC=2)C=1C1=CC=NC=N1 YHPAQNDMQXEWAS-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003921 pyrrolotriazines Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- JXAZAUKOWVKTLO-UHFFFAOYSA-L sodium pyrosulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OS([O-])(=O)=O JXAZAUKOWVKTLO-UHFFFAOYSA-L 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Abstract
本发明公开了式(I)所示的具有优异的P38MAP激酶抑制作用的异噁唑衍生物或其制药学上可接受的盐。式中,R1表示氢原子、低级烷基、氨基、卤素原子、低级烷氧基等;R2表示取代或未取代的芳基等;R3表示氢原子或低级烷基;R4表示取代或未取代的苯基等;Y表示-CH2-、-CO-、-CH(CH3)-、-O-、-NH-等。
Description
技术领域
本发明涉及新型的嘧啶基异噁唑衍生物或其盐、其制备方法以及用途。本发明的化合物具有P38MAP激酶抑制作用和基于该作用的肿瘤坏死因子-α(以下称为“TNF-α”)、白细胞介素-1(以下称为“IL-1”)、白细胞介素-6(以下称为“IL-6”)、白细胞介素-8(以下称为“IL-8”)、环加氧酶-II(以下称为“COX-II”)等的生成抑制作用,作为TNF-α关连疾病、IL-1关连疾病、IL-6关连疾病、IL-8关连疾病、COX-II关连疾病等的处置剂有效。
背景技术
已知TNF-α、IL-1、IL-6、IL-8和COX-II为主要由巨噬细胞、中性粒细胞等免疫系统的细胞产生的蛋白质(细胞因子),除了具有免疫调节功能或炎症症状等之外,还是参与造血系统、内分泌系统、神经系统等的重要因子之一。
另一方面,P38MAP激酶具有激活NF-кB、AP-1、CREB等转录因子的作用,这些转录因子与TNF-α、IL-1、IL-6、IL-8、COX-II等上共通的序列的DNA结合,促进合成各自的细胞因子的mRNA的转录,因此P38MAP激酶具有促进TNF-α等细胞因子生成的作用。另外,转录的mRNA与特定的蛋白质结合而失活,然后迅速分解,而P38MAP激酶具有使mRNA与特定的蛋白质的结合解离的作用,单从这一点也可以说P38MAP激酶有助于TNF-α等细胞因子的产生。
因此,P38MAP激酶的抑制与抑制TNF-α等细胞因子的生成相关,结果,期待对下述的与TNF-α等细胞因子相关的疾病的处置或预防有效,所述疾病例如有:急性炎症、慢性炎症、类风湿性关节炎、变形性膝关节症、痛风、炎症性肠疾病、节段性肠炎、溃疡性大肠炎、胃炎、结肠息肉、大肠癌、结肠癌、哮喘、支气管炎、支气管哮喘、过敏性鼻炎、急性呼吸窘迫综合征(ARDS)、慢性阻塞性肺疾病、肺纤维变性、充血性心脏病、局部缺血性心脏病、心肌梗死、动脉硬化、高血压、心绞痛、早老性痴呆、再灌流损伤、血管炎、脑血管障碍、脑膜炎、多发性大脑硬化、骨质疏松症、骨硬化、贝切特氏病、骨转移、多发性骨髓瘤、急性感染、内毒素休克、败血病、毒素性休克综合征、结核、弥散性血管内凝血病(DIC)、银屑病、特应性皮炎、肝硬化、肾纤维变性、恶病质、艾滋病(AIDS)、恶性肿瘤、自体免疫疾病、糖尿病、巨大淋巴结增生症(Castleman病)、肾小球膜细胞增殖性肾炎、子宫内膜异位、早产等。
到目前为止,作为具有P38MAP激酶抑制作用的化合物,已提案的有:咪唑衍生物(参照Bioorganic & Medicinal Chemistry,Vol.5,No.1,49-64(1997)和日本特表平7-503017号公报)、吡唑衍生物(参照PCT国际公开WO98/52940小册子和PCT国际公开WO00/39116小册子)、异噁唑衍生物(参照日本特表平11-503722号公报、日本特开2002-179656号公报、PCT国际公开WO2004/17968小册子、日本特开2000-86657号公报和PCT国际公开WO2004/22555小册子)等。但是,这些化合物有许多副作用,还不能作为药品在市。
最近,Katerina Leftheris等人发表:某种三嗪衍生物既具有强力的P38MAP激酶抑制作用又能够迅速代谢,因此有望减轻副作用,可作为抗风湿病药(参照J.Med.Chem.,Vol.47,6283-6291(2004))。
发明内容
本发明的目的在于提供既具有优异的P38MAP激酶抑制作用叉可以减轻副作用的嘧啶基异噁唑衍生物。
本发明人这次发现:某种新型的4-(4-嘧啶基)异噁唑衍生物既具有优异的P38MAP激酶抑制作用且在血液中的代谢消失速度迅速,因此P38MAP激酶抑制剂可以减轻目前成为问题的副作用,从而完成了本发明。
因此,本发明提供式(I)所示的嘧啶基异噁唑衍生物或其制药学上可接受的盐:
式中,
R1表示氢原子、低级烷基、氨基、低级烷基氨基、二低级烷基氨基、苯基低级烷基氨基、酰基氨基、卤素原子、低级烷氧基、低级烷基硫基或低级烷基亚硫酰基;
R2表示未取代的芳基或杂芳基,或者被选自卤素原子、低级烷基、低级烷氧基、低级卤代烷基、低级亚烷基二氧基或苄氧基的1~3个取代基取代的芳基或杂芳基;
R3表示氢原子或低级烷基;
R4表示取代或未取代的苯基或者取代或未取代的杂环基;
Y表示-(CH2)n-、-CO-、-CH(CH3)-、-O-、-NH-、
,其中n表示0~3的整数。
本发明还提供P38MAP激酶抑制剂,其特征在于:该抑制剂含有式(I)的嘧啶基异噁唑衍生物或其制药学上可接受的盐。
本说明书中,所说的“低”是指带有该词语下的基团的碳原子数为6个以下、优选为4个以下。
“低级烷基”可以是直链或支链,例如有:甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、正己基等,其中,优选甲基、乙基、正丙基、异丙基和正丁基,“低级烷氧基”是被该低级烷基取代的氧(O)基,例如有:甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基、正戊氧基、正己氧基等,其中,优选甲氧基、乙氧基、正丙氧基、异丙氧基和正丁氧基。
“卤素原子”包含氟、氯、溴和碘原子,特别优选氟、氯和溴原子。
R1定义中的“低级烷基氨基”是指被1个上述的低级烷基取代的氨基,“二低级烷基氨基”是指被2个上述的低级烷基取代的氨基。其中,二低级烷基氨基中的2个低级烷基可以相同、也可以相互不同。另外,“苯基低级烷基氨基”是指上述低级烷基氨基中的低级烷基部分进一步被1个苯基取代的基团。
R1定义中的“低级烷基硫基”和“低级烷基亚硫酰基”分别是指被上述的低级烷基取代的硫(S)基和亚硫酰(SO)基。
R1定义中的“酰基氨基”是指酰基化的氨基,作为酰基,例如有:甲酰基、乙酰基、丙酰基、丁酰基等低级烷酰基或苯甲酰基等芳酰基等,其中,优选乙酰基和苯甲酰基。
R2定义中的“芳基”例如有苯基、萘基等,其中,优选苯基。R2 定义中的“杂芳基”包含具有选自N、O和S的1~2个杂原子的5~6元杂芳基,根据情况可与苯环稠合,例如有:吡啶基、喹啉基、吡咯基、呋喃基、噻吩基、咪唑基、吡唑基、噁唑基、异噁唑基、噻唑基等,其中,特别优选吡啶基。
R2定义中的“低级卤代烷基”是指被1个或1个以上相同或不同的卤素原子取代的上述低级烷基,例如有:氟甲基、三氟甲基、1,2-二氯乙基、1-氯-2-溴乙基、五氟乙基、1-氯-正丙基、2-溴-2-甲基乙基、3-氯-正戊基、2-溴-3-氯-正己基等,其中,特别优选被1~5个相同或不同的卤素原子取代的碳数为1或2个的低级烷基。
R2定义中的“低级亚烷基二氧基”例如有:亚甲基二氧基、亚乙基二氧基、三亚甲基二氧基等,特别优选亚甲基二氧基。
R4定义中的“杂环基”包含具有选自N、O和S的1~3个杂原子的饱和或不饱和的5~7元杂环基,可根据情况形成稠合环,例如有:吡啶基、嘧啶基、氮杂基(アゼピニル)、喹啉基、吲哚基、喹唑啉基、吡咯基、呋喃基、噻吩基、咪唑基、吡唑基、异噁唑基、噻唑基、吡咯烷基、异苯并二氢吡喃基等,其中,优选噻吩基和异噁唑基。
作为R4定义中的“取代或未取代的苯基”的苯基上的取代基例如有:卤素原子、低级烷基、低级烷氧基、硝基、低级卤代烷基、低级卤代烷基硫基、羟基、氨基等,其中,优选卤素原子、低级烷基、低级烷氧基、硝基、低级卤代烷基和低级卤代烷基硫基,特别优选卤素原子和低级烷基。作为R4定义中的“取代或未取代的杂环基”的杂环基上的取代基,例如有:卤素原子、低级烷基、低级烷氧基、硝基、低级卤代烷基、氨基等,特别优选卤素原子和低级烷基。
本发明中优选的一组化合物为R1表示氢原子、氨基、低级烷基氨基或二低级烷基氨基时的式(I)化合物,其中,更优选的是R1表示氢原子时的式(I)化合物。R1的优选取代位置为嘧啶环的2位。
本发明中优选的另一组化合物为R2表示被选自卤素原子、低级烷基、低级烷氧基和低级亚烷基二氧基的1~3个取代基取代的苯基时的式(I)化合物,其中,更优选R2表示被选自卤素原子、低级烷基和低级亚烷基二氧基的1或2个取代基取代的苯基时的式(I)化合物,特别优选R2为4-氟苯基、2,4-二氟苯基、4-氯苯基、3-甲基苯基、2-氟-5-甲基苯基、4-氟-3-甲基苯基、2-氟-4-甲氧基苯基或2,3-亚甲基二氧基苯基时的式(I)化合物。
本发明中优选的又一组化合物为R3表示氢原子时的式(I)化合物。
本发明中优选的又一组化合物为R4表示取代或未取代的苯基时的式(I)化合物,其中,更优选R4表示未取代的苯基或被选自卤素原 子、低级烷基和低级烷氧基的1或2个取代基取代的苯基时的式(I)化合物,特别优选R4为未取代的苯基、2-卤代苯基、2,6-二卤代苯基、2-低级烷基苯基、3-低级烷基苯基、3-低级烷氧基苯基或2,5-二低级烷基苯基时的式(I)化合物。
本发明中优选的又一组化合物为Y表示-CH2-时的式(I)化合物。
本发明提供的上述式(I)化合物的代表例除了后述实施例中揭示的例子之外,还例举如下。
3-(4-氟苯基)-4-[4-(2-甲基氨基嘧啶基)]-5-(苯基乙酰氨基)异噁唑、
5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)-4-[4-(2-甲基氨基嘧啶基)]异噁唑、
4-[4-(2-二甲基氨基嘧啶基)]-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑、
5-[(2-氯苯基)乙酰氨基]-4-[4-(2-二甲基氨基嘧啶基)]-3-(4-氟苯基)异噁唑、
4-[4-(2-苄基氨基嘧啶基)]-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑、
4-[4-(2-苄基氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑、
4-[4-(2-乙酰氨基嘧啶基)]-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑、
4-[4-(2-乙酰氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑、
4-[4-(2-苯甲酰氨基嘧啶基)]-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑、
4-[4-(2-苯甲酰氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑、
3-(4-氟苯基)-5-(N-甲基-苯基乙酰氨基)-4-(4-嘧啶基)异噁唑、
3-(4-氟苯基)-5-[(2-氯苯基)乙酰基-N-甲基氨基]-4-(4-嘧啶基)异噁唑、
5-(N-乙基-苯基乙酰氨基)-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑、
5-[(2-氯苯基)乙酰基-N-乙基氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑、
3-[4-(2-甲基吡啶基)]-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑、
5-[(2-氯苯基)乙酰氨基]-3-[4-(2-甲基吡啶基)]-4-(4-嘧啶基)异噁唑、
3-[2-(6-甲基吡啶基)]-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑、
5-[(2-氯苯基)乙酰氨基]-3-[2-(6-甲基吡啶基)]-4-(4-嘧啶基)异噁唑、
3-[2-(4-甲基吡啶基)]-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑、
5-[(2-氯苯基)乙酰氨基]-3-[2-(4-甲基吡啶基)]-4-(4-嘧啶基)异噁唑等。
本发明的式(I)化合物根据情况可以以盐的形态存在,其盐例如有:与盐酸、氢溴酸、硫酸、硝酸、磷酸等无机酸的盐;与乙酸、草酸、柠檬酸、乳酸、酒石酸、对甲苯磺酸等有机酸的盐等,其中,优选制药学上可接受的盐。
本发明的式(I)化合物例如可以通过下述方法(a)或(b)来制备。
方法(a):上述式(I)中R3表示氢原子时的化合物,即,下述式的化合物:
式中,R1、R2、R4和Y具有上述的定义,
可以通过使下述式的化合物:
式中,R1和R2具有上述的定义,
与下述式的羧酸化合物或其反应性衍生物(例如酰卤、酸酐、混合酸酐、活性酰胺、活性酯等)反应制备。
式中,R4和Y具有上述的定义。
方法(b):上述式(I)中R3表示低级烷基时的式(I)化合物,即,下述式的化合物:
式中,R1、R2、R4和Y具有上述的定义,R表示低级烷基,
可以通过将上述式(I-1)的化合物进行N-低级烷基化来制备。
方法(a)中,式(III)的羧酸化合物优选事先利用例如1,1-羰基二咪唑(CDI)、1,1-亚硫酰二咪唑等进行处理,然后再变换为活性酰胺等反应性衍生物。使用酰基卤、例如酰基氯作为上述式(III)的羧酸化合物的反应性衍生物时,该酰基卤可以事先利用例如咪唑和DBU等进行处理,然后再变换为咪唑烷酮(イミダゾリド)等其它反应性衍生物。
应说明的是,上述式(II)的化合物中R1表示氨基或低级烷基氨基时,根据需要,该氨基或该低级烷基氨基可以是事先利用适当的保护基进行保护的状态,例如制成使用二碳酸二叔丁基酯(BOC)、丙酮 基丙酮、苄氧基羰基氯(Z-氯)等进行保护的状态,反应结束后将该保护基脱离。
上述式(II)的化合物与上述式(III)的羧酸化合物或其反应性衍生物的反应通常在惰性有机溶剂,例如二噁烷、四氢呋喃、二甲氧基乙烷等醚类;苯、甲苯、二甲苯等芳族烃类;二氯甲烷、氯仿等卤代烃类;二甲基甲酰胺、二甲基乙酰胺等酰胺类;二甲基亚砜等中,根据需要在碱例如1,8-二氮杂双环[5.4.0]十一碳-7-烯(DBU)、三乙胺、二异丙基乙胺、吡啶等存在下进行。反应温度通常适合在0℃至反应混合物的回流温度,优选冰冷却下至50℃范围内的温度。
通常每1摩尔式(II)的化合物中,式(III)的羧酸化合物或其反应性衍生物可以在至少1摩尔、优选1.5~10摩尔、进一步优选2~5摩尔的范围内使用。另外,通常每1摩尔式(III)的羧酸化合物或其反应性衍生物中,碱的使用比例可以为至少1摩尔、优选1~2摩尔的范围。
应说明的是,作为起始物质使用的上述式(II)的化合物可以按照其本身已知的合成方法,例如下述反应式1中所示的途径容易地合成。关于反应式1中的反应条件等细节请参照后述实施例1的a)~c)。
反应式1:
式中,R1和R2具有上述的定义、X表示卤素原子。
方法(b)中,上述式(I-1)的化合物的N-低级烷基化反应通常在惰性有机溶剂,例如甲醇、乙醇、异丙醇等醇类;二噁烷、四氢呋喃、二甲氧基乙烷等醚类;苯、甲苯、二甲苯等芳族烃类;二甲基甲酰胺、二甲基乙酰胺等酰胺类;二甲基亚砜等中,在适当的碱例如氢氧化钠、碳酸钾、吡啶等存在下,使低级烷基卤,例如碘甲烷、溴乙烷、溴丙烷等反应。反应温度,通常在0℃至反应混合物的回流温度,优选室温至50℃范围内的温度。
通常每1摩尔式(I-1)的化合物中,低级烷基卤可以在至少1摩尔、优选1.1~5摩尔、进一步优选1.2~4摩尔的范围内使用。另外,通常每1摩尔式(I-1)的化合物中,碱的使用比例可以为至少1摩尔、优选1~5摩尔的范围。
按照上述方法制备的本发明的式(I)化合物可以通过其本身已知的手段,例如重结晶、柱层析、薄层色谱等方法,从反应混合物中分离、纯化。
本发明的由式(D所示的嘧啶基异噁唑衍生物或其制药学上可接受的盐既具有优异的P38MAP激酶抑制作用又可以减轻副作用,对处置或预防人、其他哺乳动物的下述的与TNF-α、IL-1、IL-6、IL-8、COX-II等相关的疾病有效,所述疾病例如:急性炎症、慢性炎症、类风湿性关节炎、变形性膝关节症、痛风、炎症性肠疾病、节段性肠炎、溃疡性大肠炎、胃炎、结肠息肉、大肠癌、结肠癌、哮喘、支气管炎、支气管哮喘、过敏性鼻炎、急性呼吸窘迫综合征、慢性阻塞性肺疾病、肺纤维变性、充血性心脏病、局部缺血性心脏病、心肌梗死、动脉硬化、高血压、心绞痛、早老性痴呆、再灌流损伤、血管炎、脑血管障碍、脑膜炎、多发性大脑硬化、骨质疏松症、骨硬化、贝切特氏病、骨转移、多发性骨髓瘤、急性感染、内毒素休克、败血病、毒素性休克综合征、结核、弥散性血管内凝血病、银屑病、特应性皮炎、肝硬化、肾纤维变性、恶病质、艾滋病、恶性肿瘤、自体免疫疾病、糖尿病、巨大淋巴结增生症、肾小球膜细胞增殖性肾炎、子宫内膜异位、早产等。
本发明的式(I)化合物所具有的TNF-α生成抑制作用、本发明的式(I)化合物在血液中的代谢消失速度和本发明的式(I)化合物所具有的P38MAP激酶抑制作用可以通过下述实验显示。
(1)TNF-α生成抑制作用的测定:
将来自人的培养细胞THP-1(购自大日本制药)悬浮在RPMI 1640培养基(含有10%胎牛血清、100单位/mL青霉素)(1×105细胞/mL)中。在培养用24孔板上接种1.6mL THP-1细胞悬浮液,再加入溶解于RPMI 1640培养基的0.2mL受试物质和0.2mL 10μg/mL浓度的LPS(E.coli 055:来自B5、溶解于RPMI 1640培养基、Difco),然后在37℃、5%CO2条件下培养2小时。离心(500×g、5分钟),利用ELISA(酶联免疫吸附测定,Amersham Biosciences,TNF-αHuman,ELISABiotrak System)法测定得到的上清液,进行TNF-α的定量。各受试物质的50%抑制浓度(IC50)如下求出。首先,通过下式求出各种浓度下的TNF-α的生成抑制率(%)。
由该式得到的TNF-α的生成抑制率(%)和此时的受试物质浓度通过Prism 4 for WIndows Ver 4.02(Graph Pad Software,Inc)计算,算出IC50值。其结果与下述(2)化合物代谢速度的测定结果一起如后述表A所示。
(2)化合物的代谢速度的测定:
向含有NADPH生成物(含有3.3mmol/L MgCL2、3.3mmol/L葡糖-6-磷酸酯、1.3mmol/L β-NADP+和0.4单位/mL葡糖-6-磷酸脱氢酶)的磷酸钾缓冲液(50mmol/L,pH7.4)中添加化合物(此时,使终浓度为1μmol/L),在37℃下温育2分钟。温育后,添加人肝脏S9(人 肝脏细胞破碎液在9000×g下离心而得到的上清液组分)的磷酸钾缓冲液悬浮液,使终浓度为0.5mg蛋白/mL。将该反应混合液在37℃下温育5分钟,然后添加反应混合液的4倍容积的乙腈,混合、冰冷却。冰冷却后离心(2000×g、10分钟),采集上清液的一部分,利用LC/MS/MS进行分析,算出反应溶液中的未变化体的残留率。其结果与上述(1)的TNF-α生成抑制作用的测定结果一起如下述表A所示。
表A
(3)P38MAP激酶抑制活性的测定:
使用人P38MAP激酶在大杆菌中表达的重组蛋白作为酶源,使用10μg/mL髓鞘碱性蛋白(MBP)作为底物。温育缓冲液使用50mmol/L HEPES、20mmol/L MgCl2、0.2mmol/L Na3VO4、1mmol/L二硫苏糖醇(DTT)、pH7.4。利用ELISA法测定P38MAP激酶引起的MBP的磷酸化。温育温度和时间为:25℃下预温育15分钟、25℃下温育60分钟。各化合物的浓度为1nmol/L~10μmol/L,使用1%DMSO作为载体。测定结果如下述表B所示。
表B
化合物 | 对P38MAP激酶α的IC50值(nM) |
实施例13 | 19.0 |
实施例201 | 9.32 |
因此,本发明的式(I)表示的嘧啶基异噁唑衍生物或其制药学上可接受的盐作为既具有优异的作用代谢速度又快的P38MAP激酶抑制剂,作为用于人或人以外的哺乳物的疾病的治疗、处置、疾病预防等药品,可以对患者口服或肠道外给药(例如肌肉注射、静脉注射、直肠给药、经皮给药等)。
本发明的化合物作为药品使用时,根据其用途,可以与无毒性的添加剂一起制成下述任一种制剂形态:固体形态(例如片剂、硬胶囊剂、软胶囊剂、颗粒剂、散剂、细粒剂、丸剂、糖锭等)、半固体形态(例如栓剂、软膏等)或液体形态(例如注射剂、乳剂、悬浮液、洗液、喷雾剂等)。上述制剂中可使用的无毒性添加物例如有:淀粉、明胶、葡萄糖、乳糖、果糖、麦芽糖、碳酸镁、滑石粉、硬脂酸镁、甲基纤维素、羧甲基纤维素或其盐、阿拉伯树胶、聚乙二醇、对羟基苯甲酸烷基酯、糖浆、乙醇、丙二醇、凡士林、聚乙二醇、甘油、氯化钠、亚硫酸钠、磷酸钠、柠檬酸等。该制剂还可以含有治疗学上有效的其它药物。
该制剂中本发明的化合物的含量根据其剂型而不同,通常,固体和半固体形态时优选为0.1~50%重量的范围内,液体形态时优选为0.05~10%重量的范围内。
本发明的化合物的给药量可以根据对象为以人为代表的恒温动物的种类、年龄、体重、给药途径、症状的轻重、医师的诊断等可广范围地改变,一般来说,每日给药量可以在0.02~20mg/kg、优选0.2~8mg/kg的范围内。但是,根据患者症状的轻重、医师的诊断等,当然可以给予低于上述范围下限的量或高于上限的量。上述给药量可以每日给药1次或分数次给药。
实施例
以下,通过实施例和制剂例更具体地说明本发明。
实施例1
3-(4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:二甲基-[(E)-2-(4-嘧啶基)乙烯基]胺的合成
将10g 4-甲基嘧啶与38g N,N-二甲基甲酰胺二甲基缩醛(DMFDMA)和46.6g DMF的混合物在140℃密封管中搅拌24小时。将反应溶液冷却,然后减压下馏去溶剂,得到15.08g(收率:95%)茶色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.73(bs,1H),8.22(d,J=5.5Hz,1H),7.77(d,J=12.9Hz,1H),6.72(dd,J=5.5Hz,12.9Hz,1H),5.00(d,J=12.9Hz,1H),2.96(s,6H)。
b:4-嘧啶基乙腈的合成
向5g二甲基-[(E)-2-(4-嘧啶基)乙烯基]胺的70mL水溶液中加入9.48g羟胺-O-磺酸,50℃下搅拌30分钟。冰冷却下向反应溶液中加入饱和碳酸氢钠水溶液,使溶液呈碱性,然后用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用30g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=30∶1)纯化,得到1.56g(收率:39%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:9.21(d,J=1.2Hz,1H),8.80(d,J=5.2Hz,1H),7.51(dd,J=1.2Hz,5.2Hz,1H),3.93(s,2H)。
c:5-氨基-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑的合成
将2.50g甲醇钠溶解于50mL甲醇中,滴入5g 4-嘧啶基乙腈的50mL THF溶液,然后室温下搅拌30分钟。接着,滴入7.29g 4-氟苯甲酰氯(4-フルオロベンズヒドロキシモイルクロリド)的50mL甲醇溶液,然后室温下搅拌7小时。减压下馏去反应溶液中的溶剂,然后加水、滤取析出的残余物,水洗后减压下干燥。将所得残余物用80g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=50∶1~30∶1)纯化,用乙醚洗涤,得到7.86g(收率:73%)淡灰色结晶的标题化合物。
1H-NMR(CDCl3)δ:9.03(d,J=1.4Hz,1H),8.32(d,J=5.6Hz,1H),7.54~7.49(m,2H),7.24~7.18(m,2H),6.88(bs,2H),6.70(dd,J=1.4Hz,5.6Hz,1H)。
Mass,m/e:256(M+),111(base)。
d:3-(4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑的合成
将0.43g咪唑和1.9g DBU溶解于40mL THF中,冰冷却搅拌下,滴入0.97g苯乙酰氯,然后室温下搅拌20分钟。随后,滴入0.8g 5-氨基-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑的40mL THF溶液,然后室温下搅拌6小时。减压下馏去反应溶液中的溶剂,加水,用乙酸乙酯萃取。用无水硫酸镁干燥有机层,然后减压下馏去溶剂。将所得残余物用40g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=100∶1)纯化,然后用乙醚洗涤,得到0.77g(收率:66%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.39(s,1H),8.49(s,1H),8.36(d,J=5.6Hz,1H),7.50~7.38(m,7H),7.20(t,J=8.5Hz,2H),6.73(dd,J=1.3Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:374(M+),240(base)。
实施例2
3-(4-氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
向0.12g 2’-氟苯基乙酸的5mL THF溶液中加入0.126g CDI,室温下搅拌1小时。接着,加入0.237g DBU与0.1g 5-氨基-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑的5mL THF溶液,室温下搅拌11小时。减压下馏去反应溶液中的溶剂,加水用乙酸乙酯萃取。用无水硫酸镁干燥有机层,然后减压下馏去溶剂。将所得残余物用15g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=100∶1)纯化,然后用乙醚·己烷洗涤,得到0.090g(收率:59%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.57(s,1H),8.62(s,1H),8.39(d,J=5.7Hz,1H),7.50~7.40(m,4H),7.30~7.17(m,4H),6.76(dd,J=1.6Hz,5.7Hz,1H),3.97(s,2H)。
Mass,m/e:392(M+),109(base)。
以下,与实施例2进行同样地操作,合成实施例3~43的化合物。
实施例3
3-(4-氟苯基)-5-[(3-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.66(s,1H),8.39(d,J=5.4Hz,1H),7.48~7.43(m,3H),7.22~7.18(m,3H),7.15~7.12(m,2H),6.76(dd,J=1.2Hz,5.4Hz,1H),3.94(s,2H)。
Mass,m/e:392(M+),109(base。)
实施例4
3-(4-氟苯基)-5-[(4-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(bs,1H),8.65(s,1H),8.40(d,J=5.8Hz,1H),7.48~7.44(m,2H),7.39~7.36(m,2H),7.22~7.13(m,4H),6.76(dd,J=1.5Hz,5.8Hz,1H),3.91(s,2H)。
Mass,m/e:392(M+),109(base)。
实施例5
5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(bs,1H),8.54(s,1H),8.38(d,J=5.7Hz,1H),7.55~7.38(m,6H),7.20(t,J=8.7Hz,2H),6.75(dd,J=1.3Hz,5.7Hz,1H),4.06(s,2H)。
Mass,m/e:408(M+),240(base)。
实施例6
5-[(3-氯苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.69(s,1H),8.40(d,J=5.4Hz,1H),7.50~7.38(m,5H),7.29(dt,J=1.9Hz,6.6Hz,1H),7.21(t,J=8.7Hz,2H),6.77(dd,J=1.3Hz,5.4Hz,1H),3.92(s,2H)。
Mass,m/e:408(M+),240(base)。
实施例7
5-[(4-氯苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.65(s,1H),8.42(d,J=5.5Hz,1H),7.50~7.42(m,4H),7.35(d,J=8.6Hz,2H),7.21(t,J=8.6Hz,2H),6.77(dd,J=1.4Hz,5.5Hz,1H),3.92(s,2H)。
Mass,m/e:408(M+),240(base)。
实施例8
5-[(2-溴苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.53(s,1H),8.38(d,J=5.5Hz,1H),7.72(dd,J=1.2Hz,7.7Hz,1H),7.50~7.43(m,4H),7.37~7.31(m,1H),7.20(t,J=8.7Hz,2H),6.75(dd,J=1.3Hz,5.5Hz,1H),4.09(s,2H)。
Mass,m/e:454(M+),240(base)。
实施例9
5-[(2-碘苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.51(s,1H),8.38(d,J=5.5Hz,1H),8.00(d,J=7.7Hz,1H),7.52~7.43(m,4H),7.24~7.13(m,3H),6.75(dd,J=1.3Hz,5.5Hz,1H),4.10(s,2H)。
Mass,m/e:500(M+),240(base)。
实施例10
3-(4-氟苯基)-5-[(2,5-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.62(bs,1H),8.80(s,1H),8.43(d,J=5.6Hz,1H),7.50~7.46(m,2H),7.23~7.06(m,5H),6.79(dd,J=1.5Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:410(M+),240(base)。
实施例11
5-[(2,6-二氟苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.65(s,1H),8.70(s,1H),8.41(d,J=5.4Hz,1H),7.48(dd,J=5.2Hz,8.6Hz,2H),7.45~7.36(m,1H),7.21(t,J=8.6Hz,2H),7.04(t,J=7.7Hz,2H),6.79(dd,J=1.3Hz,5.4Hz,1H),4.02(s,2H)。
Mass,m/e:410(M+),240(base)。
实施例12
5-[(2-氯-4-氟苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.72(s,1H),8.42(d,J=5.4Hz,1H),7.51~7.43(m,4H),7.30~7.18(m,2H),7.12(dt,J=2.7Hz,8,1Hz,1H),6.79(dd,J=1.5Hz,5.4Hz,1H),4.04(s,2H)。
Mass,m/e:426(M+),240(base)。
实施例13
5-[(2-氯-6-氟苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(s,1H),8.64(s,1H),8.40(d,J=5.7Hz,1H),7.51~7.45(m,2H),7.43~7.34(m,2H),7.26~7.13(m,3H),6.78(dd,J=1.3Hz,5.7Hz,1H),4.14(s,2H)。
Mass,m/e:426(M+),240(base)。
实施例14
5-[(2,4-二氯苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(s,1H),8.71(s,1H),8.42(d,J=5.6Hz,1H),7.54(d,J=1.9Hz,1H),7.48(dd,J=5.4Hz,8.9Hz,2H),7.43~7.35(m,2H),7.21(t,J=8.9Hz,2H),6.79(dd,J=5.6Hz,1H),4.04(s,2H)。
Mass,m/e:442(M+),240(base)。
实施例15
5-[(3,4-二氯苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(s,1H),8.78(s,1H),8.43(d,J=5.7Hz,1H),7.54~7.51(m,2H),7.48(dd,J=5.2Hz,8.7Hz,2H),7.27~7.19(m,3H),6.79(dd,J=1.4Hz,5.7Hz,1H),3.91(s,2H)。
Mass,m/e:442(M+),240(base)。
实施例16
5-[(2,6-二氯苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.62(s,1H),8.41(d,J=5.6Hz,1H),7.49(t,J=7.5Hz,4H),7.37(dd,J=7.3Hz,8.5Hz,1H),7.2 3(t,J=8.5Hz,2H),6.79(dd,J=1.5Hz,5.6Hz,1H),4.33(s,2H)。
Mass,m/e:442(M+),240(base)。
实施例17
3-(4-氟苯基)-5-[(2-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.34(s,1H),8.46(s,1H),8.35(d,J=5.5Hz,1H),7.49~7.42(m,3H),7.34(dd,J=1.7Hz,7.5Hz,1H),7.19(t,J=8.6Hz,2H),7.09(dt,J=1.0Hz,7.5Hz,1H),6.99(d,J=8.6Hz,1H),6.72(dd,J=1.3Hz,5.5Hz,1H),3.88(s,2H),3.81(s,3H)。
Mass,m/e:404(M+),148(base)。
实施例18
5-[(3-甲氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(s,1H),8.60(d,J=1.3Hz,1H),8.37(d,J=5.5Hz,1H),7.49~7.43(m,2H),7.40(t,J=7.9Hz,1H),7.20(t,J=8.7Hz,2H),7.00~6.93(m,3H),6.73(dd,J=1.3Hz,5.5Hz,1H),3.90(s,2H),3.84(s,3H)。
Mass,m/e:404(M+),240(base)。
实施例19
5-[(4-甲氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.57(d,J=1.3Hz,1H),8.37(d,J=5.5Hz,1H),7.49~7.43(m,2H),7.31(d,J=8.8Hz,2H),7.20(t,J=8.8Hz,2H),7.00(d,J=8.8Hz,2H),6.74(dd,J=1.3Hz,5.5Hz,1H),3.87(s,2H),3.86(s,3H)。
Mass,m/:404(M+),148(base)。
实施例20
5-[(2-乙氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.33(bs,1H),8.43(d,J=1.5Hz,1H),8.34(d,J=5.8Hz,1H),7.48~7.40(m,3H),7.34(dd,J=1.5Hz,7.3Hz,1H),7.22~7.16(m,2H),7.07(dt,J=1.2Hz,7.7Hz,1H),6.97(d,J=7.7Hz,1H),6.71(dd,J=1.5Hz,5.8Hz,1H),4.03(q,J=6.9H,2H),3.88(s,2H),1.32(t,J=6.9Hz,3H)。
Mass,m/e:418(M+),240(base)。
实施例21
5-[(3-乙氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(bs,1H),8.61(d,J=1.3Hz,1H),8.37(d,J=5.6Hz,1H),7.48~7.43(m,2H),7.27(t,J=8.1Hz,1H),7.22~7.16(m,2H),6.97~6.92(m,3H),6.73(dd,J=1.3Hz,5.6Hz,1H),4.05(q,J=7.3Hz,2H),3.88(s,2H),1.41(t,J=7.3Hz,3H)。
Mass,m/e:418(M+),162(base)。
实施例22
3-(4-氟苯基)-5-[(2-丙氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.33(bs,1H),8.42(d,J=1.3Hz,1H),8.34(d,J=5.8Hz,1H),7.47~7.41(m,3H),7.34(dd,J=1.5Hz,7.3Hz,1H),7.21~7.16(m,2H),7.07(dt,J=0.8Hz,7.3Hz,1H),6.97(d,J=8.1Hz,1H),6.71(dd,J=1.3Hz,5.8Hz,1H),3.92~3.88(m,4H),3.88(s,2H),1.72(dt,J=7.3Hz,13.8Hz,2H),0.92(t,J=7.3Hz,3H)。
Mass,m/e:432(M+),107(base)。
实施例23
3-(4-氟苯基)-5-[(3-丙氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.61(d,J=1.2Hz,1H),8.37(d,J=5.6Hz,1H),7.47~7.44(m,2H),7.37(t,J=8.1Hz,1H),7.21~7.17(m,2H),6.98~6.94(m,3H),6.73(dd,J=1.2Hz,5.6Hz,1H),3.94(t,J=6.6Hz,2H),3.88(s,2H),1.85~1.76(m,2H),1.02(t,J=7.3Hz,3H)。
Mass,m/e:432(M+),240(base)。
实施例24
3-(4-氟苯基)-5-[(2-异丙氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.31(bs,1H),8.39(d,J=1.0Hz,1H),8.34(d,J=5.6Hz,1H),7.48~7.40(m,3H),7.33(dd,J=1.5Hz,7.7Hz,1H),7.20~7.16(m,2H),7.02(t,J=7.3Hz,1H),6.97(d,J=8.5Hz,1H),6.70(dd,J=1.0Hz,5.6Hz,1H),4.55(m,J=6.2Hz,1H),3.85(s,2H),1.24(d,J=6.2Hz,6H)。
Mass,m/e:432(M+),134(base)。
实施例25
3-(4-氟苯基)-5-[(3-异丙氧基苯基)乙酰氨基]-4-(嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(bs,1H),8.63(d,J=1.4Hz,1H),8.37(d,J=5.4Hz,1H),7.48~7.43(m,2H),7.36(t,J=8.1Hz,1H),7.22~7.16(m,2H),6.96~6.92(m,3H),6.72(dd,J=1.4Hz,5.4Hz,1H),4.58(m,J=5.8Hz,1H),3.87(s,2H),1.33(d,J=5.8Hz,6H)。
Mass,m/e:432(M+),240(base)。
实施例26
5-[(2,3-二甲氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(s,1H),8.62(d,J=1.4Hz,1H),8.36(d,J=5.5Hz,1H),7.49~7.43(m,2H),7.23~7.16(m,2H),7.14(d,J=7.7Hz,1H),7.00(dd,J=1.4Hz,8.3Hz,1H),6.95(dd,J=1.4Hz,7.7Hz,1H),6.72(dd,J=1.4Hz,5.5Hz,1H),3.90(s,3H),3.89(s,3H)。
Mass,m/e:434(M+),178(base)。
实施例27
5-[(2,5-二甲氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.35(s,1H),8.58(d,J=1.3Hz,1H),8.36(d,J=5.5Hz,1H),7.46(dd,J=5.2Hz,8.7Hz,2H),7.19(t,J=8.7Hz,2H),6.97~6.89(m,3H),6.73(dd,J=1.3Hz,5.5Hz,1H),3.86(s,2H),3.81(s,3H),3.77(s,3H)。
Mass,m/e:434(M+),178(base)。
实施例28
5-[(3,5-二甲氧基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.70(d,J=1.3Hz,1H),8.38(d,J=5.7Hz,1H),7.49~7.43(m,2H),7.23~7.17(m,2H),6.74(dd,J=1.3Hz,5.7Hz,1H),6.54(d,J=2.2Hz,2H),6.51(t,J=2.2Hz,1H),3.84(s,2H),3.81(s,6H)。
Mass,m/e:434(M+),178(base)。
实施例29
3-(4-氟苯基)-4-(4-嘧啶基)-5-[(3,4,5-三甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.71(s,1H),8.40(d,J=5.5Hz,1H),7.50~7.44(m,2H),7.24~7.17(m,2H),6.75(dd,J=1.0Hz,5.5Hz,1H),6.60(s,2H),3.89(s,2H),3.87(s,6H),3.86(s,3H)。
Mass,m/e:464(M+),208(base)。
实施例30
3-(4-氟苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.35(s,1H),8.42(s,1H),8.35(d,J=5.5Hz,1H),7.48~7.30(m,6H),7.19(t,J=8.7Hz,2H),6.71(dd,J=1.3Hz,5.5Hz,1H),3.92(s,2H),2.36(s,3H)。
Mass,m/e:388(M+),240(base)。
实施例31
3-(4-氟苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(bs,1H),8.48(s,1H),8.36(d,J=5.4Hz,1H),7.45(dd,J=5.4Hz,8.5Hz,2H),7.37(t,J=7.7Hz,1H),7.27(s,1H),7.21~7.17(m,4H),6.73(dd,J=1.2Hz,5.4Hz,1H),3.88(s,2H),2.39(s,3H)。
Mass,m/e:388(M+),240(base)。
实施例32
5-[(2,5-二甲基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.32(s,1H),8.39(d,J=1.4Hz,1H),8.35(d,J=5.4Hz,1H),7.49~7.43(m,2H),7.23~7.14(m,5H),6.72(dd,J=1.4Hz,5.4Hz,1H),3.88(s,2H),2.39(s,3H),2.31(s,3H)。
Mass,m/e:402(M+),240(base)。
实施例33
5-[(3,5-二甲基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.36(s,1H),8.46(s,1H),8.36(d,J=5.7Hz,1H),7.49~7.43(m,2H),7.20(t,J=8.7Hz,2H),7.08(s,1H),7.00(s,2H),6.73(dd,J=1.3Hz,5.7Hz,1H),3.84(s,2H),2.35(s,6H)。
Mass,m/e:402(M+),283(base)。
实施例34
3-(4-氟苯基)-5-[(2-硝基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.67(s,1H),8.89(bs,1H),8.89(s,1H),8.44(d,J=5.4Hz,1H),8.20(d,J=8.5Hz,1H),7.72(dt,J=1.5Hz,7.7Hz,1H),7.59(t,J=7.7Hz,2H),7.53~7.47(m,2H),7.22(t,J=8.7Hz,1H),6.80(dd,J=1.5Hz,5.4Hz,1H),4.31(s,2H)。
Mass m/e:419(M+),240(base)。
实施例35
3-(4-氟苯基)-5-[(4-硝基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.88(s,1H),8.45(d,J=5.5Hz,1H),8.29(d,J=8.9Hz,2H),7.59(d,J=8.9Hz,2H),7.52~7.46(m,2H),7.25~7.20(m,2H),6.82(dd,J=1.3Hz,5.5Hz,1H),4.10(s,2H)。
Mass,m/e:419(M+),240(base)。
实施例36
3-(4-氟苯基)-4-(4-嘧啶基)-5-[(2-三氟甲基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.58(s,1H),8.39(d,J=5.7Hz,1H),7.82(d,J=8.1Hz,1H),7.67(t,J=7.3Hz,1H),7.61~7.53(m,2H),7.50~7.44(m,2H),7.20(t,J=8.7Hz,2H),6.76(dd,J=1.4Hz,5.7Hz,1H),4.12(s,2H)。
Mass,m/e:442(M+),240(base)。
实施例37
3-(4-氟苯基)-4-(4-嘧啶基)-5-[(3-三氟甲基苯硫基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.47(s,1H),8.64(s,1H),8.41(d,J=5.5Hz,1H),7.74~7.68(m,2H),7.57~7.45(m,4H),7.25~7.18(m,2H),6.78(dd,J=1.3Hz,5.5Hz,1H),3.99(s,2H)。
Mass,m/e:474(M+),240(base)。
实施例38
3-(4-氟苯基)-5-(2-苯基丙酰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(bs,1H),8.57(d,J=1.4Hz,1H),8.35(d,J=5.6Hz,1H),7.50~7.38(m,7H),7.19(t,J=8.7Hz,2H),6.72(dd,J=1.4Hz,5.6Hz,1H),3.93(q,J=7.3Hz,1H),1.68(d,J=7.3Hz,3H)。
Mass,m/e:388(M+),240(base)。
实施例39
3-(4-氟苯基)-5-(2-甲基-2-苯基丙酰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.32(s,1H),8.43(d,J=1.4Hz,1H),8.33(d,J=5.4Hz,1H),7.52~7.42(m,6H),7.41~7.36(m,1H),7.19(t,J=8.7Hz,2H),6.70(dd,J=1.4Hz,5.4Hz,1H),1.74(s,6H)。
Mass,m/e:402(M+),240(base)。
实施例40
3-(4-氟苯基)-5-[2-(4-异丁基苯基)丙酰基氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.62(d,J=1.4Hz,1H),8.36(d,J=5.4Hz,1H),7.46(dd,J=5.4Hz,8.9Hz,2H),7.31(d,J=8.3Hz,2H),7.22(d,J=8.3Hz,2H),7.18(d,J=8.9Hz,2H),6.72(dd,J=1.4Hz,5.4Hz,1H),3.89(q,J=7.1Hz,1H),2.51(d,J=7.3Hz,2H),1.94~1.82(m,1H),1.66(d,J=7.1Hz,3H),0.89(dd,J=3.9Hz,6.6Hz,6H)。
Mass,m/e:444(M+),240(base)。
实施例41
3-(4-氟苯基)-4-(4-嘧啶基)-5-[(2-噻吩基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.62(bs,1H),8.68(s,1H),8.39(d,J=5.6Hz,1H),7.47(dd,J=5.4Hz,8.9Hz,2H),7.42(dd,J=1.5Hz,5.0Hz,1H),7.22~7.14(m,4H),6.76(dd,J=1.5Hz,5.6Hz,1H),4.13(s,2H)。
Mass,m/e:380(M+),240(base)。
实施例42
3-(4-氟苯基)-5-{[5-(3-甲基异噁唑基)]乙酰氨基}-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.96(bs,1H),9.13(d,J=1.4Hz,1H),8.46(d,J=5.6Hz,1H),7.49(dd,J=5.4Hz,8.9Hz,2H),7.22(t,J=8.9Hz,2H),6.81(dd,J=1.4Hz,5.6Hz,1H),6.21(s,1H),4.09(s,2H),2.35(s,3H)。
Mass,m/e:379(M+),240(base)。
实施例43
3-(4-氟苯基)-4-(4-嘧啶基)-5-[(3-噻吩基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.44(s,1H),8.75(s,1H),8.40(d,J=5.4Hz,1H),7.50~7.44(m,3H),7.37~7.35(m,1H),7.20(t,J=8.5Hz,2H),7.13(d,J=5.0Hz,1H),6.76(dd,J=1.2Hz,5.4Hz,1H),3.97(s,2H)。
Mass,m/e:380(M+),240(base)。
以下,与实施例1和实施例2进行同样地操作,合成实施例44~299的化合物。
实施例44
3-苯基-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-苯基-4-(4-嘧啶基)异噁唑
1H-NMR(DMSO-d6)δ:8.99(d,J=1.4Hz,1H),8.35(d,J=5.4Hz,1H),8.29(bs,2H),7.59~7.50(m,5H),6.56(dd,J=1.4Hz,5.4Hz,1H)。
Mass,m/e:238(M+),77(base)。
b:3-苯基-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.48(s,1H),8.32(d,J=5.6Hz,1H),7.53~7.39(m,10H),6.73(dd,J=1.5Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:356(M+),222(base)。
实施例45
5-[(2-氯苯基)乙酰氨基]-3-苯基-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.52(s,1H),8.34(d,J=5.4Hz,1H),7.54~7.39(m,9H),6.75(dd,J=0.8Hz,5.4Hz,1H),4.06(s,2H)。
Mass,m/e:390(M+),222(base)。
实施例46
5-[(2,6-二氯苯基)乙酰氨基]-3-苯基-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(bs,1H),8.59(s,1H),8.36(d,J=5.4Hz,1H),7.55~7.46(m,7H),7.35(dd,J=7.3Hz,8.5Hz,1H),6.79(dd,J=1.6Hz,5.4Hz,1H),4.32(s,2H)。
Mass,m/e:424(M+),222(base)。
实施例47
5-[(3-甲基苯基)乙酰氨基]-3-苯基-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(s,1H),8.47(s,1H),8.33(d,J=5.4Hz,1H),7.56~7.44(m,5H),7.40~7.36(m,1H),7.28~7.18(m,3H),6.74(dd,J=1.5Hz,5.4Hz,1H),3.90(s,2H),2.40(s,3H)。
Mass,m/e:370(M+),77(base)。
实施例48
5-[(2,5-二甲基苯基)乙酰氨基]-3-苯基-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.35(s,1H),8.37(d,J=1.4Hz,1H),8.33(d,J=5.4Hz,1H),7.56~7.44(m,5H),7.40~7.36(m,1H),7.21~7.16(m,2H),6.74(dd,J=1.4Hz,5.4Hz,1H),3.88(s,2H),2.39(s,3H),2.31(s,3H)。
Mass,m/e:384(M+),222(base)。
实施例49
3-(3-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.5Hz,1H),8.33(d,J=5.7Hz,1H),7.53~7.46(m,1H),7.31(dt,J=1.3Hz,8.1Hz,1H),7.28~7.21(m,3H),6.92~6.82(bs,2H),6.71(dd,J=1.5Hz,5.7Hz,1H)。
Mass,m/e:256(M+),111(base)。
b:3-(3-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.52~8.47(bs,1H),8.37(d,J=5.4Hz,1H),7.52~7.39(m,6H),7.28~7.17(m,3H),6.74(dd,J=1.5Hz,5.4Hz,1H),3.94(s,2H)。
Mass,m/e:374(M+),91(base)。
实施例50
3-(3-氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.62(s,1H),8.40(d,J=5.5Hz,1H),7.52~7.39(m,3H),7.29~7.17(m,5H),6.77(dd,J=1.3Hz,5.5Hz,1H),3.97(s,2H)。
Mass,m/e:392(M+),109(base)。
实施例51
5-[(2-氯苯基)乙酰氨基]-3-(3-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.57~8.52(bs,1H),8.39(d,J=5.5Hz,1H),7.55~7.38(m,5H),7.28~7.18(m,3H),6.76(dd,J=1.3Hz,5.5Hz,1H),4.07(s,2H)。
Mass,m/e:408(M+),240(base)。
实施例52
3-(2-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(d,J=1.3Hz,1H),8.29(d,J=5.6Hz,1H),7.58~7.40(m,4H),6.92(bs,2H),6.41(dd,J=1.3Hz,5.6Hz,1H)。
Mass,m/e:272(M+),237(base)。
b:3-(2-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.47(bs,1H),8.33(d,J=5.7Hz,1H),7.55~7.40(m,9H),6.46(dd,J=1.3Hz,5.7Hz,1H),3.95(s,2H)。
Mass,m/e:390(M+),91(base)。
实施例53
3-(2-氯苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.67(s,1H),8.59(s,1H),8.36(d,J=5.7Hz,1H),7.56~7.40(m,5H),7.29~7.18(m,3H),6.49(dd,J=1.3Hz,5.7Hz,1H),3.98(s,2H)。
Mass,m/e:408(M+),109(base)。
实施例54
3-(2-氯苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(s,1H),8.52(s,1H),8.35(d,J=5.5Hz,1H),7.56~7.38(m,8H),6.49(dd,J=1.3Hz,5.5Hz,1H),4.08(s,2H)。
Mass,m/e:424(M+),256(base)。
实施例55
3-(3-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.3Hz,1H),8.34(d,J=5.5Hz,1H),7.56~7.50(m,2H),7.45(t,J=7.5Hz,1H),7.41(dt,J=1.5Hz,7.5Hz,1H),6.88(bs,2H),6.69(dd,J=1.3Hz,5.5Hz,1H)。
Mass,m/e:272(M+),127(base)。
b:3-(3-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.50(bs,1H),8.38(d,J=5.7Hz,1H),7.55~7.32(m,9H),6.73(dd,J=1.5Hz,5.7Hz,1H),3.94(s,2H)。
Mass,m/e:390(M+),91(base)。
实施例56
3-(3-氯苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.59(s,1H),8.62(bs,1H),8.41(d,J=5.5Hz,1H),7.55~7.34(m,6H),7.29~7.17(m,2H),6.76(dd,J=1.3Hz,5.5Hz,1H),3.97(s,2H)。
Mass,m/e:408(M+),256(base)。
实施例57
3-(3-氯苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.55(bs,1H),8.40(d,J=5.5Hz,1H),7.56~7.33(m,8H),6.75(dd,J=1.3Hz,5.5Hz,1H),4.07(s,2H)。
Mass,m/e:424(M+),256(base)。
实施例58
3-(4-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.2Hz,1H),8.32(d,J=5.4Hz,1H),7.51~7.45(m,4H),6.88(s,2H),6.70(dd,J=1.2Hz,5.4Hz,1H)。
Mass,m/e:272(M+),127(base)。
b:3-(4-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(bs,1H),8.49(s,1H),8.37(d,J=5.6Hz,1H),7.51~7.39(m,9H),6.73(dd,J=1.5Hz,5.6Hz,1H),3.93(s,2H)。
Mass,m/e:390(M+),91(base)。
实施例59
3-(4-氯苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(bs,1H),8.61(s,1H),8.40(d,J=5.6Hz,1H),7.50~7.40(m,6H),7.27~7.17(m,2H),6.77(dd,J=1.5Hz,5.6Hz,1H),3.96(s,2H)。
Mass,m/e:408(M+),109(base)。
实施例60
3-(4-氯苯基)-5-[(3-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.66(s,1H),8.40(d,J=5.4Hz,1H),7.49(d,J=8.7Hz,2H),7.46~7.40(m,1H),7.42(d,J=8.7Hz,2H),7.20~7.12(m,3H),6.77(dd,J=1.5Hz,5.4Hz,1H),3.94(s,2H)。
Mass,m/e:408(M+),109(base)。
实施例61
3-(4-氯苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.53(s,1H),8.39(d,J=5.6Hz,1H),7.54~7.39(m,8H),6.76(dd,J=1.5Hz,5.6Hz,1H),4.06(s,2H)。
Mass,m/e:424(M+),256(base)。
实施例62
5-[(2-溴苯基)乙酰氨基]-3-(4-氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.52(s,1H),8.39(d,J=5.4Hz,1H),7.72(d,J=8.1Hz,1H),7.50~7.40(m,6H),7.36~7.31(m,1H),6.76(dd,J=1.2Hz,5.4Hz,1H),4.08(s,2H)。
Mass,m/e:468(M+),256(base)。
实施例63
3-(4-氯苯基)-5-[(2-碘苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(bs,1H),8.50(s,1H),8.38(d,J=5.6Hz,1H),8.00(d,J=7.7Hz,1H),7.50~7.46(m,4H),7.42(d,J=8.5Hz,2H),7.18~7.14(m,1H),6.76(dd,J=1.5Hz,5.6Hz,1H),4.09(s,2H)。
Mass,m/e:516(M+),256(base)。
实施例64
3-(4-氯苯基)-5-[(2,5-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.61(bs,1H),8.80(s,1H),8.44(d,J=5.8Hz,1H),7.50(d,J=8.5Hz,2H),7.43(d,J=8.5Hz,2H),7.17~7.06(m,3H),6.80(dd,J=1.6Hz,5.8Hz,1H),3.94(s,2H)。
Mass,m/e:426(M+),127(base)。
实施例65
3-(4-氯苯基)-5-[(3,5-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(bs,1H),8.82(s,1H),8.44(d,J=5.4Hz,1H),7.50(d,J=8.9Hz,2H),7.43(d,J=8.9Hz,2H),6.98~6.93(m,2H),6.90~6.84(m,1H),6.80(dd,J=1.2Hz,5.4Hz,1H),3.93(s,2H)。
Mass,m/e:426(M+),256(base)。
实施例66
3-(4-氯苯基)-5-[(2,6-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.64(bs,1H),8.70(s,1H),8.42(d,J=5.4Hz,1H),7.50(d,J=8.5Hz,2H),7.43(d,J=8.5Hz,2H),7.40~7.37(m,1H),7.07~7.01(m,2H),6.80(dd,J=1.5Hz,5.4Hz,1H),4.01(s,2H)。
Mass,m/e:426(M+),127(base)。
实施例67
5-[(2-氯-4-氟苯基)乙酰氨基]-3-(4-氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.72(s,1H),8.43(d,J=5.6Hz,1H),7.51~7.41(m,5H),7.27(dd,J=2.7Hz,8.5Hz,1H),7.11(dt,J=2.7Hz,8.1Hz,1H),6.73(dd,J=1.5Hz,5.6Hz,1H),4.03(s,2H)。
Mass,m/e:442(M+),256(base)。
实施例68
5-[(2-氯-6-氟苯基)乙酰氨基]-3-(4-氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.54(bs,1H),8.64(s,1H),8.41(d,J=5.4Hz,1H),7.49(d,J=8.5Hz,2H),7.43(d,J=8.5Hz,2H),7.40~7.34(m,2H),7.17(dt,J=1.2Hz,8.9Hz,1H),6.79(dd,J=1.2Hz,5.4Hz,1H),4.13(s,2H)。
Mass,m/e:442(M+),256(base)。
实施例69
3-(4-氯苯基)-5-[(2,4-二氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.70(s,1H),8.43(d,J=5.6Hz,1H),7.54~7.48(m,3H),7.44~7.36(m,4H),6.79(dd,J=1.5Hz,5.6Hz,1H),4.04(s,2H)。
Mass,m/e:458(M+),256(base)。
实施例70
3-(4-氯苯基)-5-[(2,6-二氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.60(s,1H),8.40(d,J=5.4Hz,1H),7.51~7.47(m,4H),7.42(d,J=8.5Hz,2H),7.35(dd,J=7.3Hz,8.4Hz,1H),6.78(dd,J=1.5Hz,5.4Hz,1H),4.31(s,2H)。
Mass,m/e:458(M+),256(base)。
实施例71
3-(4-氯苯基)-5-[(2-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.33(bs,1H),8.46(d,J=1.4Hz,1H),8.37(d,J=5.6Hz,1H),7.49~7.40(m,5H),7.34(dd,J=1.4Hz,7.5Hz,1H),7.08(dt,J=1.4Hz,7.5Hz,1H),6.99(d,J=8.1Hz,1H),6.73(dd,J=1.4Hz,5.6Hz,1H),3.88(s,2H),3.80(s,3H)。
Mass,m/e:420(M+),91(base)。
实施例72
3-(4-氯苯基)-5-[(3-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(bs,1H),8.60(d,J=1.4Hz,1H),8.38(d,J=5.4Hz,1H),7.48(d,J=8.9Hz,2H),7.42~7.37(m,3H),6.99~6.94(m,3H),6.74(dd,J=1.4Hz,5.4Hz,1H),3.89(s,2H),3.83(s,3H)。
Mass,m/e:420(M+),148(base)。
实施例73
3-(4-氯苯基)-5-[(2,3-二甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(bs,1H),8.61(d,J=1.5Hz,1H),8.36(d,J=5.4Hz,1H),7.47(d,J=8.5Hz,2H),7.27(d,J=8.5Hz,2H),7.14(t,J=8.1Hz,1H),7.00(dd,J=1.5Hz,8.1Hz,1H),6.95(dd,J=1.5Hz,7.7Hz,1H),6.72(dd,J=1.5Hz,5.4Hz,1H),3.89(s,2H),3.89(s,3H),3.88(s,3H)。
Mass,m/e:450(M+),178(base)。
实施例74
3-(4-氯苯基)-5-[(2,5-二甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.34(bs,1H),8.58(d,J=1.3Hz,1H),8.37(d,J=5.4Hz,1H),7.48(d,J=8.5Hz,2H),7.41(d,J=8.5Hz,2H),6.96~6.89(m,3H),6.74(dd,J=1.3Hz,5.4Hz,1H),3.85(s,2H),3.81(s,3H),3.76(s,3H)。
Mass,m/e:450(M+),178(base)。
实施例75
3-(4-氯苯基)-5-[(3,5-二甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.70(d,J=1.3Hz,1H),8.39(d,J=5.4Hz,1H),7.48(d,J=8.5Hz,2H),7.41(d,J=8.5Hz,2H),6.74(dd,J=1.3Hz,5.4Hz,1H),6.54~6.50(m,3H),3.84(s,2H),3.81(s,6H)。
Mass,m/e:450(M+),178(base)。
实施例76
3-(4-氯苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.35(bs,1H),8.41(d,J=1.4Hz,1H),8.36(d,J=5.6Hz,1H),7.48(d,J=8.5Hz,2H),7.40(d,J=8.5Hz,2H),7.37~7.31(m,4H),6.74(dd,J=1.4Hz,5.6Hz,1H),3.92(s,2H),2.35(s,3H)。
Mass,m/e:404(M+),256(base)。
实施例77
3-(4-氯苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.48(d,J=1.2Hz,1H),8.38(d,J=5.8Hz,1H),7.50~7.47(m,2H),7.43~7.36(m,3H),7.27~7.19(m,3H),6.74(dd,J=1.5Hz,5.8Hz,1H),3.89(s,2H),2.39(s,3H)。
Mass,m/e:404(M+),105(base)。
实施例78
3-(4-氯苯基)-5-[(2,5-二甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.31(bs,1H),8.38(d,J=1.4Hz,1H),8.36(d,J=5.4Hz,1H),7.48(d,J=8.5Hz,2H),7.40(d,J=8.5Hz,2H),7.20(s,2H),7.15(s,1H),6.73(dd,J=1.4Hz,5.4Hz,1H),3.87(s,2H),2.38(s,3H),2.30(s,3H)。
Mass,m/e:418(M+),146(base)。
实施例79
3-(4-氯苯基)-4-(4-嘧啶基)-5-[(2-三氟苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.37(bs,1H),8.57(s,1H),8.40(d,J=5.6Hz,1H),7.81(d,J=8.1Hz,1H),7.68~7.54(m,3H),7.49(d,J=8.5Hz,2H),7.42(d,J=8.5Hz,2H),6.77(dd,J=1.5Hz,5.6Hz,1H),4.12(s,2H)。
Mass,m/e:458(M+),256(base)。
实施例80
3-(4-氯苯基)-5-(2-苯基丙酰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(bs,1H),8.56(d,1.3Hz,1H),8.36(d,J=5.4Hz,1H),7.49~7.38(m,9H),6.72(dd,J=1.3Hz,5.4Hz,1H),3.92(q,J=7.1Hz,1H),1.68(d,J=7.1Hz,3H)。
Mass,m/e:404(M+),91(base)。
实施例81
3-(4-氯苯基)-5-(3-苯基丙酰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),9.07(d,J=1.3Hz,1H),8.46(d,J=5.4Hz,1H),7.51(d,J=8.5Hz,2H),7.45(d,J=8.5Hz,2H),7.31~7.27(m,4H),7.20~7.16(m,1H),6.77(dd,J=1.3Hz,5.4Hz,1H),3.12(t,J=7.5Hz,2H),2.97(t,J=7.5Hz,2H)。
Mass,m/e:404(M+),105(base)。
实施例82
3-(4-氯苯基)-5-[(1-苯基-环丙烷)羰基氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(bs,1H),8.21(d,J=1.4Hz,1H),8.32(d,J=5.4Hz,1H),7.56~7.45(m,7H),7.40~7.37(m,2H),6.69(dd,J=1.4Hz,5.4Hz,1H),1.81(q,J=3.5Hz,2H),1.31(q,J=3.5Hz,2H)。
Mass,m/e:416(M+),117(base)。
实施例83
3-(3-溴苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-溴苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.4Hz,1H),8.34(d,J=5.7Hz,1H),7.71~7.66(m,2H),7.46(dt,J=1.3Hz,7.7Hz,1H),7.39(t,J=7.7Hz,1H),6.90(bs,2H),6.71(dd,J=1.4Hz,5.7Hz,1H)。
Mass,m/e:316(M+),76(base)。
b:3-(3-溴苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.50(bs,1H),8.39(d,J=5.7Hz,1H),7.68(dt,J=1.9Hz,6.9Hz,1H),7.65~7.63(m,1H),7.52~7.35(m,7H),6.73(dd,J=1.3Hz,5.7Hz,1H),3.94(s,2H)。
Mass,m/e:434(M+),91(base)。
实施例84
3-(3-溴苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.62(s,1H),8.41(d,J=5.7Hz,1H),7.69(dt,J=1.9Hz,7.3Hz,1H),7.66~7.64(m,1H),7.47~7.36(m,4H),7.29~7.17(m,2H),6.77(dd,J=1.3Hz,5.7Hz,1H),3.97(s,2H)。
Mass,m/e:452(M+),109(base)。
实施例85
3-(3-溴苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.55(dd,J=1.3Hz,1H),8.40(d,J=5.5Hz,1H),7.68(dt,J=1.9Hz,7.3Hz,1H),7.67~7.64(m,1H),7.56~7.45(m,2H),7.45~7.35(m,4H),6.76(dd,J=1.3Hz,5.5Hz,1H),4.07(s,2H)。
Mass,m/e:468(M+),125(base)。
实施例86
3-(3-溴苯基)-5-[(2-溴苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(s,1H),8.53(s,1H),8.40(d,J=5.5Hz,1H),7.72(dd,J=0.8Hz,8.8Hz,1H),7.68(dt,J=1.9Hz,6.9Hz,1H),7.67~7.64(m,1H),7.51~7.31(m,5H),6.76(dd,J=1.5Hz,5.5Hz,1H),4.09(s,2H)。
Mass,m/e:512(M+),300(base)。
实施例87
3-(3-溴苯基)-5-[(2-氯-4-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.73(s,1H),8.44(d,J=5.4Hz,1H),7.69(dt,J=1.9Hz,7.3Hz,1H),7.67~7.65(m,1H),7.48~7.36(m,3H),7.28(dd,J=2.7Hz,8.1Hz,1H),7.12(td,J=2.7Hz,8.1Hz,1H),6.79(dd,J=1.5Hz,5.4Hz,1H),4.04(s,2H)。
Mass,m/e:486(M+),143(base)。
实施例88
3-(3-溴苯基)-5-[(2-氯-6-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.56(s,1H),8.65(s,1H),8.43(d,J=5.7Hz,1H),7.69(dt,J=1.8Hz,7.1Hz,1H),7.67~7.64(m,1H),7.44~7.34(m,4H),7.17(td,J=1.7Hz,8.1Hz,1H),6.79(dd,J=1.3Hz,5.7Hz,1H),4.15(d,J=1.5Hz,2H)。
Mass,m/e:486(M+),143(base)。
实施例89
3-(3-溴苯基)-5-[(2,6-二氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.61(s,1H),8.42(d,J=5.4Hz,1H),7.69(dt,J=1.9Hz,7.3Hz,1H),7.67~7.64(m,1H),7.49(d,J=8.1Hz,2H),7.44~7.33(m,3H),6.78(dd,J=1.3Hz,5.5Hz,1H),4.32(s,2H)。
Mass,m/e:502(M+),300(base)。
实施例90
3-(3-溴苯基)-5-[(3-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.61(d,J=1.3Hz,1H),8.39(d,J=5.5Hz,1H),7.68(dt,J=2.1Hz,6.9Hz,1H),7.66~7.62(m,1H),7.43~7.36(m,3H),7.00~6.93(m,3H),6.74(dd,J=1.3Hz,5.5Hz,1H),3.90(s,2H),3.84(s,3H)。
Mass,m/e:464(M+),148(base)。
实施例91
3-(3-溴苯基)-5-[(2,5-二甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.36(s,1H),8.59(d,J=1.4Hz,1H),8.39(d,J=5.7Hz,1H),7.67(dt,J=1.9Hz,7.3Hz,1H),7.66~7.63(m,1H),7.42~7.34(m,2H),6.98~6.89(m,3H),6.74(dd,J=1.4Hz,5.7Hz,1H),3.86(s,2H),3.81(s,3H),3.77(s,3H)。
实施例92
3-(3-溴苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(s,1H),8.42(d,J=1.4Hz,1H),8.37(d,J=5.5Hz,1H),7.68(dt,J=2.1Hz,6.6Hz,1H),7.65~7.62(m,1H),7.43~7.31(m,6H),6.72(dd,J=1.4Hz,5.5Hz,1H),3.93(s,2H),2.36(s,3H)。
Mass,m/e:448(M+),132(base)。
实施例93
3-(3-溴苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.49(s,1H),8.39(d,J=5.7Hz,1H),7.68(dt,J=2.1Hz,6.9Hz,1H),7.66~7.63(m,1H),7.42~7.35(m,3H),7.29~7.18(m,3H),6.74(dd,J=1.3Hz,5.7Hz,1H),3.89(s,2H),2.40(s,3H)。
Mass,m/e:448(M+),132(base)。
实施例94
3-(3-溴苯基)-5-[(2,5-二甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.33(s,1H),8.39(d,J=1.4Hz,1H),8.37(d,J=5.7Hz,1H),7.68(dt,J=1.9Hz,6.9Hz,1H),7.65~7.62(m,1H),7.41~7.34(m,2H),7.21(bs,2H),7.15(bs,1H),6.72(dd,J=1.4Hz,5.7Hz,1H),3.88(s,2H),2.39(s,3H),2.31(s,3H)。
Mass,m/e:462(M+),119(base)。
实施例95
3-(3-溴苯基)-4-(4-嘧啶基)-5-[(2-三氟甲基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.58(s,1H),8.41(d,J=5.4Hz,1H),7.82(d,J=8.1Hz,1H),7.71~7.63(m,3H),7.61~7.54(m,2H),7.43~7.36(m,2H),6.76(dd,J=1.5Hz,5.4Hz,1H),4.13(s,2H)。
Mass,m/e:502(M+),159(base)。
实施例96
3-(4-溴苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-溴苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.5Hz,1H),8.34(d,J=5.8Hz,1H),7.66(dt,J=2.3Hz,8.5Hz,2H),7.41(dt,J=2.3Hz,8.5Hz,2H),6.87(bs,2H),6.80(dd,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:315(M+),173(base)。
b:3-(4-溴苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.50(s,1H),8.38(d,J=5.8Hz,1H),7.66~7.63(m,2H),7.51~7.34(m,7H),6.74(dd,J=1.5Hz,5.8Hz,1H),3.94(s,2H)。
Mass,m/e:434(M+),91(base)。
实施例97
3-(4-溴苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.62(s,1H),8.42(d,J=5.4Hz,1H),7.67~7.63(dt,J=2.1Hz,8.5Hz,2H),7.47~7.40(m,2H),7.38~7.34(m,2H),7.28~7.18(m,2H),6.78(dd,J=1.5Hz,5.4Hz,1H),3.97(s,2H)。
Mass,m/e:452(M+),109(base)。
实施例98
3-(4-溴苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(s,1H),8.54(s,1H),8.40(d,J=5.8Hz,1H),7.67~7.63(m,2H),7.54~7.40(m,4H),7.37~7.34(m,2H),6.77(dd,J=1.5Hz,5.8Hz,1H),4.07(s,2H)。
Mass,m/e:468(M+),125(base)。
实施例99
3-(2,3-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,3-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.5Hz,1H),8.36(d,J=5.4Hz,1H),7.41~7.24(m,3H),6.92(bs,2H),6.60(dt,J=1.5Hz,5.4Hz,1H)。
Mass,m/e:274(M+),52(base)。
b:3-(2,3-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.49(d,J=1.2Hz,1H),8.41(d,J=5.4Hz,1H),7.52~7.35(m,6H),7.30~7.24(m,2H),6.74(dt,J=1.5Hz,5.4Hz,1H),3.95(s,2H)。
Mass,m/e:392(M+),91(base)。
实施例100
3-(2,3-二氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.63(s,1H),8.62(d,J=1.2Hz,1H),8.44(d,J=5.8Hz,1H),7.47~7.36(m,3H),7.31~7.19(m,4H),6.68(dt,J=1.5Hz,5.8Hz,1H),3.98(d,J=1.2Hz,2H)。
Mass,m/e:410(M+),109(base)。
实施例101
5-[(2-氯苯基)乙酰氨基]-3-(2,3-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(s,1H),8.55(d,J=0.8Hz,1H),8.43(d,J=5.4Hz,1H),7.55~7.36(m,5H),7.29~7.24(m,2H),6.67(dt,J=1.5Hz,5.4Hz,1H),4.08(s,2H)。
Mass,m/e:426(M+),125(base)。
实施例102
3-(2,4-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.2Hz,1H),8.35(d,J=5.4Hz,1H),7.51(dt,J=6.6Hz,8.5Hz,1H),7.08~6.97(m,2H),6.92(bs,2H),6.60(td,J=1.2Hz,5.4Hz,1H)。
Mass,m/e:274(M+),129(base)。
b:3-(2,4-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.48(s,1H),8.40(d,J=5.6Hz,1H),7.54~7.39(m,6H),7.06(dt,J=1.9Hz,8.1Hz,1H),6.97(dt,J=2.3Hz,9.3Hz,1H),6.65(td,J=1.5Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:392(M+),91(base)。
实施例103
3-(2,4-二氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.61(bs,1H),8.61(d,J=1.4Hz,1H),8.42(d,J=5.6Hz,1H),7.51(dt,J=6.2Hz,8.1Hz,1H),7.44~7.41(m,2H),7.28~7.24(m,1H),7.20(t,J=9.6Hz,1H),7.09~7.04(m,1H),7.00~6.95(m,1H),6.71(td,J=1.4Hz,5.6Hz,1H),3.96(s,2H)。
Mass,m/e:410(M+),109(base)。
实施例104
3-(2,4-二氟苯基)-5-[(3-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(s,1H),8.65(s,1H),8.43(d,J=5.4Hz,1H),7.52(dt,J=6.2Hz,8.1Hz,1H),7.47~7.43(m,1H),7.19(d,J=7.7Hz,1H),7.16~7.12(m,2H),7.07(dt,J=2.3Hz,7.7Hz,1H),6.98(dt,J=2.3Hz,8.5Hz,1H),6.68(td,J=1.9Hz,5.4Hz,1H),3.94(s,2H)。
Mass,m/e:410(M+),258(base)。
实施例105
5-[(2-氯苯基)乙酰氨基]-3-(2,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(bs,1H),8.53(s,1H),8.41(d,J=5.4Hz,1H),7.54~7.40(m,5H),7.09~7.04(m,1H),6.98(dt,J=2.3Hz,8.5Hz,1H),6.67(td,J=1.5Hz,5.4Hz,1H),4.07(s,2H)。
Mass,m/e:426(M+),258(base)。
实施例106
5-[(2-溴苯基)乙酰氨基]-3-(2,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),9.02(d,J=1.5Hz,1H),8.52(s,1H),8.41(d,J=5.2Hz,1H),7.72(d,J=8.1Hz,1H),7.54~7.45(m,3H),7.36~7.32(m,1H),7.09~6.95(m,1H),6.67(td,J=1.5Hz,5.2Hz,1H),4.09(s,2H)。
Mass,m/e:470(M+),258(base)。
实施例107
3-(2,4-二氟苯基)-5-[(2-碘苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.51(s,1H),8.41(d,J=5.4Hz,1H),8.00(d,J=7.7Hz,1H),7.52(dt,J=6.2Hz,8.5Hz,1H),7.49~7.48(m,2H),7.18~7.14(m,1H),7.06(dt,J=2.7Hz,8.9Hz,1H),6.98(dt,J=2.3Hz,8.9Hz,1H),6.67(td,J=1.5Hz,5.4Hz,1H),4.10(s,2H)。
Mass,m/e:518(M+),258(base)。
实施例108
3-(2,4-二氟苯基)-5-[(2,4-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.64(s,1H),8.79(d,J=1.2Hz,1H),8.46(d,J=5.6Hz,1H),7.53(dt,J=6.2Hz,8.5Hz,1H),7.40(dt,J=6.6Hz,8.5Hz,1H),7.10~7.05(m,1H),7.01~6.92(m,3H),6.72(td,J=1.2Hz,5.6Hz,1H),3.93(s,2H)。
Mass,m/e:428(M+),254(base)。
实施例109
3-(2,4-二氟苯基)-5-[(2,5-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.67(s,1H),8.79(s,1H),8.46(d,J=5.6Hz,1H),7.53(dt,J=6.2Hz,8.5Hz,1H),7.18~7.05(m,4H),6.99(dt,J=2.7Hz,8.9Hz,1H),6.72(td,J=1.9Hz,5.6Hz,1H),3.95(s,2H)。
Mass,m/e:428(M+),258(base)。
实施例110
3-(2,4-二氟苯基)-5-[(2,6-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.69(s,1H),8.69(s,1H),8.46(d,J=5.4Hz,1H),7.53(dt,J=6.2Hz,8.1Hz,1H),7.45~7.37(m,1H),7.10~6.96(m,4H),6.71(td,J=1.5Hz,5.4Hz,1H),4.01(s,2H)。
Mass,m/e:428(M+),258(base)。
实施例111
5-[(2-氯-4-氟苯基)乙酰氨基]-3-(2,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.52(bs,1H),8.71(s,1H),8.45(d,J=5.4Hz,1H),7.53(dt,J=6.2Hz,8.1Hz,1H),7.45(dd,J=5.8Hz,8.5Hz,1H),7.28(dd,J=2.7Hz,8.1Hz,1H),7.14~7.05(m,2H),6.99(dt,J=2.3Hz,9.6Hz,1H),6.71(td,J=1.9Hz,5.4Hz,1H),4.04(s,2H)。
Mass,m/e:444(M+),258(base)。
实施例112
3-(2,4-二氟苯基)-5-[(2-氯-6-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.59(s,1H),8.64(s,1H),8.44(d,J=5.2Hz,1H),7.53(dt,J=6.2Hz,8.1Hz,1H),7.42~7.35(m,2H),7.16(dt,J=1.5Hz,8.9Hz,1H),7.10~7.05(m,1H),6.99(dt,J=2.3Hz,8.5Hz,1H),6.78(td,J=1.9Hz,5.2Hz,1H),4.14(s,2H)。
Mass,m/e:444(M+),258(base)。
实施例113
5-[(2,4-二氯苯基)乙酰氨基]-3-(2,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:10.11(bs,1H),8.70(s,1H),8.46(d,J=5.6Hz,1H),7.55~7.50(m,2H),7.42~7.36(m,2H),7.10~7.05(m,1H),7.01~6.96(m,1H),6.71(td,J=1.6Hz,5.6Hz,1H),4.04(s,2H)。
Mass,m/e:460(M+),258(base)。
实施例114
5-[(2,6-二氯苯基)乙酰氨基]-3-(2,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(bs,1H),8.60(s,1H),8.43(d,J=5.4Hz,1H),7.55~7.48(m,3H),7.35(dd,J=7.7Hz,8.5Hz,1H),7.07(dt,J=1.5Hz,7.7Hz,1H),6.98(dt,J=2.7Hz,9.6Hz,1H),6.70(td,J=1.9Hz,5.4Hz,1H),4.31(s,2H)。
Mass,m/e:460(M+),258(base)。
实施例115
3-(2,4-二氟苯基)-5-[(2-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.46(d,J=1.2Hz,1H),8.38(d,J=5.6Hz,1H),7.51(dt,J=6.6Hz,8.5Hz,1H),7.45(dt,J=1.5Hz,8.1Hz,1H),7.34(dd,J=1.5Hz,7.3Hz,1H),7.11~7.03(m,2H),7.00~6.94(m,2H),6.64(td,J=1.5Hz,5.6Hz,1H),3.88(s,2H),3.81(s,3H)。
Mass,m/e:422(M+),91(base)。
实施例116
3-(2,4-二氟苯基)-5-[(3-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.59(d,J=1.4Hz,1H),8.39(d,J=5.6Hz,1H),7.51(dt,J=6.6Hz,8.5Hz,1H),7.40(t,J=7.7Hz,1H),7.06(dt,J=1.5Hz,7.7Hz,1H),6.99~6.94(m,4H),6.66(td,J=1.4Hz,5.6Hz,1H),3.90(s,2H),3.83(s,3H)。
Mass,m/e:422(M+),148(base)。
实施例117
3-(2,4-二氟苯基)-5-[(2,3-二甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(s,1H),8.62(d,J=1.7Hz,1H),8.39(d,J=5.4Hz,1H),7.50(dt,J=6.2Hz,8.5Hz,1H),7.14(t,J=7.7Hz,1H),7.08~7.03(m,1H),7.01~6.94(m,3H),6.64(td,J=1.7Hz,5.4Hz,1H),3.90(s,2H),3.89(s,3H),3.89(s,3H)。
Mass,m/e:452(M+),178(base)。
实施例118
3-(2,4-二氟苯基)-5-[(2,5-二甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.58(d,J=1.4Hz,1H),8.40(d,J=5.6Hz,1H),7.51(dt,J=6.2Hz,8.5Hz,1H),7.06(dt,J=2.3Hz,8.5Hz,1H),6.99~6.90(m,4H),6.65(td,J=1.4Hz,5.6Hz,1H),3.86(s,2H),3.81(s,3H),3.77(s,3H)。
Mass,m/e:452(M+),178(base)。
实施例119
3-(2,4-二氟苯基)-5-[(3,5-二甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.70(d,J=1.7Hz,1H),8.41(d,J=5.6Hz,1H),7.51(dt,J=6.2Hz,8.5Hz,1H),7.09~7.04(m,1H),7.00~6.95(m,1H),6.66(td,J=1.7Hz,5.6Hz,1H),6.54(d,J=2.3Hz,2H),6.51(t,J=2.3Hz,1H),3.84(s,2H),3.81(s,6H)。
Mass,m/e:452(M+),178(base)。
实施例120
3-(2,4-二氟苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.41(d,J=1.54Hz,1H),8.38(d,J=5.4Hz,1H),7.50(dt,J=6.2Hz,8.5Hz,1H),7.42~7.31(m,4H),7.08~7.03(m,1H),6.97(dt,J=2.3Hz,8.9Hz,1H),6.64(td,J=1.9Hz,5.4Hz,1H),3.92(s,2H),2.36(s,3H)。
Mass,m/e:406(M+),258(base)。
实施例121
3-(2,4-二氟苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.48(s,1H),8.40(d,J=5.4Hz,1H),7.54~7.49(m,1H),7.40~7.36(m,1H),7.28~7.20(m,3H),7.09~7.04(m,1H),7.00~6.95(m,1H),6.76(dt,J=1.5Hz,5.4Hz,1H),3.89(s,2H),2.40(s,3H)。
Mass,m/e:406(M+),258(base)。
实施例122
3-(2,4-二氟苯基)-5-[(2,5-二甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.36(s,1H),8.39(d,J=5.4Hz,1H),8.38(s,1H),7.50(dt,J=6.2Hz,8.1Hz,1H),7.20(bs,2H),7.15(s,1H),7.06(dt,J=2.7Hz,8.9Hz,1H),6.97(dt,J=2.7Hz,8.9Hz,1H),6.64(td,J=1.9Hz,5.4Hz,1H),3.88(s,2H),2.38(s,3H),2.31(s,3H)。
Mass,m/e:420(M+),258(base)。
实施例123
3-(2,4-二氟苯基)-4-(4-嘧啶基)-5-[(2-三氟甲基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.57(s,1H),8.42(d,J=5.4Hz,1H),7.82(d,J=8.1Hz,1H),7.67(t,J=6.9Hz,1H),7.59~7.49(m,3H),7.07(dt,J=2.7Hz,8.9Hz,1H),6.98(dt,J=2.7Hz,8.9Hz,1H),6.68(td,J=1.9Hz,5.4Hz,1H),4.12(s,2H)。
Mass,m/e:460(M+),258(base)。
实施例124
3-(2,4-二氟苯基)-5-(3-苯基丙酰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(bs,1H),9.07(d,J=1.5Hz,1H),8.48(d,J=5.4Hz,1H),7.55(dt,J=6.2Hz,8.5Hz,1H),7.31~7.26(m,5H),7.11~7.06(m,1H),7.03~6.98(m,1H),6.73(td,J=1.5Hz,5.4Hz,1H),3.12(t,J=7.5Hz,2H),2.98(t,J=7.5Hz,2H)。
Mass,m/e:406(M+),91(base)。
实施例125
3-(2,4-二氟苯基)-5-(1-苯基环丙烷羰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.35(d,J=5.8Hz,1H),8.21(d,J=1.3Hz,1H),7.57~7.46(m,6H),7.05(dt,J=2.5Hz,8.5Hz,1H),6.95(dt,J=2.5Hz,9.3Hz,1H),6.61(td,J=1.3Hz,5.8Hz,1H),1.85(q,J=3.9Hz,2H),1.31(q,J=3.9Hz,2H)。
Mass,m/e:418(M+),117(base)。
实施例126
3-(2,6-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,6-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.5Hz,1H),8.34(d,J=5.4Hz,1H),7.58~7.50(m,1H),7.11~7.07(m,2H),6.94(bs,2H),6.57~6.54(m,1H)。
Mass,m/e:274(M+),129(base)。
b:3-(2,6-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.48(d,J=1.2Hz,1H),8.38(d,J=5.4Hz,1H),7.58~7.41(m,6H),7.11~7.06(m,2H),6.60(dd,J=1.2Hz,5.4Hz,1H),3.95(s,2H)。
Mass,m/e:392(M+),91(base)。
实施例127
5-[(2-氯苯基)乙酰氨基]-3-(2,6-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.53(s,1H),8.54(bs,1H),8.40(d,J=5.8Hz,1H),7.59~7.38(m,5H),7.10~7.06(m,2H),6.62(d,J=4.6Hz,1H),4.08(s,2H)。
Mass,m/e:426(M+),258(base)。
实施例128
3-(3,4-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,4-二氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.4Hz,1H),8.37(d,J=5.7Hz,1H),7.55~7.10(m,3H),6.90(bs,2H),6.71(dd,J=1.4Hz,5.7Hz,1H)。
Mass,m/e:274(M+),129(base)。
b:3-(3,4-二氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(s,1H),8.50(d,J=0.8Hz,1H),8.40(d,J=5.5Hz,1H),7.52~7.20(m,8H),6.74(dd,J=1.3Hz,5.5Hz,1H),3.94(s,1H)。
Mass,m/e:392(M+),91(base)。
实施例129
3-(2-氯-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氯-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(d,J=1.6Hz,1H),8.32(d,J=5.6Hz,1H),7.47(dd,J=6.2Hz,8.5Hz,1H),7.31(dd,J=2.7Hz,8.5Hz,1H),7.16(dt,J=2.7Hz,8.5Hz,1H),6.93(bs,2H),6.42(dd,J=1.6Hz,5.6Hz,1H),2.41(s,3H)。
Mass,m/e:290(M+),255(base)。
b:3-(2-氯-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(bs,1H),8.47(d,J=1.3Hz,1H),8.37(d,J=5.6Hz,1H),7.51~7.40(m,6H),7.29(dd,J=2.3Hz,8.1Hz,1H),7.15(dt,J=2.7Hz,8.5Hz,1H),6.47(dd,J=1.3Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:408(M+),91(base)。
实施例130
3-(2-氯-4-氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.65(s,1H),8.60(d,J=1.2Hz,1H),8.40(d,J=5.8Hz,1H),7.46~7.41(m,3H),7.31~7.16(m,4H),6.50(dd,J=1.2Hz,5.8Hz,1H),3.96(s,2H)。
Mass,m/e:426(M+),109(base)。
实施例131
3-(2-氯-4-氟苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.52(s,1H),8.52(d,J=1.2Hz,1H),8.41(d,J=5.6Hz,1H),7.54~7.52(m,1H),7.49~7.40(m,4H),7.29(dd,J=2.7Hz,8.3Hz,1H),7.16(td,J=2.7Hz,8.3Hz,1H),6.49(dd,J=1.2Hz,5.6Hz,1H),4.07(s,2H)。
Mass,m/e:442(M+),274(base)。
实施例132
3-(3-氯-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-氯-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.4Hz,1H),8.37(d,J=5.6Hz,1H),7.75~7.15(m,3H),6.89(bs,2H),6.71(dd,J=1.4Hz,5.6Hz,1H)。
Mass,m/e:290(M+),145(base)。
b:3-(3-氯-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.50(d,J=1.4Hz,1H),8.41(d,J=5.6Hz,1H),7.56(dd,J=2.3Hz,6.9Hz,1H),7.52~7.32(m,6H),7.28(t,J=8.5Hz,1H),6.74(dd,J=1.4Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:408(M+),91(base)。
实施例133
3-(3-氯-4-氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(s,1H),8.63(s,1H),8.44(d,J=5.4Hz,1H),7.55(t,J=7.7Hz,1H),7.47~7.40(m,2H),7.30(dd,J=1.9Hz,8.9Hz,1H),7.27(dd,J=1.2Hz,7.7Hz,1H),7.24~7.17(m,2H),6.78(dd,J=1.2Hz,5.4Hz,1H),3.96(s,2H)。
Mass,m/e:426(M+),109(base)。
实施例134
3-(2-氟-4-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-氯-2-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.3Hz,1H),8.36(d,J=5.6Hz,1H),7.47(t,J=7.7Hz,1H),7.32(dd,J=1.9Hz,8.5Hz,1H),7.28(dd,J=1.9Hz,9.2Hz,1H),6.91(bs,2H),6.61(dd,J=1.3Hz,5.6Hz,1H)。
Mass,m/e:290(M+),145(base)。
b:3-(2-氟-4-氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.49(d,J=1.4Hz,1H),8.41(d,J=5.4Hz,1H),7.51~7.39(m,6H),7.32(dd,J=2.3Hz,8.5Hz,1H),7.25(dd,J=1.9Hz,9.3Hz,1H),6.66(td,J=1.4Hz,5.4Hz,1H),3.94(s,2H)。
Mass,m/e:384(M+),91(base)。
实施例135
3-(4-氯-2-氟苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.62(s,1H),8.61(d,J=1.5Hz,1H),8.44(d,J=5.2Hz,1H),7.49~7.40(m,3H),7.33(dd,J=1.9Hz,7.7Hz,1H),7.28~7.24(m,2H),7.20(t,J=8.5Hz,1H),6.69(td,J=1.5Hz,5.2Hz,1H),3.96(s,2H)。
Mass,m/e:426(M+),109(base)。
实施例136
3-(4-氯-2-氟苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.54(s,1H),8.42(d,J=5.8Hz,1H),7.54~7.52(m,1H),7.49~7.45(m,2H),7.42~7.40(m,2H),7.32(dd,J=1.9Hz,8.5Hz,1H),7.26(dd,J=2.3Hz,8.9Hz,1H),6.49(td,J=1.5Hz,5.8Hz,1H),4.07(s,2H)。
Mass,m/e:442(M+),274(base)。
实施例137
3-(4-氯-3-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-氯-3-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.5Hz,1H),8.36(d,J=5.8Hz,1H),7.55(t,J=8.1Hz,1H),7.35(dd,J=1.9Hz,9.3Hz,1H),7.28~7.26(m,1H),6.91(bs,2H),6.72(dd,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:290(M+),145(base)。
b:3-(4-氯-3-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(bs,1H),8.50(d,J=1.3Hz,1H),8.41(d,J=5.6Hz,1H),7.54(t,J=8.5Hz,1H),7.49~7.45(m,3H),7.41~7.39(m,2H),7.29(dd,J=1.9Hz,8.9Hz,1H),7.22~7.20(m,1H),6.75(dd,J=1.3Hz,5.6Hz,1H),3.93(s,2H)。
Mass,m/e:408(M+),91(base)。
实施例138
3-(4-氯-3-氟苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.55(d,J=1.2Hz,1H),8.42(d,J=5.6Hz,1H),7.57~7.52(m,2H),7.48~7.46(m,1H),7.43~7.40(m,2H),7.30(dd,J=1.9Hz,8.9Hz,1H),7.23~7.21(m,1H),6.77(dd,J=1.2Hz,5.6Hz,1H),4.06(s,2H)。
Mass,m/e:442(M+),274(base)。
实施例139
3-(3-溴-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-溴-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.5Hz,1H),8.36(d,J=5.8Hz,1H),7.77(dd,J=1.5Hz,6.4Hz,1H),7.48~7.44(m,1H),7.28~7.25(m,1H),6.88(bs,2H),6.71(dd,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:334(M+),94(base)。
b:3-(3-溴-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.51(bs,1H),8.41(d,J=5.4Hz,1H),7.71(dd,J=6.6Hz,2.3Hz,1H),7.51~7.39(m,6H),7.25~7.23(m,1H),6.74(dd,J=5.4Hz,1.5Hz,1H),3.94(s,2H)。
Mass,m/e:452(M+),91(base)。
实施例140
3-(3-溴-4-氟苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:10.09(s,1H),8.55(bs,1H),8.42(d,J=5.4Hz,1H),7.72(dd,J=2.1Hz,6.4Hz,1H),7.54~7.52(m,1H),7.47~7.39(m,4H),7.28~7.24(m,1H),6.76(dd,J=1.2Hz,5.4Hz,1H),4.06(s,2H)。
Mass,m/e:486(M+),125(base)。
实施例141
3-(3,4-二氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,4-二氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.5Hz,1H),8.37(d,J=5.8Hz,1H),7.66(d,J=1.9Hz,1H),7.60(d,J=8.1Hz,1H),7.37(dd,J=1.9Hz,8.1Hz,1H),6.89(bs,2H),6.72(dd,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:305(M+),161(base)。
b:3-(3,4-二氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.51(s,1H),8.42(d,J=5.6Hz,1H),7.60~7.57(m,2H),7.52~7.39(m,5H),7.30(dd,J=1.9Hz,8.1Hz,1H),6.75(dd,J=1.5Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:424(M+),91(base)。
实施例142
3-(3,4-二氯苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.56(s,1H),8.63(s,1H),8.45(d,J=5.8Hz,1H),7.62~7.59(m,2H),7.47~7.41(m,2H),7.32(dd,J=1.9Hz,8.1Hz,1H),7.28~7.18(m,2H),6.79(dd,J=1.5Hz,5.8Hz,1H),3.96(s,2H)。
Mass,m/e:442(M+),109(base)。
实施例143
5-[(2-氯苯基)乙酰氨基]-3-(3,4-二氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.56(d,J=1.2Hz,1H),8.43(d,J=5.6Hz,1H),7.61~7.58(m,2H),7.55~7.38(m,4H),7.32(dd,J=1.9Hz,8.1Hz,1H),6.78(dd,J=1.5Hz,5.6Hz,1H),4.07(s,2H)。
Mass,m/e:459(M++1),125(base)。
实施例144
3-(3,5-二氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,5-二氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.05(d,J=1.3Hz,1H),8.39(d,J=5.5Hz,1H),7.54(t,J=1.9Hz,1H),7.43(d,J=1.9Hz,2H),6.91(bs,2H),6.71(dd,J=1.3Hz,5.5Hz,1H)。
Mass,m/e:306(M+),161(base)。
b:3-(3,5-二氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.51(d,J=1.3Hz,1H),8.44(d,J=5.4Hz,1H),7.54(t,J=1.9Hz,1H),7.52~7.39(m,5H),7.37(d,J=1.9Hz,2H),6.74(dd,J=1.3Hz,5.4Hz,1H),3.94(s,2H)。
Mass,m/e:424(M+),91(base)。
实施例145
3-(3,5-二氯苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.64(d,J=1.4Hz,1H),8.47(d,J=5.5Hz,1H),7.55(t,J=1.9Hz,1H),7.48~7.40(m,2H),7.38(d,J=1.9Hz,2H),7.30~7.24(m,1H),7.20(t,J=8.9Hz,1H),6.77(dd,J=1.4Hz,5.5Hz,1H),3.97(d,J=1.2Hz,2H)。
Mass,m/e:442(M+),109(base)。
实施例146
5-[(2-氯苯基)乙酰氨基]-3-(3,5-二氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.56(d,J=1.3Hz,1H),8.45(d,J=5.4Hz,1H),7.56~7.52(m,2H),7.50~7.40(m,3H),7.38(d,2H),6.75(dd,J=1.3Hz,5.4Hz,1H),4.07(s,2H)。
Mass,m/e:458(M+),125(base)。
实施例147
3-(2,6-二氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,6-二氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(d,J=1.4Hz,1H),8.30(d,J=5.6Hz,1H),7.50~7.43(m,3H),7.00(bs,2H),6.29(dd,J=1.4Hz,5.6Hz,1H)。
Mass,m/e:306(M+),271(base)。
b:3-(2,6-二氯苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.47(s,1H),8.35(d,J=5.6Hz,1H),7.52~7.42(m,8H),6.34(dd,J=1.5Hz,5.6Hz,1H),3.96(s,2H)。
Mass,m/e:424(M+),91(base)。
实施例148
3-(2,6-二氯苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.68(s,1H),8.60(s,1H),8.38(d,J=5.6Hz,1H),7.50~7.43(m,5H),7.29~7.19(m,2H),6.37(dd,J=1.2Hz,5.6Hz,1H),3.99(s,2H)。
Mass,m/e:442(M+),109(base)。
实施例149
5-[(2-氯苯基)乙酰氨基]-3-(2,6-二氯苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(s,1H),8.54(s,1H),8.36(d,J=5.6Hz,1H),7.55~7.40(m,7H),6.36(dd,J=1.5Hz,5.6Hz,1H),4.09(s,2H)。
Mass,m/e:460(M+),125(base)。
实施例150
5-(苯基乙酰氨基)-4-(4-嘧啶基)-3-(2,3,4-三氟苯基)异噁唑
a:5-氨基-4-(4-嘧啶基)-3-(2,3,4-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.5Hz,1H),8.39(d,J=5.8Hz,1H),7.31~7.25(m,1H),7.21~7.13(m,1H),6.92(bs,2H),6.60(dt,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:292(M+),147(base)。
b:5-(苯基乙酰氨基)-4-(4-嘧啶基)-3-(2,3,4-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.50(d,J=1.2Hz,1H),8.44(d,J=5.8Hz,1H),7.52~7.39(m,5H),7.30~7.13(m,2H),6.64(dt,J=1.2Hz,5.8Hz,1H),3.95(s,2H)。
Mass,m/e:410(M+),91(base)。
实施例151
5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)-3-(2,3,4-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.61(s,1H),8.63(d,J=1.2Hz,1H),8.47(d,J=5.4Hz,1H),7.48~7.41(m,2H),7.31~7.14(m,4H),6.68(dt,J=1.2Hz,5.4Hz,1H),3.97(s,2H)。
Mass,m/e:428(M+),109(base)。
实施例152
5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)-3-(2,3,4-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.56(d,J=1.2Hz,1H),8.46(d,J=5.4Hz,1H),7.55~7.41(m,3H),7.31~7.25(m,2H),7.20~7.13(m,1H),6.67(dt,J=1.2Hz,5.4Hz,1H),4.07(s,2H)。
Mass,m/e:444(M+),125(base)。
实施例153
3-(2,4,5-三氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-4-(4-嘧啶基)-3-(2,4,5-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.5Hz,1H),8.39(d,J=5.4Hz,1H),7.43~7.37(m,1H),7.16~7.09(m,1H),6.91(bs,2H),6.63(dt,J=1.5Hz,5.4Hz,1H)。
Mass,m/e:292(M+),147(base)。
b:3-(2,4,5-三氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.50(bs,1H),8.44(d,J=5.4Hz,1H),7.52~7.36(m,6H),7.13~7.07(m,1H),6.68~6.67(m,1H),3.94(s,2H)。
Mass,m/e:410(M+),91(base)。
实施例154
5-[(2-氟苯基)乙酰氨基]-3-(2,4,5-三氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.61(s,1H),8.63(d,J=1.2Hz,1H),8.46(d,J=5.4Hz,1H),7.45~7.37(m,3H),7.29~7.18(m,2H),7.14~7.09(m,1H),6.71(dt,J=1.2Hz,5.4Hz,1H),3.97(s,2H)。
Mass,m/e:428(M+),109(base)。
实施例155
5-[(2-氯苯基)乙酰氨基]-3-(2,4,5-三氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.55(bs,1H),8.45(d,J=5.4Hz,1H),7.55~7.36(m,5H),7.14~7.08(m,1H),6.71~6.69(m,1H),4.07(s,2H)。
Mass,m/e:444(M+),276(base)。
实施例156
5-(苯基乙酰氨基)-4-(4-嘧啶基)-3-(2,4,6-三氟苯基)异噁唑
a:5-氨基-4-(4-嘧啶基)-3-(2,4,6-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.3Hz,1H),8.38(d,J=5.7Hz,1H),7.07~6.50(m,5H)。
Mass,m/e:292(M+),147(base)。
b:5-(苯基乙酰氨基)-4-(4-嘧啶基)-3-(2,4,6-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.49(d,J=1.2Hz,1H),8.42(d,J=5.4Hz,1H),7.52~7.40(m,5H),6.89~6.82(m,2H),6.61(dd,J=5.4Hz,1.2Hz,1H),3.95(s,2H)。
Mass,m/e:410(M+),91(base)。
实施例157
5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)-3-(2,4,6-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.64(s,1H),8.62(bs,1H),8.45(d,J=5.4Hz,1H),7.47~7.41(m,2H),7.29~7.18(m,2H),6.90~6.83(m,2H),6.65(dd,J=1.2Hz,5.4Hz,1H),3.98(s,2H)。
Mass,m/e:428(M+),276(base)。
实施例158
5-[(2-氯苯基)乙酰氨基]-3-(2,4,6-三氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.52(s,1H),8.55(bs,1H),8.44(d,J=5.4Hz,1H),7.55~7.53(m,1H),7.49~7.47(m,1H),7.43~7.40(m,2H),6.87(dd,J=7.3Hz,8.5Hz,2H),6.64(d,J=5.4Hz,1H),4.08(s,2H)。
Mass,m/e:444(M+),276(base)。
实施例159
5-[(3-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)-3-(2,4,6-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.60(d,J=1.5Hz,1H),8.43(d,J=5.4Hz,1H),7.40(t,J=7.9Hz,1H),7.00~6.95(m,3H),6.89~6.84(m,2H),6.61(dd,J=1.5Hz,5.4Hz,1H),3.91(s,2H),3.84(s,3H)。
Mass,m/e:440(M+),148(base)。
实施例160
5-(苯基乙酰氨基)-4-(4-嘧啶基)-3-(3,4,5-三氟苯基)异噁唑
a:5-氨基-4-(4-嘧啶基)-3-(3,4,5-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:9.04(d,J=1.5Hz,1H),8.40(d,J=5.4Hz,1H),7.19(t,J=7.7Hz,2H),6.94(bs,2H),6.71(dd,J=1.5Hz,5.4Hz,1H)。
Mass,m/e:292(M+),147(base)。
b:5-(苯基乙酰氨基)-4-(4-嘧啶基)-3-(3,4,5-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.35(bs,1H),8.51(d,J=1.2Hz,1H),8.45(d,J=5.4Hz,1H),7.51~7.44(m,3H),7.41~7.38(m,2H),7.14(t,J=6.2Hz,2H),6.75(dd,J=1.2Hz,5.4Hz,1H),3.93(s,2H)。
Mass,m/e:410(M+),91(base)。
实施例161
5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)-3-(3,4,5-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.54(s,1H),8.64(d,J=1.4Hz,1H),8.47(d,J=5.6Hz,1H),7.47~7.39(m,2H),7.28~7.13(m,4H),6.73(dd,J=1.4Hz,5.6Hz,1H),3.96(s,2H)。
Mass,m/e:428(M+),109(base)。
实施例162
5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)-3-(3,4,5-三氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.41(s,1H),8.56(d,J=1.2Hz,1H),8.41(d,J=5.4Hz,1H),7.54~7.52(m,1H),7.48~7.40(m,3H),7.15(t,J=6.6Hz,2H),6.77(dd,J=1.2Hz,5.4Hz,1H),4.10(s,2H)。
Mass,m/e:444(M+),125(base)。
实施例163
3-(2-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.99(d,J=1.5Hz,1H),8.26(d,J=5.8Hz,1H),7.51(td,J=1.7Hz,7.7Hz,1H),7.42(dd,J=1.7Hz,1H),7.09(ddd,J=1.0Hz,7.7Hz,15.7Hz,1H),7.02(d,J=7.7Hz,1H),6.83(bs,2H),6.55(dd,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:268(M+),123(base)。
b:3-(2-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.47(bs,1H),8.31(d,J=5.7Hz,1H),7.55~7.22(m,6H),7.16~7.05(m,2H),6.98(d,J=8.5Hz,1H),6.60(dd,J=1.5Hz,5.7Hz,1H),3.94(s,2H),3.62(s,3H)。
Mass,m/e:386(M+),252(base)。
实施例164
5-[(2-氟苯基)乙酰氨基]-3-(2-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.63(s,1H),8.59(s,1H),8.33(d,J=5.5Hz,1H),7.55~7.49(m,1H),7.47~7.39(m,3H),7.29~7.16(m,2H),7.09(td,J=1.0Hz,7.3Hz,1H),6.99(d,J=8.1Hz,1H),6.63(dd,J=1.3Hz,5.5Hz,1H),3.97(s,2H),3.63(s,3H)。
Mass,m/e:404(M+),252(base)。
实施例165
5-[(2-氯苯基)乙酰氨基]-3-(2-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(s,1H),8.52(s,1H),8.32(d,J=5.5Hz,1H),7.55~7.45(m,3H),7.44~7.38(m,3H),7.09(td,J=0.9Hz,7.3Hz,1H),6.99(d,J=8.1Hz,1H),6.63(dd,J=1.3Hz,5.5Hz,1H),4.07(s,2H)。
Mass,m/e:420(M+),252(base)。
实施例166
3-(3-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.3Hz,1H),8.30(d,J=5.7Hz,1H),7.42(t,J=7.9Hz,1H),7.11(m,3H),6.87(bs,2H),6.76(dd,J=1.3Hz,5.7Hz,1H),3.83(s,3H)。
Mass,m/e:268(M+),77(base)。
b:3-(3-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.49(s,1H),8.35(d,J=5.5Hz,1H),7.52~7.37(m,6H),7.10~6.95(m,3H) ,6.78(dd,J=1.3Hz,5.5Hz,1H),3.94(s,2H),3.81(s,3H)。
Mass,m/e:386(M+),91(base)。
实施例167
5-[(2-氟苯基)乙酰氨基]-3-(3-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.60(s,1H),8.61(s,1H),8.37(d,J=5.7Hz,1H),7.47~7.38(m,3H),7.29~7.16(m,2H),7.09~6.97(m,3H),6.81(dd,J=1.3Hz,5.7Hz,1H),3.97(s,2H),3.82(s,3H)。
Mass,m/e:404(M+-1),252(base)。
实施例168
5-[(2-氯苯基)乙酰氨基]-3-(3-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.56~8.50(bs,1H),8.36(d,J=5.6Hz,1H),7.56~7.37(m,5H),7.09(m,3H),6.79(dd,J=1.3Hz,5.6Hz,1H),4.07(s,2H),3.81(s,3H)。
Mass,m/e:420(M+),252(base)。
实施例169
3-(4-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.5Hz,1H),8.30(d,J=5.8Hz,1H),7.46~7.43(m,2H),7.04~7.00(m,2H),6.84(bs,2H),6.79(dd,J=1.5Hz,5.8Hz,1H),3.88(s,3H)。
Mass,m/e:268(M+),123(base)。
b:3-(4-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.48(s,1H),8.35(d,J=5.4Hz,1H),7.50~7.36(m,7H),7.02~6.98(m,2H),6.82(dd,J=1.5Hz,5.4Hz,1H),3.93(s,2H),3.87(s,3H)。
Mass,m/e:386(M+),91(base)。
实施例170
5-[(2-氟苯基)乙酰氨基]-3-(4-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.60(s,1H),8.38(d,J=5.4Hz,1H),7.46~7.38(m,4H),7.27~7.17(m,2H),7.03~6.99(m,2H),6.83(dd,J=1.5Hz,5.4Hz,1H),3.96(s,2H),3.87(s,3H)。
Mass,m/e:404(M+),109(base)。
实施例171
5-[(2-氯苯基)乙酰氨基]-3-(4-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.53(s,1H),8.36(d,J=5.4Hz,1H),7.54~7.52(m,1H),7.48~7.46(m,1H),7.42~7.38(m,4H),7.03~7.00(m,2H),6.84(dd,J=1.5Hz,5.4Hz,1H),4.06(s,2H),3.87(s,3H)。
Mass,m/e:420(M+),135(base)。
实施例172
3-(2-氟-4-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氟-4-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.98(d,J=1.5Hz,1H),8.41(d,J=5.8Hz,1H),8.31(bs,2H),7.47(t,J=8.5Hz,1H),7.06(dd,J=2.3Hz,11.9Hz,1H),6.97(dd,J=2.3Hz,8.5Hz,1H),6.57(td,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:286(M+),141(base)。
b:3-(2-氟-4-甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.47(s,1H),8.38(d,J=5.8Hz,1H),7.51~7.38(m,6H),6.83(dd,J=2.7Hz,8.5Hz,1H),6.75~6.71(m,2H),3.93(s,2H),3.86(s,3H)。
Mass,m/e:404(M+),91(base)。
实施例173
3-(2-氟-4-甲氧基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.62(bs,1H),8.59(s,1H),8.41(d,J=5.8Hz,1H),7.45~7.39(m,3H),7.27~7.24(m,1H),7.19(t,J=9.3Hz,1H),6.84(dd,J=2.3Hz,8.5Hz,1H),6.77~6.72(m,2H),3.96(s,2H),3.87(s,3H)。
Mass,m/e:422(M+),270(base)。
实施例174
5-[(2-氯苯基)乙酰氨基]-3-(2-氟-4-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.52(s,1H),8.39(d,J=5.8Hz,1H),7.54~7.51(m,1H),7.48~7.46(m,1H),7.43~7.39(m,3H),6.84(dd,J=2.3Hz,8.5Hz,1H),6.76~6.72(m,2H),4.06(s,2H),3.87(s,3H)。
Mass,m/e:438(M+),270(base)。
实施例175
3-(2-氟-4-甲氧基苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(bs,1H),8.40(d,J=1.2Hz,1H),8.37(d,J=5.4Hz,1H),7.42~7.31(m,5H),6.83(dd,J=1.9Hz,8.1Hz,1H),6.75~6.70(m,2H),3.92(s,2H),3.86(s,3H),2.36(s,3H)。
Mass,m/e:418(M+),270(base)。
实施例176
3-(2-氟-4-甲氧基苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.46(s,1H),8.38(d,J=5.8Hz,1H),7.40(t,J=8.5Hz,2H),7.37(t,J=7.3Hz,1H),7.26(d,J=7.3Hz,1H),7.21(d,J=7.3Hz,1H),6.83(dd,J=2.7Hz,8.9Hz,1H),6.75~6.71(m,2H),3.88(s,2H),3.86(s,3H),2.39(s,3H)。
Mass,m/e:418(M+),270(base)。
实施例177
5-[(2,5-二甲基苯基)乙酰氨基]-3-(2-氟-4-甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.36(bs,1H),8.37(s,1H),8.37(d,J=5.4Hz,1H),7.40(t,J=8.1Hz,1H),7.20(s,2H),7.15(s,1H),6.83(dd,J=2.3Hz,8.5Hz,1H),6.75~6.71(m,2H),3.87(s,2H),3.86(s,3H),2.38(s,3H),2.31(s,3H)。
Mass,m/e:432(M+),270(base)。
实施例178
3-(4-乙基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-乙氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.5Hz,1H),8.30(d,J=5.8Hz,1H),7.45~7.41(m,2H),7.02~6.99(m,2H),6.83(bs,2H),6.79(dd,J=1.5Hz,5.8Hz,1H),4.11(q,J=6.9Hz,2H),1.46(t,J=6.9Hz,3H)。
Mass,m/e:282(M+),137(base)。
b:3-(4-乙基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.48(s,1H),8.34(d,J=5.8Hz,1H),7.50~7.35(m,7H),7.00~6.97(m,2H),6.82(dd,J=1.5Hz,5.8Hz,1H),4.09(q,J=6.9Hz,2H),3.92(s,2H),1.45(t,J=6.9Hz,3H)。
Mass,m/e:400(M+),266(base)。
实施例179
3-(4-乙氧基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.60(s,1H),8.37(d,J=5.4Hz,1H),7.46~7.36(m,4H),7.27~7.17(m,2H),7.01~6.97(m,2H),6.85(dd,J=1.5Hz,5.4Hz,1H),4.09(q,J=6.9Hz,2H),3.92(s,2H),1.45(t,J=6.9Hz,3H)。
Mass,m/e:418(M+),266(base)。
实施例180
3-(4-乙氧基苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.53(s,1H),8.36(d,J=5.4Hz,1H),7.54~7.36(m,6H),7.01~6.97(m,2H),6.85(dd,J=1.5Hz,5.4Hz,1H),4.12~4.06(m,4H),1.45(t,J=6.9Hz,3H)。
Mass,m/e:434(M+),266(base)。
实施例181
3-(3-苄氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-苄氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.99(d,J=1.5Hz,1H),8.29(d,J=5.6Hz,1H),7.43~7.29(m,7H),7.11~7.07(m,2H),6.95(bs,2H),6.45(dd,J=1.5Hz,5.6Hz,1H),5.06(s,2H)。
Mass,m/e:344(M+),91(base)。
b:3-(3-苄氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(bs,1H),8.46(d,J=1.4Hz,1H),8.33(d,J=5.6Hz,1H),7.51~7.29(m,12H),7.09(dd,J=3.1Hz,8.9Hz,1H),7.04(d,J=3.1Hz,1H),6.50(dd,J=1.4Hz,5.6Hz,1H),5.05(s,2H),3.94(s,2H)。
Mass,m/e:461(M+),91(base)。
实施例182
3-(3-苄氧基苯基)-5-[(2-氯-4-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.56(bs,1H),8.69(s,1H),8.39(d,J=5.6Hz,1H),7.48~7.26(m,9H),7.14~7.09(m,2H),7.06(d,J=3.1Hz,1H),6.55(dd,J=1.5Hz,5.6Hz,1H),5.06(s,2H),4.05(s,2H)。
Mass,m/e:513(M+),91(base)。
实施例183
3-(3-苄氧基苯基)-5-[(2,4-二氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(bs,1H),8.68(s,1H),8.39(d,J=5.6Hz,1H),7.54(d,J=1.9Hz,1H),7.43~7.31(m,9H),7.10(dd,J=3.1Hz,8.9Hz,1H),7.06(d,J=3.1Hz,1H),6.56(dd,J=1.5Hz,5.6Hz,1H),5.06(s,2H),4.05(s,2H)。
Mass,m/e:529(M+),91(base)。
实施例184
3-(3-苄氧基苯基)-5-[(2,6-二氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(bs,1H),8.58(s,1H),8.37(d,J=5.6Hz,1H),7.49(d,J=8.1Hz,2H),7.42~7.29(m,8H),7.10(dd,J=3.1Hz,8.9Hz,1H),7.06(d,J=3.1Hz,1H),6.55(dd,J=1.2Hz,5.6Hz,1H),5.06(s,2H),4.32(s,2H)。
Mass,m/e:529(M+),91(base)。
实施例185
3-(2,3-二甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,3-二甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.97(d,J=1.3Hz,1H),8.26(d,J=5.8Hz,1H),7.19(t,J=7.8Hz,1H),7.10(dd,J=1.5Hz,8.5Hz,1H),6.97(dd,J=1.5Hz,7.8Hz,1H),6.86(bs,2H),6.56(dd,J=1.3Hz,5.8Hz,1H),3.93(s,3H),3.72(s,3H)。
Mass,m/e:298(M+),267(base)。
b:3-(2,3-二甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(s,1H),8.44(s,1H),8.31(d,J=5.7Hz,1H),7.52~7.40(m,5H),7.18(t,J=7.8Hz,1H),7.10(dd,J=1.5Hz,8.5Hz,1H),6.93(dd,J=1.5Hz,7.8Hz,1H),6.61(dd,J=1.5Hz,5.7Hz,1H),3.95(s,2H),3.91(s,3H),3.65(s,3H)。
Mass,m/e:416(M+),91(base)。
实施例186
3-(2,3-二甲氧基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.69(s,1H),8.56(s,1H),8.34(d,J=5.5Hz,1H),7.47~7.40(m,2H),7.31~7.15(m,4H),6.94(dd,J=1.5Hz,7.3Hz,1H),6.64(dd,J=1.5Hz,5.5Hz,1H),3.98(s,2H),3.92(s,3H),3.66(s,3H)。
Mass,m/e:434(M+),109(base)。
实施例187
3-(2,3-二甲氧基苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.32(s,1H),8.49(s,1H),8.32(d,J=5.4Hz,1H),7.55~7.38(m,4H),7.19(t,J=8.5Hz,1H),7.10(dd,J=1.5Hz,8.5Hz,1H),6.94(dd,J=1.5Hz,7.2Hz,1H),6.64(dd,J=1.5Hz,5.4Hz,1H),4.08(s,2H),3.92(s,3H),3.66(s,3H)。
Mass,m/e:450(M+),282(base)。
实施例188
3-(3,4-二甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,4-二甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.3Hz,1H),8.31(d,J=5.5Hz,1H),7.08(dd,J=1.9Hz,8.4Hz,1H),7.02(s,1H),7.00(t,J=8.4Hz,1H),6.85(bs,2H),6.81(dd,J=1.3Hz,5.5Hz,1H),3.96(s,3H),3.87(s,3H)。
Mass,m/e:298(M+),153(base)。
b:3-(3,4-二甲氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.50(bs,1H),8.36(d,J=5.7Hz,1H),7.52~7.38(m,5H),7.04~6.93(m,3H),6.84(dd,J=1.3Hz,5.7Hz,1H),3.94(s,3H),3.94(s,2H),3.84(s,3H)。
Mass,m/e:416(M+),91(base)。
实施例189
3-(3,4-二甲氧基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.61(s,1H),8.38(d,J=5.5Hz,1H),7.47~7.39(m,2H),7.30~7.16(m,2H),7.03(dd,J=1.9Hz,8.1Hz,1H),6.99~6.95(m,2H),6.87(dd,J=1.3Hz,5.5Hz,1H),3.97(s,2H),3.95(s,3H),3.85(s,3H)。
Mass,m/e:434(M+),282(base)。
实施例190
5-[(2-氯苯基)乙酰氨基]-3-(3,4-二甲氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.54(s,1H),8.37(d,J=5.5Hz,1H),7.55~7.50(m,1H),7.49~7.45(m,1H),7.45~7.38(m,2H),7.02(dd,J=1.7Hz,8.3Hz,1H),6.99~6.94(m,2H),6.86(dd,J=5.5Hz,1H),4.07(s,2H),3.95(s,3H),3.84(s,3H)。
Mass,m/e:450(M+),282(base)。
实施例191
3-(2,3-亚甲基二氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,3-亚甲基二氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.5Hz,1H),8.39(d,J=5.8Hz,1H),7.04~6.91(m,1H),6.83~6.81(m,2H),6.87(bs,2H),6.63(dd,J=1.5Hz,5.8Hz,1H),5.95(s,2H)。
Mass,m/e:282(M+),137(base)。
b:3-(2,3-亚甲基二氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.50(bs,1H),8.41(d,J=5.8Hz,1H),7.51~7.40(m,5H),6.99~6.95(m,3H),6.84(dd,J=1.4Hz,5.8Hz,1H),5.89(s,2H),3.94(s,2H)。
Mass,m/e:400(M+),91(base)。
实施例192
5-[(2-氯苯基)乙酰氨基]-3-(2,3-亚甲基二氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.54(bs,1H),8.42(d,J=5.4Hz,1H),7.54~7.52(m,1H),7.48~7.46(m,1H),7.42~7.39(m,2H),6.99~6.96(m,3H),6.87(dd,J=1.5Hz,5.4Hz,1H),5.89(s,2H),4.07(s,2H)。
Mass,m/e:434(M+),266(base)。
实施例193
3-(3,4-亚甲基二氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,4-亚甲基二氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.1Hz,1H),8.34(d,J=5.7Hz,1H),7.05~6.70(m,6H),6.06(s,2H)。
Mass,m/e:282(M+),137(base)。
b:3-(3,4-亚甲基二氧基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(s,1H),8.48(s,1H),8.38(d,J=5.8Hz,1H),7.52~7.38(m,5H),6.97~6.85(m,4H),6.05(s,2H),3.93(s,1H)。
Mass,m/e:400(M+),91(base)。
实施例194
3-(3,4-亚乙基二氧基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,4-亚乙基二氧基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.2Hz,1H),8.32(d,J=5.8Hz,1H),7.04(bs,1H),6.98(d,J=1.2Hz,2H),6.86(dd,J=1.2Hz,5.6Hz,1H),6.82(bs,2H),4.35~4.30(m,4H)。
Mass,m/e:296(M+),151(base)。
b:3-(3,4-亚乙基二氧基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.60(s,1H),8.40(d,J=5.4Hz,1H),7.46~7.40(m,2H),7.28~7.17(m,2H),7.00~6.91(m,4H),4.34~4.28(m,4H),3.96(s,2H)。
Mass,m/e:432(M+),280(base)。
实施例195
3-(2-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.99(d,J=1.5Hz,1H),8.23(d,J=5.7Hz,1H),7.46~7.43(m,1H),7.36~7.29(m,3H),6.90(bs,2H),6.34(dd,J=1.5Hz,5.7Hz,1H),2.22(s,3H)。
Mass,m/e:252(M+),130(base)。
b:3-(2-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.46(bs,1H),8.28(d,J=5.7Hz,1H),7.52~7.40(m,6H),7.34~7.25(m,3H),6.39(dd,J=1.5Hz,5.7Hz,1H),3.96(s,2H),2.13(s,3H)。
Mass,m/e:370(M+),91(base)。
实施例196
5-[(2-氟苯基)乙酰氨基]-3-(2-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.67(s,1H),8.58(s,1H),8.31(d,J=1.5Hz,1H),7.48~7.40(m,3H),7.35~7.18(m,5H),6.42(dd,J=1.5Hz,5.4Hz,1H),3.99(d,J=0.8Hz,2H),2.14(s,3H)。
Mass,m/e:388(M+),236(base)。
实施例197
5-[(2-氯苯基)乙酰氨基]-3-(2-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(s,1H),8.51(s,1H),8.29(d,J=5.7Hz,1H),7.56~7.19(m,8H),6.41(dd,J=1.3Hz,5.7Hz,1H),4.09(s,2H),2.14(s,3H)。
Mass,m/e:404(M+),236(base)。
实施例198
3-(3-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(d,J=1.6Hz,1H),8.28(d,J=5.6Hz,1H),7.40~7.28(m,4H),6.86(bs,2H),6.73(dd,J=1.6Hz,5.6Hz,1H),2.41(s,3H)。
Mass,m/e:252(M+),91(base)。
b:3-(3-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.48(s,1H),8.32(d,J=5.6Hz,1H),7.48~7.21(m,9H),6.75(dd,J=1.5Hz,5.6Hz,1H),3.93(s,2H),2.39(s,3H)。
Mass,m/e:370(M+),91(base)。
实施例199
5-[(2-氟苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.60(s,1H),8.60(s,1H),8.35(d,J=5.4Hz,1H),7.45~7.17(m,8H),6.79(dd,J=1.5Hz,5.4Hz,1H),3.96(s,2H),2.39(s,3H)。
Mass,m/e:388(M+),236(base)。
实施例200
5-[(3-氟苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.65(s,1H),8.36(d,J=5.4Hz,1H),7.47~7.33(m,3H),7.29(s,1H),7.24~7.13(m,4H),6.79(dd,J=1.2Hz,5.4Hz,1H),3.94(s,2H),2.40(s,3H)。
Mass,m/e:388(M+),236(base)。
实施例201
5-[(2-氯苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.52(s,1H),8.34(d,J=5.4Hz,1H),7.54~7.20(m,8H),6.78(dd,J=1.5Hz,5.4Hz,1H),4.07(s,2H),2.39(s,3H)。
Mass,m/e:404(M+),236(base)。
实施例202
5-[(2-溴苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(bs,1H),8.51(s,1H),8.34(d,J=5.5Hz,1H),7.41(d,J=8.1Hz,1H),7.49~7.31(m,5H),7.29(s,1H),7.23(d,J=7.3Hz,1H),6.77(dd,J=1.2Hz,5.5Hz,1H),4.09(s,2H),2.39(s,3H)。
Mass,m/e:448(M+),236(base)。
实施例203
5-[(2-碘苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(bs,1H),8.49(s,1H),8.33(d,J=5.6Hz,1H),8.00(d,J=7.7Hz,1H),7.48(d,J=3.9Hz,2H),7.39~7.32(m,2H),7.29(s,1H),7.24(d,J=9.3Hz,1H),7.18~7.12(m,1H),6.77(dd,J=1.2Hz,5.6Hz,1H),4.12(s,2H),2.39(s,3H)。
Mass,m/e:496(M+),236(base)。
实施例204
5-[(2,4-二氟苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.62(bs,1H),8.78(s,1H),8.39(d,J=5.6Hz,1H),7.42~7.34(m,3H),7.30(s,1H),7.24(d,J=6.6Hz,1H),7.00~6.91(m,2H),6.82(dd,J=1.6Hz,5.6Hz,1H),3.94(s,2H),2.40(s,3H)。
Mass,m/e:406(M+),236(base)。
实施例205
5-[(2,5-二氟苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.65(bs,1H),8.79(s,1H),8.39(d,J=5.6Hz,1H),7.40~7.34(m,2H),7.30(bs,1H),7.25~7.24(m,1H),7.17~7.05(m,3H),6.82(dd,J=1.2Hz,5.6Hz,1H),3.95(s,2H),2.40(s,3H)。
Mass,m/e:406(M+),236(base)。
实施例206
5-[(2-氯-4-氟苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.70(s,1H),8.38(d,J=5.6Hz,1H),7.45(dd,J=5.8Hz,8.5Hz,1H),7.40~7.33(m,2H),7.30~7.23(m,3H),7.11(dt,J=2.3Hz,7.7Hz,1H),6.81(dd,J=1.5Hz,5.6Hz,1H),4.04(s,2H),2.40(s,3H)。
Mass,m/e:422(M+),236(base)。
实施例207
5-[(2-氟-6-氯苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.63(s,1H),8.37(d,J=5.6Hz,1H),7.41~7.33(m,4H),7.30(s,1H),7.24(d,J=5.8Hz,1H),7.16(dt,J=1.5Hz,8.9Hz,1H),6.80(dd,J=1.5Hz,5.6Hz,1H),4.14(d,J=1.5Hz,2H),2.40(s,3H)。
Mass,m/e:422(M+),236(base)。
实施例208
5-[(2,6-二氯苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.59(s,1H),8.36(d,J=5.4Hz,1H),7.48(d,J=7.7Hz,2H),7.40~7.32(m,3H),7.30(s,1H),7.25~7.23(m,1H),6.80(dd,J=1.9Hz,5.4Hz,1H),4.32(s,2H),2.40(s,3H)。
Mass,m/e:438(M+),236(base)。
实施例209
5-[(2-甲氧基苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.36(s,1H),8.44(d,J=1.2Hz,1H),8.31(d,J=5.6Hz,1H),7.44(dt,J=1.5Hz,8.1Hz,1H),7.38~7.31(m,3H),7.28(s,1H),7.22(d,J=7.3Hz,1H),7.08(t,J=7.3Hz,1H),6.99(d,J=8.1Hz,1H),6.74(dd,J=1.2Hz,5.6Hz,1H),3.88(s,2H),3.80(s,3H),2.38(s,3H)。
Mass,m/e:400(M+),91(base)。
实施例210
5-[(3-甲氧基苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(s,1H),8.58(s,1H),8.33(d,J=5.6Hz,1H),7.41~7.32(m,3H),7.28(s,1H),7.22(d,J=7.3Hz,1H),6.99~6.94(m,3H),6.76(dd,J=1.2Hz,5.6Hz,1H),3.89(s,2H),3.83(s,3H),2.39(s,3H)。
Mass,m/e:400(M+),236(base)。
实施例211
5-[(2,5-二甲氧基苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(s,1H),8.56(d,J=1.4Hz,1H),8.33(d,J=5.4Hz,1H),7.38~7.31(m,2H),7.28(s,1H),7.22(d,J=7.3Hz,1H),6.94~6.92(m,3H),6.76(dd,J=1.4Hz,5.4Hz,1H),3.86(s,2H),3.81(s,3H),3.77(s,3H),2.39(s,3H)。
Mass,m/e:430(M+),178(base)。
实施例212
5-[(2,3-二甲氧基苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.59(d,J=1.5Hz,1H),8.32(d,J=5.4Hz,1H),7.38~7.31(m,2H),7.28(s,1H),7.22(d,J=6.9Hz,1H),7.14(t,J=8.1Hz,1H),7.00(dd,J=1.2Hz,8.1Hz,1H),6.95(dd,J=1.2Hz,7.3Hz,1H),6.74(dd,J=1.5Hz,5.4Hz,1H),3.90(s,2H),3.89(s,3H),3.88(s,3H),2.42(s,3H)。
Mass,m/e:430(M+),178(base)。
实施例213
5-[(3,5-二甲氧基苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.69(d,J=1.3Hz,1H),8.34(d,J=5.6Hz,1H),7.36(q,J=7.3Hz,1H),7.33(d,J=7.3Hz,1H),7.28(s,1H),7.22(d,J=7.3Hz,1H),6.76(dd,J=1.3Hz,5.6Hz,1H),6.54(d,J=2.3Hz,2H),6.50(t,J=2.3Hz,1H),3.84(s,2H),3.81(s,6H),2.39(s,3H)。
Mass,m/e:430(M+),178(base)。
实施例214
3-(3-甲基苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.40(d,J=1.4Hz,1H),8.31(d,J=5.6Hz,1H),7.41~7.31(m,6H),7.27(bs,1H),7.21(dd,J=7.7Hz,1H),6.74(dd,J=1.4Hz,5.6Hz,1H),3.92(s,2H),2.38(s,3H),2.36(s,3H)。
Mass,m/e:384(M+),236(base)。
实施例215
3-(3-甲基苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.47(s,1H),8.33(d,J=5.4Hz,1H),7.39~7.32(m,3H),7.28~7.19(m,5H),6.76(dd,J=1.5Hz,5.4Hz,1H),3.89(s,2H),2.39(s,6H)。
Mass,m/e:384(M+),236(base)。
实施例216
5-[(2,5-二甲基苯基)乙酰氨基]-3-(3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.34(s,1H),8.31(d,J=5.8Hz,1H),8.37(d,J=1.4Hz,1H),7.38~7.32(m,2H),7.28(s,1H),7.22~7.20(m,3H),7.15(s,1H),6.74(dd,J=1.4Hz,5.8Hz,1H),3.87(s,2H),2.39(s,6H),2.31(s,3H)。
Mass,m/e:398(M+),236(base)。
实施例217
3-(3-甲基苯基)-4-(4-嘧啶基)-5-[(2-三氟甲基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.41(bs,1H),8.56(s,1H),8.35(d,J=5.6Hz,1H),7.81(d,J=7.7Hz,1H),7.66(t,J=7.7Hz,1H),7.58(d,J=6.9Hz,1H),7.54(d,J=7.7Hz,1H),7.39~7.32(m,2H),7.29(s,1H),7.23(d,J=6.9Hz,1H),6.78(dd,J=1.5Hz,5.6Hz,1H),4.12(s,2H),2.35(s,3H)。
Mass,m/e:438(M+),236(base)。
实施例218
3-(3-甲基苯基)-5-(3-苯基丙酰基氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(bs,1H),9.06(d,J=1.4Hz,1H),8.41(d,J=5.4Hz,1H),7.41~7.25(m,8H),7.20~7.17(m,1H),6.83(dd,J=1.4Hz,5.4Hz,1H),3.12(t,J=7.5Hz,2H),2.98(t,J=7.5Hz,2H),2.41(s,3H)。
Mass,m/e:384(M+),91(base)。
实施例219
3-(3-甲基苯基)-5-[(1-苯基-环丙烷)羰基氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(bs,1H),8.28(d,J=5.6Hz,1H),8.19(d,J=1.5Hz,1H),7.57~7.50(m,5H),7.37~7.30(m,2H),7.26(s,1H),7.20(d,J=7.3Hz,1H),6.72(dd,J=1.5Hz,5.6Hz,1H),2.38(s,3H),1.84(q,J=3.9Hz,2H),1.30(q,J=3.9Hz,2H)。
Mass,m/e:396(M+),117(base)。
实施例220
3-(4-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.4Hz,1H),8.29(d,J=5.7Hz,1H),7.50~7.20(m,4H),6.87(bs,2H),6.76(dd,J=1.4Hz,5.7Hz,1H),2.45(s,3H)。
Mass,m/e:252(M+),107(base)。
b:3-(4-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(s,1H),8.48(s,1H),8.33(d,J=5,6Hz,1H),7.51~7.38(m,5H),7.36~7.27(m,4H),6.79(dd,J=1.4Hz,5.6Hz,1H),3.94(s,2H),2.43(s,3H)。
Mass,m/e:370(M+),236(base)。
实施例221
3-(4-乙基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-乙基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.2Hz,1H),8.30(d,J=5.4Hz,1H),7.43(d,J=8.1Hz,2H),7.33(d,J=8.1Hz,2H),6.85(bs,2H),6.77(dd,J=1.2Hz,5.4Hz,1H),2.74(q,J=7.7Hz,2H),1.30(t,J=7.7Hz,3H)。
Mass,m/e:266(M+),106(base)。
b:3-(4-乙基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.48(s,1H),8.34(d,J=5.8Hz,1H),7.49~7.30(m,9H),6.80(dd,J=1.5Hz,5.8Hz,1H),3.94(s,2H),2.56(q,J=7.7Hz,2H),1.27(t,J=7.7Hz,3H)。
Mass,m/e:384(M+),250(base)。
实施例222
3-(4-乙基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.60(s,1H),8.61(s,1H),8.37(d,J=5.4Hz,1H),7.46~7.17(m,8H),6.84(dd,J=1.5Hz,5.4Hz,1H),4.00(s,2H),2.73(q,J=7.7Hz,2H),1.29(t,J=7.7Hz,3H)。
Mass,m/e:402(M+),250(base)。
实施例223
3-(4-乙基苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.53(s,1H),8.36(d,J=5.8Hz,1H),7.54~7.31(m,8H),6.83(dd,J=1.5Hz,5.8Hz,1H),4.07(s,2H),2.73(q,J=7.7Hz,2H),1.28(t,J=7.7Hz,3H)。
Mass,m/e:418(M+),250(base)。
实施例224
3-(2-氟-5-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(d,J=1.5Hz,1H),8.32(d,J=5.4Hz,1H),7.10(t,J=9.3Hz,1H),7.34~7.30(m,2H),6.88(bs,2H),6.65(td,J=1.5Hz,5.4Hz,1H)。
Mass,m/e:270(M+),125(base)。
b:3-(2-氟-5-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(bs,1H),8.47(s,1H),8.37(d,J=5.4Hz,1H),7.51~7.40(m,5H),7.34~7.28(m,2H),7.07(t,J=9.3Hz,1H),6.70(td,J=1.9Hz,5.4Hz,1H),3.94(s,2H),2.37(s,3H)。
Mass,m/e:388(M+),254(base)。
实施例225
3-(2-氟-5-甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.64(s,1H),8.60(s,1H),8.39(d,J=5.8Hz,1H),7.42(t,J=6.9Hz,2H),7.33~7.26(m,3H),7.20(t,J=9.6Hz,1H),7.08(t,J=8.9Hz,1H),6.73(d,J=5.8Hz,1H),3.97(s,2H),2.38(s,3H)。
Mass,m/e:406(M+),254(base)。
实施例226
3-(2-氟-5-甲基苯基)-5-[(3-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(bs,1H),8.64(s,1H),8.40(d,J=6.0Hz,1H),7.47~7.42(m,1H),7.35~7.29(m,2H),7.20(d,J=7.7Hz,1H),7.16~7.11(m,2H),7.08(t,J=9.3Hz,1H),6.73(td,J=1.5Hz,6.0Hz,1H),3.94(s,2H),2.38(s,3H)。
Mass,m/e:406(M+),254(base)。
实施例227
5-[(2-氯苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(s,1H),8.52(s,1H),8.38(d,J=5.6Hz,1H),7.54~7.51(m,1H),7.49~7.46(m,1H),7.42~7.39(m,2H),7.34~7.29(m,2H),7.07(t,J=9.3Hz,1H),6.72(td,J=1.5Hz,5.6Hz,1H),4.07(s,2H),2.37(s,3H)。
Mass,m/e:422(M+),254(base)。
实施例228
5-[(2-溴苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(bs,1H),8.51(s,1H),8.38(d,J=5.2Hz,1H),7.72(dd,J=1.2Hz,7.7Hz,1H),7.50~7.43(m,2H),7.35~7.29(m,3H),7.08(t,J=9.3Hz,1H),6.72(td,J=1.9Hz,5.2Hz,1H),4.09(s,2H),2.38(s,3H)。
Mass,m/e:466(M+),254(base)。
实施例229
3-(2-氟-5-甲基苯基)-5-[(2-碘苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(bs,1H),8.49(s,1H),8.38(d,J=5.4Hz,1H),8.00(d,J=7.7Hz,1H),7.48(d,J=4.2Hz,2H),7.34~7.30(m,2H),7.18~7.13(m,1H),7.08(t,J=8.5Hz,1H),6.72(td,J=1.9Hz,5.4Hz,1H),4.10(s,2H),2.38(s,3H)。
Mass,m/e:514(M+),254(base)。
实施例230
3-(2-氟-5-甲基基基)-5-[(2,4-二氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.66(bs,1H),8.77(s,1H),8.43(d,J=5.6Hz,1H),7.40(dt,J=6.2Hz,8.5Hz,1H),7.36~7.30(m,2H),7.09(t,J=8.9Hz,1H),7.01~6.92(m,2H),6.78(d,J=5.6Hz,1H),3.94(s,2H),2.38(s,3H)。
Mass,m/e:424(M+),254(base)。
实施例231
5-[(2,5-二氟苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.69(bs,1H),8.78(s,1H),8.43(d,J=5.4Hz,1H),7.36~7.29(m,2H),7.18~7.06(m,4H),6.77(td,J=1.9Hz,5.4Hz,1H),3.95(s,2H),2.39(s,3H)。
Mass,m/e:424(M+),254(base)。
实施例232
5-[(2-氯-4-氟苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.54(bs,1H),8.70(s,1H),8.42(d,J=5.6Hz,1H),7.45(dd,J=6.2Hz,8.9Hz,1H),7.36~7.26(m,3H),7.14~7.06(m,2H),6.75(td,J=1.5Hz,5.6Hz,1H),4.04(s,2H),2.38(s,3H)。
Mass,m/e:440(M+),254(base)。
实施例233
5-[(2-氯-6-氟苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.61(bs,1H),8.63(s,1H),8.41(d,J=5.4Hz,1H),7.42~7.29(m,4H),7.16(dd,J=2.3Hz,6.9Hz,1H),7.09(t,J=9.3Hz,1H),6.75(td,J=1.9Hz,5.4Hz,1H),4.14(d,J=1.9Hz,2H),2.38(s,3H)。
Mass,m/e:440(M+),254(base)。
实施例234
5-[(2,6-二氯苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.54(bs,1H),8.59(s,1H),8.40(d,J=5.4Hz,1H),7.48(d,J=8.1Hz,2H),7.37~7.30(m,3H),7.09(t,J=8.9Hz,1H),6.74(td,J=1.9Hz,5.4Hz,1H),4.31(s,2H),2.38(s,3H)。
Mass,m/e:456(M+),254(base)。
实施例235
3-(2-氟-5-甲基苯基)-5-[(3-甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(bs,1H),8.58(d,J=1.5Hz,1H),8.37(d,J=5.2Hz,1H),7.39(t,J=7.7Hz,1H),7.34~7.28(m,2H),7.07(t,J=9.2Hz,1H),7.00~6.94(m,3H),6.70(td,J=1.5Hz,5.2Hz,1H),3.90(s,2H),3.83(s,3H),2.37(s,3H)。
Mass,m/e:418(M+),148(base)。
实施例236
5-[(2,3-二甲氧基苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.54(bs,1H),8.60(d,J=1.7Hz,1H),8.36(d,J=5.6Hz,1H),7.33~7.28(m,2H),7.14(t,J=8.1Hz,1H),7.06(t,J=9.3Hz,1H),7.00(dd,J=1.4Hz,8.1Hz,1H),6.96(dd,J=1.4Hz,7.7Hz,1H),6.69(td,J=1.7Hz,5.6Hz,1H),3.91(s,2H),3.89(s,3H),3.88(s,3H),2.37(s,3H)。
Mass,m/e:448(M+),178(base)。
实施例237
5-[(2,5-二甲氧基苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(bs,1H),8.56(J=1.5Hz,1H),8.36(d,J=5.4Hz,1H),7.33~7.29(m,2H),7.07(t,J=8.9Hz,1H),6.96~6.90(m,3H),6.70(td,J=1.5Hz,5.4Hz,1H),3.86(s,2H),3.81(s,3H),3.77(s,3H),2.37(s,3H)。
Mass,m/e:448(M+),178(base)。
实施例238
3-(2-氟-5-甲基苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.40(d,J=1.3Hz,1H),8.35(d,J=5.4Hz,1H),7.41~7.28(m,6H),7.07(t,J=8.9Hz,1H),6.68(td,J=1.3Hz,5.4Hz,1H),3.92(s,2H),2.37(s,3H),2.36(s,3H)。
Mass,m/e:402(M+),254(base)。
实施例239
5-[(2,5-二甲基苯基)乙酰氨基]-3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(bs,1H),8.37~8.35(m,2H),7.34~7.28(m,2H),7.20(t,J=8.1Hz,2H),7.15(s,1H),7.07(t,J=9.2Hz,1H),6.69(td,J=1.9Hz,5.8Hz,1H),3.88(s,2H),2.38(s,3H),2.37(s,3H),2.31(s,3H)。
Mass,m/e:416(M+),254(base)。
实施例240
3-(2-氟-5-甲基苯基)-4-(4-嘧啶基)-5-[(2-三氟甲基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.45(bs,1H),8.55(s,1H),8.39(d,J=5.6Hz,1H),7.81(d,J=8.1Hz,1H),7.67(t,J=7.7Hz,1H),7.58(d,J=6.9Hz,1H),7.55(d,J=7.7Hz,1H),7.35~7.29(m,2H),7.08(t,J=9.3Hz,1H),6.73(td,J=1.9Hz,5.6Hz,1H),4.12(s,2H),2.38(s,3H)。
Mass,m/e:456(M+),254(base)。
实施例241
3-(3-甲基-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.5Hz,1H),8.32(d,J=5.4Hz,1H),7.37(dd,J=7.3Hz,1.6Hz,1H),7.32~7.28(m,1H),7.13(t,J=8.5Hz,1H),6.89(bs,2H),6.73(dd,J=1.2Hz,5.4Hz,1H),2.33(d,J=1.5Hz,3H)。
Mass,m/e:270(M+),125(base)。
b:3-(3-甲基-4-氟苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(bs,1H),8.48(s,1H),8.35(d,J=5.8Hz,1H),7.51~7.39(m,4H),7.34~7.30(m,1H),7.26~7.21(m,2H),7.11(t,J=8.5Hz,1H),6.76(dd,J=1.5Hz,5.8Hz,1H),3.93(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:388(M+),91(base)。
实施例242
5-[(2-氟苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(bs,1H),8.61(s,1H),8.38(d,J=5.8Hz,1H),7.46~7.40(m,3H),7.32(dd,J=1.9Hz,7.3Hz,1H),7.28~7.17(m,2H),7.12(t,J=8.5Hz,1H),6.78(dd,J=1.5Hz,5.8Hz,1H),3.96(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:406(M+),254(base)。
实施例243
5-[(3-氟苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(bs,1H),8.65(s,1H),8.39(d,J=5.6Hz,1H),7.47~7.40(m,2H),7.32(dd,J=1.9Hz,7.3Hz,1H),7.28~7.17(m,3H),7.12(t,J=8.5Hz,1H),6.78(dd,J=1.5Hz,5.6Hz,1H),3.96(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:406(M+),254(base)。
实施例244
5-[(2-氯苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(bs,1H),8.53(s,1H),8.37(d,J=5.6Hz,1H),7.54~7.51(m,1H),7.48~7.45(m,1H),7.42~7.39(m,2H),7.32(d,J=7.3Hz,1H),7.26~7.22(m,1H),7.12(t,J=8.9Hz,1H),6.77(dd,J=1.6Hz,5.6Hz,1H),4.06(s,2H),2.31(d,J=1.5Hz,3H)。
Mass,m/e:422(M+),254(base)。
实施例245
5-[(2-溴苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(bs,1H),8.51(s,1H),8.37(d,J=5.8Hz,1H),7.71(d,J=8.1Hz,1H),7.49~7.43(m,2H),7.35~7.31(m,2H),7.26~7.22(m,1H),7.12(t,J=8.9Hz,1H),6.77(dd,J=1.6Hz,5.8Hz,1H),4.08(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:468(M+),254(base)。
实施例246
5-[(2-碘苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(bs,1H),8.50(s,1H),8.37(d,J=5.4Hz,1H),8.00(d,J=7.7Hz,1H),7.49~7.46(m,2H),7.32(d,J=6.9Hz,1H),7.26~7.22(m,1H),7.18~7.10(m,2H),6.76(dd,J=1.2Hz,5.4Hz,1H),4.09(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:514(M+),254(base)。
实施例247
5-[(2,4-二氟苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.59(s,1H),8.79(s,1H),8.42(d,J=5.4Hz,1H),7.39(t,J=6.6Hz,8.5Hz,1H),7.33(dd,J=1.9Hz,7.3Hz,1H),7.29~7.24(m,1H),7.13(t,J=8.9Hz,1H),7.00~6.91(m,2H),6.82(dd,J=1.2Hz,5.4Hz,1H),3.97(s,2H),2.32(d,J=1.9Hz,3H)。
Mass,m/e:424(M+),254(base)。
实施例248
5-[(2,5-二氟苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.62(bs,1H),8.79(s,1H),8.42(d,J=5.4Hz,1H),7.33(dd,J=1.5Hz,7.3Hz,1H),7.28~7.24(m,1H),7.17~7.06(m,4H),6.82(dd,J=1.6Hz,5.4Hz,1H),3.94(s,2H),2.32(d,J=1.5Hz,3H)。
Mass,m/e:424(M+),254(base)。
实施例249
5-[(2-氯-4-氟苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(bs,1H),8.71(s,1H),8.41(d,J=5.6Hz,1H),7.45(dd,J=6.2Hz,8.9Hz,1H),7.33(dd,J=1.9Hz,7.3Hz,1H),7.28~7.23(m,2H),7.15~7.09(m,2H),6.81(dd,J=1.5Hz,5.6Hz,1H),4.03(s,2H),2.32(d,J=1.9Hz,3H)。
Mass,m/e:440(M+),254(base)。
实施例250
5-[(2-氯-6-氟苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.55(bs,1H),8.63(s,1H),8.40(d,J=5.4Hz,1H),7.42~7.32(m,3H),7.27~7.23(m,1H),7.18~7.11(m,2H),6.80(dd,J=1.2Hz,5.4Hz,1H),4.14(s,2H),2.32(d,J=1.9Hz,3H)。
Mass,m/e:440(M+),254(base)。
实施例251
5-[(2,6-二氯苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.60(s,1H),8.39(d,J=5.6Hz,1H),7.48(d,J=8.1Hz,2H),7.37~7.32(m,2H),7.27~7.23(m,1H),7.13(t,J=9.3Hz,1H),6.80(dd,J=1.5Hz,5.6Hz,1H),4.31(s,2H),2.32(d,J=1.9Hz,3H)。
Mass,m/e:456(M+),254(base)。
实施例252
5-[(2-甲氧基苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.34(bs,1H),8.45(d,J=1.4Hz,1H),8.34(d,J=5.6Hz,1H),7.45(dt,J=1.9Hz,8.1Hz,1H),7.35~7.30(m,2H),7.24~7.20(m,1H),7.13~7.06(m,2H),6.99(d,J=8.1Hz,1H),6.73(dd,J=1.4Hz,5.6Hz,1H),3.88(s,2H),3.80(s,3H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:418(M+),148(base)。
实施例253
5-[(3-甲氧基苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.41(s,1H),8.59(s,1H),8.36(d,J=5.8Hz,1H),7.39(t,J=8.1Hz,1H),7.31(d,J=7.0Hz,1H),7.25~7.22(m,1H),7.11(t,J=9.3Hz,1H),6.98~6.94(m,3H),6.76(dd,J=1.2Hz,5.8Hz,1H),3.89(s,2H),3.83(s,3H),2.31(s,3H)。
Mass,m/e:418(M+),254(base)。
实施例254
5-[(2,3-二甲氧基苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(bs,1H),8.60(d,J=1.4Hz,1H),8.39(d,J=5.6Hz,1H),7.31(dd,J=1.9Hz,6.9Hz,1H),7.24~7.21(m,1H),7.16~7.09(m,2H),7.00(dd,J=1.5Hz,8.1Hz,1H),6.95(dd,J=1.5Hz,7.7Hz,1H),6.74(dd,J=1.4Hz,5.6Hz,1H),3.90(s,2H),3.89(s,3H),3.88(s,3H),2.31(s,3H)。
Mass,m/e:448(M+),178(base)。
实施例255
5-[(2,5-二甲氧基苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.35(bs,1H),8.57(d,J=1.4Hz,1H),8.35(d,J=5.4Hz,1H),7.32(dd,J=1.5Hz,6.9Hz,1H),7.25~7.21(m,1H),7.11(t,J=8.5Hz,1H),6.96~6.91(m,3H),6.75(dd,J=1.4Hz,5.4Hz,1H),3.85(s,2H),3.81(s,3H),3.76(s,3H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:448(M+),178(base)。
实施例256
5-[(3,5-二甲氧基苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(bs,1H),8.69(d,J=1.5Hz,1H),8.37(d,J=5.8Hz,1H),7.31(dd,J=1.9Hz,7.3Hz,1H),7.25~7.21(m,1H),7.12(t,J=8.9Hz,1H),6.76(dd,J=1.5Hz,5.8Hz,1H),6.53(d,J=2.3Hz,2H),6.50(t,J=2.3Hz,1H),3.84(s,2H),3.81(s,6H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:448(M+),178(base)。
实施例257
3-(3-甲基-4-氟苯基)-5-[(2-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.35(bs,1H),8.41(d,J=1.4Hz,1H),8.34(d,J=5.4Hz,1H),7.41~7.30(m,5H),7.24~7.20(m,1H),7.11(t,J=9.3Hz,1H),6.74(dd,J=1.4Hz,5.4Hz,1H),3.92(s,2H),2.35(s,3H),2.30(d,J=1.9Hz,3H)。
Mass,m/e:402(M+),254(base)。
实施例258
3-(3-甲基-4-氟苯基)-5-[(3-甲基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.37(bs,1H),8.48(s,1H),8.35(d,J=5.6Hz,1H),7.37(t,J=7.3Hz,1H),7.31(d,J=7.3Hz,1H),7.27~7.18(m,4H),7.11(t,J=8.9Hz,1H),6.76(dd,J=1.2Hz,5.6Hz,1H),3.88(s,2H),2.39(s,3H),2.31(s,3H)。
Mass,m/e:402(M+),254(base)。
实施例259
5-[(2,5-二甲基苯基)乙酰氨基]-3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.32(bs,1H),8.38(d,J=1.2Hz,1H),8.35(d,J=5.6Hz,1H),7.31(dd,J=1.5Hz,7.3Hz,1H),7.24~7.20(m,3H),7.15(s,1H),7.11(t,J=8.9Hz,1H),6.74(dd,J=1.2Hz,5.6Hz,1H),3.87(s,2H),2.38(s,3H),2.31(s,3H),2.31(s,3H)。
Mass,m/e:416(M+),254(base)。
实施例260
3-(3-甲基-4-氟苯基)-5-[(2-硝基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.67(bs,1H),8.88(s,1H),8.43(d,J=5.8Hz,1H),8.20(d,J=8.5Hz,1H),7.72(t,J=7.7Hz,1H),7.58(t,J=7.7Hz,2H),7.35(d,J=7.3Hz,1H),7.29~7.25(m,1H),7.14(t,J=8.9Hz,1H),6.83(dd,J=1.5Hz,5.8Hz,1H),4.31(s,2H),2.33(d,J=1.5Hz,3H)。
Mass,m/e:433(M+),254(base)。
实施例261
3-(3-甲基-4-氟苯基)-4-(4-嘧啶基)-5-[(2-三氟甲基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.38(bs,1H),8.57(s,1H),8.38(d,J=5.4Hz,1H),7.81(d,J=8.1Hz,1H),7.66(t,J=6.9Hz,1H),7.58~7.54(m,2H),7.32(dd,J=1.5Hz,6.9Hz,1H),7.26~7.22(m,1H),7.12(t,J=8.9Hz,1H),6.78(dd,J=1.5Hz,5.4Hz,1H),4.12(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:456(M+),254(base)。
实施例262
3-(3-氟-4-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-氟-4-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.4Hz,1H),8.32(d,J=5.8Hz,1H),7.32(t,J=8.1Hz,1H),7.20~7.17(m,2H),6.87(bs,2H),6.75(dd,J=1.4Hz,5.8Hz,1H),2.46(s,3H)。
Mass,m/e:270(M+),125(base)。
b:3-(3-氟-4-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.39(bs,1H),8.49(s,1H),8.37(d,J=5.4Hz,1H),7.51~7.39(m,5H),7.30(t,J=7.1Hz,1H),7.13(d,J=9.3Hz,2H),6.78(dd,J=1.5Hz,5.4Hz,1H),3.93(s,2H),2.35(d,J=1.5Hz,3H)。
Mass,m/e:388(M+),254(base)。
实施例263
3-(3-氟-4-甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.61(s,1H),8.40(d,J=5.4Hz,1H),7.46~7.40(m,2H),7.39~7.13(m,5H),6.82(dd,J=1.5Hz,5.4Hz,1H),3.96(d,J=0.8Hz,2H),2.36(d,J=1.6Hz,3H)。
Mass,m/e:406(M+),109(base)。
实施例264
5-[(2-氯苯基)乙酰氨基]-3-(3-氟-4-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.53(s,1H),8.38(d,J=5.4Hz,1H),7.54~7.51(m,1H),7.48(m,1H),7.42~7.39(m,1H),7.33(t,J=7.7Hz,2H),7.15~7.13(m,2H),6.81(dd,J=1.2Hz,5.4Hz,1H),4.06(s,2H),2.35(d,J=1.9Hz,3H)。
Mass,m/e:422(M+),254(base)。
实施例265
3-(4-氯-3-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-氯-3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.02(d,J=1.5Hz,1H),8.33(d,J=5.8Hz,1H),7.48(d,J=8.1H,1H),7.41(d,J=1.9Hz,1H),7.28(dd,J=1.5Hz,8.1Hz,1H),6.86(bs,2H),6.74(dd,J=1.5Hz,5.8Hz,1H),2.43(s,3H)。
Mass,m/e:286(M+),141(base)。
b:3-(4-氯-3-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.49(s,1H),8.37(d,J=5.7Hz,1H),7.51~7.36(m,7H),7.20(dd,J=1.5Hz,8.1Hz,1H),6.76(dd,J=1.5Hz,5.7Hz,1H),3.97(s,2H),2.39(s,3H)。
Mass,m/e:404(M+),91(base)。
实施例266
3-(4-氯-3-甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.61(s,1H),8.40(d,J=5.8Hz,1H),7.48~7.37(m,5H),7.28~7.18(m,2H),6.80(dd,J=1.5Hz,5.8Hz,1H),3.96(s,2H),2.42(s,3H)。
Mass,m/e:422(M+),109(base)。
实施例267
5-[(2-氯苯基)乙酰氨基]-3-(4-氯-3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.53(s,1H),8.39(d,J=5.4Hz,1H),7.54~7.36(m,6H),7.21(dd,J=1.9Hz,8.1Hz,1H),6.79(dd,J=1.5Hz,5.4Hz,1H),4.07(s,2H),2.42(s,3H)。
Mass,m/e:438(M+),270(base)。
实施例268
3-(4-甲氧基-3-甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-甲氧基-3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(bs,1H),8.31(d,J=5.4Hz,1H),7.32~7.29(m,2H),6.92(d,J=8.1Hz,1H),6.83~6.81(m,3H),3.90(s,3H),2.26(s,3H)。
Mass,m/e:282(M+),137(base)。
b:3-(4-甲氧基-3-甲基苯基)-5-(苯基基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.40(s,1H),8.48(s,1H),8.34(d,J=5.4Hz,1H),7.51~7.39(m,5H),7.23~7.22(m,1H),6.90(d,J=8.1Hz,1H),6.85(dd,J=1.5Hz,5.4Hz,1H),6.67(dt,J=1.5Hz,5.4Hz,1H),3.93(s,2H),3.89(s,3H),2.23(s,3H)。
Mass,m/e:400(M+),91(base)。
实施例269
5-[(2-氟苯基)乙酰氨基]-3-(4-甲氧基-3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.60(s,1H),8.37(d,J=5.4Hz,1H),7.45~7.40(m,2H),7.27~7.17(m,3H),6.91(d,J=8.1Hz,1H),6.80(dd,J=1.5Hz,5.8Hz,1H),6.67(dt,J=1.5Hz,5.4Hz,1H),4.00(s,2H),3.89(s,3H),2.24(s,3H)。
Mass,m/e:418(M+),109(base)。
实施例270
5-[(2-氯苯基)乙酰氨基]-3-(4-甲氧基-3-甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.46(s,1H),8.53(s,1H),8.36(d,J=5.8Hz,1H),7.54~7.39(m,4H),7.26~7.24(m,1H),6.91(d,J=8.5Hz,1H),6.87(dd,J=1.5Hz,5.8Hz,1H),6.67(dt,J=1.5Hz,5.4Hz,1H),4.06(s,2H),3.89(s,3H),2.24(s,3H)。
Mass,m/e:434(M+),121(base)。
实施例271
3-(2,3-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,3-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.97(d,J=1.5Hz,1H),8.22(d,J=5.6Hz,1H),7.31(d,J=7.3Hz,1H),7.22(d,J=7.3Hz,1H),7.15(d,J=9.3Hz,1H),6.93(bs,2H),6.33(dd,J=1.5Hz,5.6Hz,1H),2.35(s,3H),2.11(s,3H)。
Mass,m/e:266(M+),77(base)。
b:3-(2,3-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(bs,1H),8.45(s,1H),8.27(d,J=5.4Hz,1H),7.49~7.41(m,5H),7.31(d,J=7.3Hz,1H),7.20(t,J=7.3Hz,1H),7.10(d,J=6.9Hz,1H),6.39(dd,J=1.5Hz,5.4Hz,1H),3.95(s,2H),2.32(s,3H),2.02(s,3H)。
Mass,m/e:384(M+),94(base)。
实施例272
3-(2,3-二甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.67(bs,1H),8.57(s,1H),8.29(d,J=5.4Hz,1H),7.46(m,2H),7.32(d,J=7.7Hz,1H),7.28~7.18(m,3H),7.11(d,J=6.9Hz,1H),6.42(dd,J=1.2Hz,5.4Hz,1H),3.98(s,2H),2.33(s,6H),2.04(s,3H)。
Mass,m/e:402(M+),250(base)。
实施例273
3-(2,5-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,5-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.97(d,J=1.3Hz,1H),8.24(d,J=5.4Hz,1H),7.26~7.20(m,2H),7.15(s,1H),6.91(bs,2H),6.38(dd,J=1.3Hz,5.4Hz,1H),2.35(s,3H),2.15(s,3H)。
Mass,m/e:266(M+),77(base)。
b:3-(2,5-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(bs,1H),8.45(s,1H),8.28(d,J=5.8Hz,1H),7.51~7.41(m,5H),7.24~7.18(m,2H),7.08(bs,1H),6.42(dd,J=1.5Hz,5.8Hz,1H),3.95(s,2H),2.33(s,3H),2.06(s,3H)。
Mass,m/e:384(M+),91(base)。
实施例274
3-(2,5-二甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.66(bs,1H),8.57(s,1H),8.31(d,J=5.4Hz,1H),7.45~7.41(m,2H),7.28~7.17(m,4H),7.09(bs,1H),6.45(dd,J=1.5Hz,5.4Hz,1H),3.98(s,2H),2.33(s,3H),2.07(s,3H)。
Mass,m/e:402(M+),109(base)。
实施例275
5-[(2-氯苯基)乙酰氨基]-3-(2,5-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.54(bs,1H),8.50(s,1H),8.30(d,J=5.4Hz,1H),7.54~7.52(m,1H),7.50~7.46(m,1H),7.44~7.38(m,2H),7.22~7.19(m,2H),7.09(bs,1H),6.45(dd,J=1.6Hz,5.4Hz,1H),4.08(s,2H),2.33(s,3H),2.07(s,3H)。
Mass,m/e:418(M+),250(base)。
实施例276
3-(2,6-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2,6-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.97(d,J=1.2Hz,1H),8.21(d,J=5.6Hz,1H),7.31(t,J=7.5Hz,1H),7.16(d,J=7.5Hz,2H),6.96(bs,2H),6.21(dd,J=1.2Hz,5.6Hz,1H),2.15(s,6H)。
Mass,m/e:266(M+),77(base)。
b:3-(2,6-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.54(bs,1H),8.45(s,1H),8.26(d,J=5.4Hz,1H),7.52~7.43(m,5H),7.31(t,J=7.5Hz,1H),7.14(d,J=7.5Hz,2H),6.26(dd,J=1.6Hz,5.4Hz,1H),3.96(s,2H),2.06(s,6H)。
Mass,m/e:384(M+),91(base)。
实施例277
3-(2,6-二甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.71(s,1H),8.56(s,1H),8.29(d,J=5.6Hz,1H),7.47~7.41(m,2H),7.33~7.19(m,3H),7.15(d,J=7.7Hz,2H),6.29(td,J=1.5Hz,5.6Hz,1H),3.99(s,2H),2.07(s,6H)。
Mass,m/e:402(M+),250(base)。
实施例278
5-[(2-氯苯基)乙酰氨基]-3-(2,6-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.50(s,1H),8.28(d,J=5.6Hz,1H),7.55~7.53(m,1H),7.51~7.49(m,1H),7.44~7.39(m,2H),7.31(t,J=7.5Hz,1H),7.15(d,J=7.5Hz,2H),6.28(td,J=1.2Hz,5.6Hz,1H),4.09(s,2H),2.07(s,6H)。
Mass,m/e:418(M+),250(base)。
实施例279
3-(3,4-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,4-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.01(d,J=1.3Hz,1H),8.29(d,J=5.7Hz,1H),7.34~7.12(m,3H),7.00~6.70(m,3H),2.35(s,3H),2.32(s,3H)。
Mass,m/e:266(M+),121(base)。
b:3-(3,4-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(s,1H),8.48(bs,1H),8.33(d,J=5.4Hz,1H),7.51~7.39(m,5H),7.24~7.22(m,2H),7.16~7.14(m,1H),6.85(dd,J=1.4Hz,5.4Hz,1H),4.07(s,2H),2.34(s,3H),2.29(s,3H)。
Mass,m/e:384(M+),91(base)。
实施例280
3-(3,4-二甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.59(s,1H),8.60(bs,1H),8.36(d,J=5.4Hz,1H),7.45~7.40(m,2H),7.27~7.16(m,5H),6.82(dd,J=1.5.Hz,5.4Hz,1H),3.97(s,2H),2.38(s,3H),2.34(s,3H)。
Mass,m/e:402(M+),109(base)。
实施例281
5-[(2-氯苯基)乙酰氨基]-3-(3,4-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.47(s,1H),8.52(bs,1H),8.35(d,J=5.4Hz,1H),7.54~7.52(m,1H),7.49~7.46(m,1H),7.43~7.38(m,2H),7.25~7.23(m,2H),7.17~7.15(m,1H),6.84(dd,J=1.4Hz,5.4Hz,1H),4.07(s,2H),2.34(s,3H),2.29(s,3H)。
Mass,m/e:418(M+),250(base)。
实施例282
3-(3,5-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3,5-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.00(d,J=1.4Hz,1H),8.28(d,J=5.8Hz,1H),7.14(s,1H),7.11(s,2H),6.88(bs,2H),6.75(dd,J=1.4Hz,5.8Hz,1H),2.34(s,6H)。
Mass,m/e:266(M+),121(base)。
b:3-(3,5-二甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.48(s,1H),8.33(d,J=5.6Hz,1H),7.48~7.39(m,5H),7.14(s,1H),7.04(s,2H),6.78(dd,J=1.5Hz,5.6Hz,1H),3.93(s,2H),2.34(s,6H)。
Mass,m/e:384(M+),250(base)。
实施例283
3-(3,5-二甲基苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.60(s,1H),8.60(s,1H),8.36(d,J=5.4Hz,1H),7.46~7.40(m,2H),7.27~7.23(m,1H),7.19~7.17(m,1H),7.15(s,1H),7.06(s,2H),6.81(dd,J=1.2Hz,5.4Hz,1H),3.96(d,J=0.8Hz,2H),2.34(s,6H)。
Mass,m/e:402(M+),250(base)。
实施例284
5-[(2-氯苯基)乙酰氨基]-3-(3,5-二甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.48(s,1H),8.52(s,1H),8.34(d,J=5.6Hz,1H),7.53(m,1H),7.48(m,1H),7.41~7.39(m,2H),7.15(s,1H),7.05(s,2H),6.80(dd,J=1.5Hz,5.6Hz,1H),4.08(s,2H),2.34(s,6H)。
Mass,m/e:418(M+),250(base)。
实施例285
3-(4-联苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(4-联苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.5Hz,1H),8.32(d,J=5.4Hz,1H),7.75~7.38(m,9H),6.88(bs,2H),6.84(dd,J=1.5Hz,5.4Hz,1H)。
Mass,m/e:314(M+),169(base)。
b:3-(4-联苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(s,1H),8.51(s,1H),8.37(d,J=5.8Hz,1H),7.73~7.71(m,2H),7.65~7.63(m,2H),7.55~7.38(m,10H),6.87(dd,J=1.5Hz,5.8Hz,1H),3.95(s,2H)。
Mass,m/e:432(M+),298(base)。
实施例286
3-(4-联苯基)-5-[(2-氟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.61(s,1H),8.63(s,1H),8.40(d,J=5.4Hz,1H),7.74~7.72(m,2H),7.66~7.64(m,2H),7.57~7.54(m,2H),7.50~7.38(m,5H),7.29~7.18(m,2H),6.89(dd,J=1.5Hz,5.4Hz,1H),3.98(s,2H)。
Mass,m/e:450(M+),298(base)。
实施例287
3-(4-联苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.49(s,1H),8.55(s,1H),8.38(d,J=5.8Hz,1H),7.75~7.72(m,2H),7.66~7.64(m,2H),7.56~7.38(m,9H),6.90(dd,J=1.5Hz,5.8Hz,1H),4.08(s,2H)。
Mass,m/e:466(M+),298(base)。
实施例288
5-[(2-氯苯基)乙酰氨基]-3-(2-氟-3-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氟-3-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(d,J=1.7Hz,1H),8.34(d,J=5.2Hz,1H),7.83(t,J=7.7Hz,1H),7.75(t,J=7.7Hz,1H),7.43(t,J=7.7Hz,1H),6.98(bs,2H),6.53(td,J=1.7Hz,5.2Hz,1H)。
Mass,m/e:324(M+),179(base)。
b:5-[(2-氯苯基)乙酰氨基]-3-(2-氟-3-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.54(d,J=1.5Hz,1H),8.41(d,J=5.2Hz,1H),7.84(t,J=8.1Hz,1H),7.75(t,J=7.7Hz,1H),7.54~7.40(m,5H),6.60(td,J=1.5Hz,5.2Hz,1H),4.07(s,2H)。
Mass,m/e:476(M+),351(base)。
实施例289
5-[(2-氯苯基)乙酰氨基]-3-(2-氟-4-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氟-4-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.04(s,1H),8.37(d,J=5.6Hz,1H),7.69(t,J=7.7Hz,1H),7.60(t,J=8.1Hz,1H),7.52(d,J=9.3Hz,1H),6.94(bs,2H),6.56(td,J=5.6Hz,1H)。
Mass,m/e:324(M+),52(base)。
b:5-[(2-氯苯基)乙酰氨基]-3-(2-氟-4-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.55(d,J=1.5Hz,1H),8.43(d,J=5.4Hz,1H),7.69(t,J=7.7Hz,1H),7.61(d,J=8.1Hz,1H),7.54~7.40(m,5H),6.63(td,J=5.4Hz,1H),4.10(s,2H)。
Mass,m/e:476(M+),308(base)。
实施例290
5-[(2-氯苯基)乙酰氨基]-3-(2-氟-5-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-氟-5-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(DMSO-d6)δ:8.98(d,J=1.5Hz,1H),8.43(d,J=5.6Hz,1H),8.37(bs,2H),8.10(m,1H),8.02(dd,J=2.3Hz,6.2Hz,1H),7.69(t,J=9.3Hz,1H),6.59(td,J=1.5Hz,5.6Hz,1H)。
Mass,m/e:324(M+),179(base)。
b:5-[(2-氯苯基)乙酰氨基]-3-(2-氟-5-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.50(s,1H),8.55(d,J=1.5Hz,1H),8.42(d,J=5.4Hz,1H),7.87~7.83(m,2H),7.55~7.52(m,1H),7.49~7.47(m,1H),7.43~7.40(m,2H),7.35(t,J=9.3Hz,1H),6.62(td,J=1.5Hz,5.4Hz,1H),4.08(s,2H)。
Mass,m/e:476(M+),308(base)。
实施例291
3-(3-氟-5-三氟甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(3-氟-5-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.05(d,J=1.4Hz,1H),8.37(d,J=5.6Hz,1H),7.62(s,1H),7.51(d,J=8.1Hz,1H),7.46(d,J=8.5Hz,1H),7.00(bs,2H),6.65(dd,J=1.4Hz,5.6Hz,1H)。
Mass,m/e:324(M+),59(base)。
b:3-(3-氟-5-三氟甲基苯基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.38(s,1H),8.52(d,J=1.4Hz,1H),8.42(d,J=5.6Hz,1H),7.56(s,1H),7.53~7.39(m,7H),6.68(dd,J=1.4Hz,5.6Hz,1H),3.94(s,2H)。
Mass,m/e:442(M+),91(base)。
实施例292
5-[(2-氟苯基)乙酰氨基]-3-(3-氟-5-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.57(s,1H),8.65(d,J=1.4Hz,1H),8.44(d,J=5.8Hz,1H),7.57(s,1H),7.52(d,J=8.1Hz,1H),7.47~7.41(m,3H),7.28(d,J=7.3Hz,1H),7.20(t,J=9.6Hz,1H),6.71(dd,J=1.4Hz,5.8Hz,1H),3.97(s,2H)。
Mass,m/e:460(M+),109(base)。
实施例293
5-[(2-氯苯基)乙酰氨基]-3-(3-氟-5-三氟甲基苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.44(s,1H),8.56(d,J=1.2Hz,1H),8.43(d,J=5.4Hz,1H),7.57(s,1H),7.55~7.41(m,6H),6.70(dd,J=1.2Hz,5.4Hz,1H),4.07(s,2H)。
Mass,m/e:476(M+),308(base)。
实施例294
3-(1-萘基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(1-萘基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:8.97(d,J=1.5Hz,1H),8.05~8.00(m,2H),7.95(d,J=8.1Hz,1H),7.73(d,J=8.1Hz,1H),7.62~7.58(m,2H),7.55~7.50(m,1H),7.45~7.41(m,1H),7.00(bs,2H),6.06(dd,J=1.5Hz,5.8Hz,1H)。
Mass,m/e:288(M+),143(base)。
b:3-(1-萘基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.58(s,1H),8.44(s,1H),8.06~8.03(m,2H),7.93(d,J=8.5Hz,1H),7.60~7.37(m,10H),6.10(dd,J=1.5Hz,5.4Hz,1H),3.99(s,2H)。
Mass,m/e:406(M+),91(base)。
实施例295
5-[(2-氟苯基)乙酰氨基]-3-(1-萘基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.76(s,1H),8.56(s,1H),8.08(d,J=5.4Hz,1H),8.04(dd,J=2.3Hz,7.3Hz,1H),7.94(d,J=8.5Hz,1H),7.61~7.20(m,9H),6.13(dd,J=1.5Hz,5.6Hz,1H),4.02(s,2H)。
Mass,m/e:424(M+),109(base)。
实施例296
5-[(2-氯苯基)乙酰氨基]-3-(1-萘基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.63(s,1H),8.49(s,1H),8.07~8.03(m,2H),7.94(d,J=8.1Hz,1H),7.61~7.38(m,9H),6.12(dd,J=1.5Hz,5.6Hz,1H),4.12(s,2H)。
Mass,m/e:440(M+),127(base)。
实施例297
3-(2-萘基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
a:5-氨基-3-(2-萘基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:9.03(s,1H),8.23(d,J=5.8Hz,1H),8.07(s,1H),7.98(d,J=8.5Hz,1H),7.94~7.89(m,2H),7.62~7.55(m,3H),6.90(bs,2H),6.72(dd,J=1.2Hz,5.8Hz,1H)。
Mass,m/e:288(M+),127(base)。
b:3-(2-萘基)-5-(苯基乙酰氨基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.45(s,1H),8.50(s,1H),8.27(d,J=5.4Hz,1H),8.01(s,1H),7.96(d,J=8.5Hz,1H),7.93~7.87(m,2H),7.62~7.55(m,2H),7.52~7.42(m,6H),6.74(dd,J=1.4Hz,5.4Hz,1H),3.96(s,2H)。
Mass,m/e:406(M+),108(base)。
实施例298
5-[(2-氟苯基)乙酰氨基]-3-(2-萘基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.63(s,1H),8.62(s,1H),8.30(d,J=5.4Hz,1H),8.03(s,1H),7.98~7.88(m,3H),7.62~7.55(m,2H),7.49(dd,J=1.5Hz,8.5Hz,1H),7.47~7.42(m,2H),7.29~7.18(m,2H),6.78(dd,J=1.5Hz,5.4Hz,1H),4.00(s,2H)。
Mass,m/e:424(M+),109(base)。
实施例299
5-[(2-氯苯基)乙酰氨基]-3-(2-萘基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.51(s,1H),8.55(s,1H),8.29(d,J=5.4Hz,1H),8.03(s,1H),7.97(d,J=8.5Hz,1H),7.93~7.87(m,2H),7.62~7.39(m,7H),6.77(dd,J=1.5Hz,5.4Hz,1H),4.09(s,2H)。
Mass,m/e:440(M+),272(base)。
实施例300
3-(4-氟苯基)-5-[(2-甲氧基甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
a:(2-甲氧基甲氧基苯基)乙酸乙酯的合成
向0.6g 2’-羟苯基乙酸乙酯的30mL无水丙酮溶液中加入2g碳酸钾,室温下搅拌15分钟。接着冰冷却下滴入1.02mL甲氧基甲基氯,然后升温至室温,搅拌过夜。向反应溶液中加水,用醚萃取法萃取。用无水硫酸镁干燥醚萃取液,然后减压下馏去溶剂。将所得残余物用60g硅胶层析(洗脱溶剂,乙酸乙酯∶己烷=1∶3)纯化,得到0.69g(收率:93%)油状物的标题化合物。
1H-NMR(CDCl3)δ:7.31~6.86(m,4H),5.17(s,2H),4.15(q,J=7.1Hz,2H),3.64(s,2H),3.45(s,3H),1.24(t,J=7.1Hz,3H)。
Mass;m/e:224(M+),134(base)。
b:(2-甲氧基甲氧基苯基)乙酸的合成
向0.69g(2-甲氧基甲氧基苯基)乙酸乙酯的20mL甲醇溶液中加入16mL 1M氢氧化钠水溶液,室温下搅拌5小时。减压下馏去反应溶液中的溶剂,加入2M柠檬酸水溶液使溶液呈酸性,进行乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂,得到0.47g(收率:77%)油状物的标题化合物。
1H-NMR(CDCl3)δ:8.40~8.00(bs,1H),7.35~6.86(m,4H),5.18(s,2H),3.68(s,2H),3.44(s,3H)。
Mass;m/e:196(M+),134(base)。
c:3-(4-氟苯基)-5-[(2-甲氧基甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑的合成
将0.47g(2-甲氧基甲氧基苯基)乙酸和0.5g CDI溶解于16mLTHF,室温下搅拌2小时。接着,加入0.92g DBU、0.31g 5-氨基-3-(4-氟苯基)-4-嘧啶基异噁唑的16mL THF溶液,室温下搅拌21小时。减压下馏去反应溶液中的溶剂,向残余物中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用50g硅胶层析(洗脱溶剂,氯仿∶甲醇=100∶1)纯化,然后残余物用醚-己烷洗涤,得到0.32g(收率:60%)标题化合物。
1H-NMR(CDCl3)δ:11.38(bs,1H),8.44(d,J=1.5Hz,1H),8.35(d,J=5.6Hz,1H),7.47~7.41(m,3H),7.35(dd,J=1.5Hz,7.3Hz,1H),7.24~7.12(m,4H),6.72(dd,J=1.5Hz,5.6Hz,1H),5.18(s,2H),3.91(s,2H),3.32(s,3H)。
Mass,m/e:434(M+),240(base)。
实施例301
3-(4-氟苯基)-5-[(2-羟基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
将50mg 3-(4-氟苯基)-5-[(2-甲氧基甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑溶解于30mL二氯甲烷中,加入460mg固定于硅胶上的硫酸氢钠试剂,室温下搅拌4小时。向反应溶液中加入饱和碳酸氢钠水溶液,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,然后减压下馏去溶剂。用醚-己烷洗涤所得残余物,得到16mg(收率:34%)标题化合物。
1H-NMR(CDCl3)δ:11.60(bs,1H),8.73(s,1H),8.37(d,J=5.6Hz,1H),7.45(dd,J=5.4Hz,8.7Hz,2H),7.31~7.26(m,2H),7.19(t,J=8.7Hz,2H),7.00(dt,J=0.8Hz,7.3Hz,1H),6.93(d,J=8.1Hz,1H),6.76(dd,J=1.6Hz,5.6Hz,1H),3.92(s,2H)。
Mass,m/e:390(M+),78(base)。
实施例302
3-(4-氟苯基)-5-[(3-甲氧基甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
与实施例300进行同样的操作,合成标题化合物。
1H-NMR(CDCl3)δ:11.42(bs,1H),8.61(d,J=1.3Hz,1H),8.37(d,J=5.6Hz,1H),7.48~7.43(m,2H),7.39(t,J=7.7Hz,1H),7.22~7.17(m,2H),7.12(dd,J=1.9Hz,8.5Hz,1H),7.70(t,J=1.9Hz,1H),7.03(d,J=7.7Hz,1H),6.73(dd,J=1.3Hz,5.6Hz,1H),5.19(s,2H),3.89(s,2H),3.45(s,3H)。
Mass,m/e:434(M+),240(base)。
实施例303
3-(4-氟苯基)-5-[(3-羟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
与实施例301进行同样的操作,合成标题化合物。
1H-NMR(DMSO-d6)δ:11.36(bs,1H),9.48(s,1H),8.93(d,J=1.5Hz,1H),8.59(d,J=5.4Hz,1H),7.58~7.54(m,2H),7.37~7.33(m,2H),7.19(t,J=7.7Hz,1H),6.94(dd,J=1.5Hz,5.4Hz,1H),6.80~6.78(m,2H),6.76~6.73(m,1H),3.73(s,2H)。
Mass,m/e:390(M+),240(base)。
实施例304
3-(4-氟苯基)-5-[(4-甲氧基甲氧基苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
与实施例300同样地操作,合成标题化合物。
1H-NMR(CDCl3)δ:11.40(bs,1H),8.58(s,1H),8.37(d,J=5.6Hz,1H),7.47~7.43(m,2H),7.32~7.30(m,2H),7.22~7.12(m,4H),6.73(dd,J=1.6Hz,5.6Hz,1H),5.23(s,2H),3.87(s,2H),3.52(s,3H)。
Mass,m/e:434(M+),178(base)。
实施例305
3-(4-氟苯基)-5-[(4-羟苯基)乙酰氨基]-4-(4-嘧啶基)异噁唑
与实施例301同样地操作,合成标题化合物。
1H-NMR(DMSO-d6)δ:11.31(bs,1H),9.42(s,1H),8.87(d,J=1.5Hz,1H),8.59(d,J=5.4Hz,1H),7.56(dd,J=5.8Hz,8.9Hz,2H),7.35(t,J=8.9Hz,2H),7.17(d,J=8.5Hz,2H),6.93(dd,J=1.5Hz,5.4Hz,1H),6.79(d,J=8.5Hz,2H),3.70(s,2H)。
Mass,m/e:390(M+),107(base)。
实施例306
5-[(4-氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
a:4-叔丁氧基羰基氨基苯基乙酸乙酯的合成
向1.94g 4-氨基苯基乙酸乙酯的23mL DMF溶液中加入0.15gDMAP、4.6mL三乙胺和3g二碳酸二叔丁酯,室温下搅拌15小时。向反应溶液中加水,用乙醚萃取。用无水硫酸镁干燥乙醚萃取液,然后减压下馏去溶剂。将所得残余物用200g硅胶层析(洗脱溶剂,乙酸乙酯∶己烷=1∶5)纯化,得到0.70g(收率:17%)油状物的标题化合物。
1H-NMR(CDCl3)δ:7.29(d,J=8.4Hz,2H),7.19(d,J=8.4Hz,2H),6.44(bs,1H),4.12(q,J=7.3Hz,2H),3.53(s,2H),1.50(s,9H),1.22(t,J=7.3Hz,3H)。
Mass,m/e:279(M+),57(base)。
b:5-[(4-叔丁氧基羰基氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑的合成
向0.7g 4-叔丁氧基羰基氨基苯基乙酸乙酯的20mL甲醇溶液中加入13mL 1M氢氧化钠水溶液,室温下搅拌24小时。减压下浓缩反应溶液,加入2M柠檬酸水溶液,使溶液呈酸性。冰冷却下,滤取析出的结晶,得到淡黄色结晶的0.40g 4-叔丁氧基羰基氨基苯基乙酸。将本化合物溶解于13mL THF,加入0.40g CDI,室温下搅拌2小时。接着,加入0.71g DBU、0.26g 5-氨基-3-(4-氟苯基)-4-嘧啶基异噁唑的13mL THF溶液,室温下搅拌过夜。减压下馏去反应溶液中的溶剂,向残余物中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用30g硅胶层析(洗脱溶剂,氯仿∶甲醇=100∶1)纯化,然后用乙醚-己烷洗涤结晶残余物,得到0.364g(收率:46%)标题化合物。
1H-NMR(CDCl3)δ:11.41(bs,1H),8.61(d,1H),8.37(d,J=5.6Hz,1H),7.49~7.44(m,4H),7.32~7.30(m,2H),7.22~7.17(m,2H),6.73(dd,J=1.2Hz,5.6Hz,1H),6.59(bs,1H),3.86(s,2H),1.52(s,9H)。
Mass,m/e:489(M+),57(base)。
c:5-[(4-氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑的合成
冰冷却下向59mg 5-[(4-叔丁氧基羰基氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑中加入1mL TFA,然后升温至室温,搅 拌20分钟。冰冷却下,用饱和碳酸氢钠水溶液中和反应溶液,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,然后减压下馏去溶剂。将所得残余物用二乙醚-己烷洗涤,得到24mg(收率:51%)标题化合物。
1H-NMR(CDCl3)δ:11.41(bs,1H),8.62(s,1H),8.36(d,J=5.6Hz,1H),7.47~7.44(m,2H),7.20(d,J=8.5Hz,2H),7.15(d,J=8.5Hz,2H),6.75(d,J=8.5Hz,2H),6.72(dd,J=1.5Hz,5.6Hz,1H),3.79(s,2H)。
Mass,m/e:389(M+),133(base)。
实施例307
5-[(3-氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
与实施例306同样地操作,合成标题化合物。
a:5-[(3-叔丁氧基羰基氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.43(bs,1H),8.62(d,J=1.2Hz,1H),8.36(d,J=5.4Hz,1H),7.63(s,1H),7.47~7.43(m,2H),7.37(t,J=8.1Hz,1H),7.28~7.26(m,1H),7.22~7.16(m,2H),7.06(d,J=7.7Hz,1H),6.72(dd,J=1.2Hz,5.4Hz,1H),6.58(bs,1H),3.89(s,2H),1.50(s,9H)。
Mass,m/e:489(M+),57(base)。
b:5-[(3-氨基苯基)乙酰氨基]-3-(4-氟苯基)-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.42(bs,1H),8.68(d,J=1.2Hz,1H),8.36(d,J=5.4Hz,1H),7.47~7.44(m,2H),7.27~7.17(m,3H),6.76~6.69(m,4H),3.81(s,2H)。
Mass,m/e:389(M+),133(base)。
实施例308
3-(4-氟苯基)-5-[2-(2-氯苯基)丙酰基氨基]-4-[4-嘧啶基]异噁唑
a:2-(2-氯苯基)丙酸的合成
冰冷却下,向1g 2-氯苯基乙酸中滴入8.8mL 2M的LDA庚烷、THF、乙基苯溶液,再加入1.58g HMPA和5mL THF,室温下搅拌1小时。接着,冰冷却下加入1.25g甲基碘,室温下搅拌30分钟。向反应溶液中注入冰水,加入10%盐酸水溶液使溶液呈酸性,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用30g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=20∶1)纯化,得到0.928g(收率:86%)淡黄色油状性物质的标题化合物。
1H-NMR(CDCl3)δ:7.50~7.10(m,4H),4.27(q,J=7.2Hz,1H),1.52(d,J=7.2Hz,3H)。
Mass,m/e:184(M+),139(base)。
b:3-(4-氟苯基)-5-[2-(2-氯苯基)丙酰基氨基]-4-[4-嘧啶基]异噁唑的合成
将0.144g 2-(2-氯苯基)丙酸和0.126g CDI溶解于5mL THF,室温下搅拌1小时。接着,加入0.237g DBU、0.1g 5-氨基-3-(4-氟苯基)-4-嘧啶基异噁唑的5mL THF溶液,室温下搅拌3小时。减压下馏去反应溶液中的溶剂,向残余物中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用20g硅胶层析(洗脱溶剂,氯仿∶甲醇=50∶1)纯化,然后用乙醚洗涤残余物,得到0.118g(收率:72%)标题化合物。
1H-NMR(CDCl3)δ:11.53(s,1H),8.66(d,J=1.5Hz,1H),8.38(d,J=5.8Hz,1H),7.52~7.43(m,4H),7.39~7.30(m,2H),7.23~7.17(m,2H),6.73(dd,J=1.5Hz,5.8Hz,1H),4.45(q,J=7.1Hz,1H),1.67(d,J=7.1Hz,3H)。
Mass,m/e:422(M+),240(base)。
实施例309
3-(4-氟苯基)-5-[2-(2,6-二氯苯基)丙酰基氨基]-4-(4-嘧啶基)异噁唑
与实施例308同样地操作,合成标题化合物。
a:2-(2,6-二氯苯基)丙酸
1H-NMR(CDCl3)δ:7.45~7.00(m,3H),4.58(q,J=7.2Hz,1H),1.54(d,J=7.2Hz,3H)。
Mass,m/e:218(M+),183(base)。
b:3-(4-氟苯基)-5-[2-(2,6-二氯苯基)丙酰基氨基]-4-(4-嘧啶基)异噁唑
1H-NMR(CDCl3)δ:11.65(s,1H),8.37~8.34(m,2H),7.52~7.38(m,4H),7.31(t,J=8.1Hz,1H),7.20(t,J=8.7Hz,2H),6.75(dd,J=1.4Hz,5.6Hz,1H),4.77(q,J=6.9Hz,1H),1.70(d,J=6.9Hz,3H)。
Mass,m/e:456(M+),240(base)。
实施例310
3-(4-氟苯基)-4-[4-(2-甲硫基)嘧啶基]-5-(苯基乙酰氨基)异噁唑
a:4-甲基-2-甲硫基嘧啶的合成
向25.5g 2-(4-甲基嘧啶)硫醇的400mL甲苯溶液加入50mLDMFDMA,接着加入42mL二异丙基乙胺,加热回流6.5小时。将反应溶液冷却,然后减压下馏去溶剂,向残余物中加水,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,然后减压下馏去溶剂。将所得残余物用120g硅胶柱层析(洗脱溶剂,氯仿)纯化,得到24.13g(收率:85%)褐色油状性物质的标题化合物。
1H-NMR(CDCl3)δ:8.36(d,J=5.1Hz,1H),6.80(d,J=5.1Hz,1H),2.56(s,3H),2.45(s,3H)。
b:1-氟-4-[4-(2-甲硫基嘧啶基)乙酰基]苯的合成
在-78℃下,向12.64g 4-甲基-2-甲硫基嘧啶的100mL THF溶液中滴入54.1mL 2M的LDA庚烷、THF、乙基苯溶液,滴完后在-78℃下搅拌15分钟。接着,在-78℃下滴入15.17g 4-氟苯甲酸乙酯的100mL THF溶液,滴完后一边缓慢升温至室温一边搅拌1小时。向反应溶液中加入50mL饱和氯化铵水溶液和50mL水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物溶解于氯仿,用120g硅胶柱层析(洗脱溶剂,己烷∶乙酸乙酯=4∶1)纯化,然后用己烷洗涤,得到3.39g(收率:14%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:14.61(s,1H),8.30(d,J=5.4Hz,1H),7.83(dd,J=5.3Hz,8.9Hz,2H),7.10(t,J=8.9Hz,2H),6.63(d,J=5.4Hz,1H),5.90(s,1H),2.61(s,3H)。
c:5-(4-氟苯基)-4-[4-(2-甲硫基嘧啶基)]异噁唑的合成
将6.12g 1-氟-4-[4-(2-甲硫基嘧啶基)乙酰基]苯和13.90gDMFDMA的混合物加热回流45分钟。将反应溶液冷却,然后减压下馏去DMFDMA。向残余物中加入100mL乙醇,接着加入8.12g羟胺盐酸盐,加热回流30分钟。减压下馏去反应溶液中的溶剂,向残余物中加水,滤取沉淀的固体。残余物水洗后溶解于氯仿,用无水硫酸镁干燥,减压下馏去溶剂。将所得残余物用乙醚-己烷洗涤,得到5.10g(收率:76%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.73(s,1H),8.45(d,J=5.2Hz,1H),7.90~7.65(m,2H),7.35~7.05(m,2H),6.98(d,J=5.2Hz,1H),2.50(s,3H)。
Mass,m/e:287(M+),95(base)。
d:3-(4-氟苯基)-2-[4-(甲硫基嘧啶基)]-3-羟丙腈的合成
向5.09g 5-(4-氟苯基)-4-[4-(2-甲硫基嘧啶基)]异噁唑的60mL乙醇溶液中加入30mL 1N NaOH水溶液,60℃、搅拌2.5小时。将反 应溶液冷却,然后减压下浓缩至约1/3,加入冰水(10mL),然后加入10%HCl水溶液使溶液呈中性,滤取沉淀的固体。水洗后减压下干燥,得到4.95g(收率:97%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.15(d,J=6.4Hz,1H),7.80(dd,J=5.6Hz,9.0Hz,2H),7.80~7.55(m,1H),7.29(t,J=9.0Hz,2H),2.64(s,3H)。
e:4-(2-甲硫基嘧啶基)乙腈的合成
向4.94g 2-(4-氟苯基)-[4-(2-甲硫基嘧啶基)]乙腈的200mL乙醇溶液中加入1.29g肼一水合物,加热回流3.5小时。减压下馏去反应溶液中的溶剂,将所得残余物用50g硅胶柱层析(洗脱溶剂,氯仿)纯化,得到2.44g(收率:86%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.55(d,J=5.1Hz,1H),7.11(d,J=5.1Hz,1H),3.83(s,2H),2.57(s,3H)。
f:5-氨基-3-(4-氟苯基)-4-[4-(2-甲硫基)嘧啶基]异噁唑的合成
向0.54g乙醇钠的30mL乙醇溶液中加入1.20g 4-(2-甲硫基嘧啶基)乙腈的20mL THF溶液,室温下搅拌1小时。接着,冰冷却下加入1.26g 4-氟苯甲酰氯的20mL乙醇溶液,室温下搅拌1.5小时。减压下馏去反应溶液中的溶剂,向残余物中加水,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,用活性炭脱色,然后减压下馏去溶剂。将所得残余物用50g硅胶柱层析(洗脱溶剂,氯仿)纯化,然后用乙醚-己烷洗涤,得到1.57g(收率:71%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.14(d,J=5.6Hz,1H),7.62~7.08(m,4H),6.85~6.70(bs,2H),6.36(d,J=5.6Hz,1H),2.57(s,3H)。
Mass,m/e:302(M+,base)。
g:3-(4-氟苯基)-4-[4-(2-甲硫基)嘧啶基]-5-(苯基乙酰氨基)异噁唑的合成
将0.48g咪唑和4.26g DBU溶解于30mL THF,冰冷却搅拌下加入0.99g苯乙酰氯,室温下搅拌1小时。接着,加入1.06g 5-氨基-3-(4-氟苯基)-4-[4-(2-甲硫基)嘧啶基]异噁唑的20mL THF溶液,室温下搅拌24小时。向反应溶液中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用60g硅胶柱层析(洗脱溶剂:氯仿)纯化,然后用乙醚-己烷洗涤,得到0.080g(收率:29%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.35~11.31(bs,1H),8.25(d,J=5.5Hz,1H),7.60~7.05(m,9H),6.45(d,J=5.5Hz,1H),3.92(s,2H),2.62(s,3H)。
实施例311
3-(4-氟苯基)-4-[4-(2-甲基亚硫酰基)嘧啶基]-5-(苯基乙酰氨基)异噁唑
向0.18g 3-(4-氟苯基)-4-[4-(2-甲硫基)嘧啶基]-5-(苯基乙酰氨基)异噁唑的20mL甲醇悬浮液中加入0.79g OXONE的10mL水溶液,室温下搅拌2.5小时。减压下将反应溶液浓缩至液量的约1/4,加入30mL饱和NaHCO3水溶液,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,然后减压下馏去溶剂。将所得残余物用乙醚洗涤,得到0.15g(收率:78%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:12.50~12.35(bs,1H),8.48(d,J=5.4Hz,1H),7.65~7.10(m,9H),6.82(d,J=5.4Hz,1H),4.01(s,2H),2.98(s,3H)。
Mass,m/e:436(M+),91(base)。
实施例312
3-(4-氟苯基)-4-[4-(2-甲氧基嘧啶基)]-5-(苯基乙酰氨基)异噁唑
a:5-氨基-3-(4-氟苯基)-4-[4-(2-甲基亚硫酰基)嘧啶基]异噁唑的合成
向0.7g 5-氨基-3-(4-氟苯基)-4-[4-(2-甲硫基)嘧啶基]异噁唑的100mL甲醇溶液中加入1.71g OXONE的50mL水溶液,室温下搅拌20分钟。减压下将反应溶液浓缩至液量的约1/3,加入50mL饱和NaHCO3水溶液,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,然后减压下馏去溶剂,得到0.74g(收率:100%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.33(d,J=5.6Hz,1H),7.70~7.05(m,6H),6.68(d,J=5.6Hz,1H),2.93(s,3H)。
b:5-氨基-3-(4-氟苯基)-4-[4-(2-甲氧基嘧啶基)]异噁唑的合成
向0.055g 5-氨基-3-(4-氟苯基)-4-[4-(2-甲基亚硫酰基)嘧啶基]异噁唑中加入0.014g甲醇钠的5mL甲醇溶液,加热回流20分钟。将反应溶液冷却,然后减压下馏去溶剂。向残余物中加水,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,然后减压下馏去溶剂。将所得残余物用己烷洗涤,得到0.032g(收率:65%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.13(d,J=5.6Hz,1H),7.51(dd,J=5.4Hz,8.7Hz,2H),7.20(t,J=8.7Hz,2H),6.85~6.75(bs,2H),6.34(d,J=5.6Hz,1H),4.00(s,3H)。
Mass,m/e:286(M+),111(base)。
c:3-(4-氟苯基)-4-[4-(2-甲氧基嘧啶基)]-5-(苯基乙酰氨基)异噁唑的合成
将0.014g咪唑和0.124g DBU溶解于3mL THF,冰冷却搅拌下,加入0.028g苯乙酰氯,室温下搅拌2小时。接着,加入0.029g 5-氨基-3-(4-氟苯基)-4-[4-(2-甲氧基嘧啶基)]异噁唑的3mL THF溶液,室温下搅拌26小时。向反应溶液中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用薄层色谱(展开溶剂:氯仿)纯化,得到0.019g(收率:46%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.58(s,1H),8.22(d,J=5.5Hz,1H),7.52~7.43(m,5H),7.38(t,J=7.3Hz,2H),7.31(t,J=7.3Hz,1H),7.20(t,J=8.6Hz,2H),4.04(s,3H),3.92(s,2H)。
Mass,m/e:404(M+),270(base)。
实施例313
4-[4-(2-氨基)嘧啶基]-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑
a:2-[1-(2,5-二甲基吡咯基)]-4-甲基嘧啶的合成
将10.28g 2-氨基-4-甲基嘧啶和12.90g丙酮基丙酮的混合物在200℃下搅拌8小时。冷却后,向残余物中加入乙醚,过滤固体。进一步用乙醚洗涤残余物,然后将滤液与洗液合并,减压下馏去溶剂。向过滤的固体中加入8.02g丙酮基丙酮,200℃下搅拌3小时。冷却后,向残余物中加入乙醚,过滤固体,用乙醚洗涤。将滤液与洗液合并,减压下馏去溶剂。将二次的残余物合在一起,溶解于氯仿,用150g硅胶柱层析(洗脱溶剂,己烷∶乙酸乙酯=5∶1→10∶1)纯化,得到6.97g(收率:40%)淡黄色油状性物质的标题化合物。
1H-NMR(CDCl3)δ:8.59(d,J=4.8Hz,1H),7.03(d,J=4.8Hz,1H),5.88(s,2H),2.55(s,3H),2.32(s,6H)。
b:4-{2-[1-(2,5-二甲基吡咯基)]嘧啶基}乙腈的合成
将8.18g 2-[1-(2,5-二甲基吡咯基)]-4-甲基嘧啶和22.83g叔丁氧基双二甲氨基甲烷的混合物在110℃下搅拌45分钟。将反应溶液冷却,然后减压下馏去叔丁氧基双二甲氨基甲烷。向所得残余物中加入150mL水和12.36g羟胺-O-磺酸,室温下搅拌45分钟。向反应溶液中加入碳酸氢钠使溶液呈碱性,然后用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物溶解于氯仿,用120g硅胶柱层析(洗脱溶剂,己烷∶乙酸乙酯=4∶1→2∶1)纯化,得到1.923g(收率:21%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.79(d,J=5.3Hz,1H),7.28(d,J=5.3Hz,1H),5.91(s,2H),3.92(s,2H),2.38(s,6H)。
c:5-氨基-4-(4-{2-[1-(2,5-二甲基吡咯基)]嘧啶基})-3-(4-氟苯基)异噁唑的合成
向0.12g甲醇钠的10mL甲醇溶液中加入0.38g 4-{2-[1-(2,5-二甲基吡咯基)]嘧啶基}乙腈的10mL THF溶液,室温下搅拌30分钟。接着,冰冷却下加入0.31g 4-氟苯甲酰氯的10mL甲醇溶液,室温下搅拌1小时。减压下馏去反应溶液中的溶剂,向残余物中加水,用氯仿萃取。用无水硫酸镁干燥氯仿萃取液,用活性炭脱色,然后减压下馏去溶剂。将所得残余物用25g硅胶柱层析(洗脱溶剂,氯仿)纯化,然后用乙醚-己烷洗涤,得到0.21g(收率:35%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.38(d,J=5.5Hz,1H),7.70~7.10(m,4H),6.85~6.65(bs,2H),6.60(d,J=5.5Hz,1H),5.91(s,2H),2.30(s,6H)。
Mass,m/e:349(M+,base)。
d:4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑的合成
将0.058g咪唑和0.261g DBU溶解于5mL THF,冰冷却搅拌下,加入0.121g苯乙酰氯,室温下搅拌30分钟。接着,加入0.06g 5-氨基-4-(4-{2-[1-(2,5-二甲基吡咯基)]嘧啶基})-3-(4-氟苯基)异噁唑的5mLTHF溶液,室温下搅拌3小时。向反应溶液中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,减压下馏去溶剂。将所得残余物用10g硅胶柱层析(洗脱溶剂,氯仿)纯化,用乙醚-己烷洗涤,得到0.066g(收率:82%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.32(s,1H),8.49(d,J=5.3Hz,1H),7.53(dd,J=5.3Hz,9.0Hz,2H),7.25~7.15(m,5H),7.07~7.02(m,2H),6.67(d,J=5.3Hz,1H),6.05(s,2H),3.73(s,2H),2.34(s,6H)。
Mass,m/e:467(M+),91(base)。
e:4-[4-(2-氨基嘧啶基)]-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑的合成
向0.05g 4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)-5-(苯基乙酰氨基)异噁唑、1mL TFA和1mL苯的混合物中加数滴水,40℃下搅拌过夜。冰冷却下向反应溶液中加水,加入饱和碳酸氢钠水溶液使溶液呈碱性,然后用氯仿萃取。用无水硫酸钠干燥氯仿萃取液,然后减压下馏去溶剂。将所得残余物用薄层色谱(展开溶剂,氯仿∶甲醇=50∶1)纯化,然后用乙醚-己烷洗涤,得到0.020g(收率:48%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.16(s,1H),7.96(d,J=5.2Hz,1H),7.52~7.38(m,7H),7.17(t,J=8.7Hz,2H),6.06(d,J=5.2Hz,1H),4.35~4.20(bs,2H),3.97(s,2H)。
Mass,m/e:389(M+),255(base)。
实施例314
4-[4-(2-氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑
a:5-[(2-氯苯基)乙酰氨基]-4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)异噁唑的合成
向0.195g 2’-氯苯基乙酸的10mL THF溶液中加入0.186g CDI,室温下搅拌1.5小时。接着,加入0.347g DBU与0.2g 5-氨基-4-(4-{2-[1-(2,5-二甲基吡咯基)]嘧啶基})-3-(4-氟苯基)异噁唑的10mL THF溶液,室温下搅拌2.5小时。减压下馏去反应溶液中的溶剂,加水, 用乙酸乙酯萃取。用无水硫酸镁干燥有机层,然后减压下馏去溶剂。将所得残余物用20g硅胶柱层析(洗脱溶剂,氯仿)纯化,然后用乙醚-己烷洗涤,得到0.248g(收率:86%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.13(s,1H),8.49(d,J=5.4Hz,1H),7.53(dd,J=5.2Hz,8.7Hz,2H),7.30~7.07(m,6H),6.68(d,J=5.4Hz,1H),5.97(s,2H),3.92(s,2H)2.31(s,6H)。
Mass,m/e:501(M+),94(base)。
b:4-[4-(2-氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑的合成
向0.2g 5-[(2-氯苯基)乙酰氨基]-4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)异噁唑、2mL TFA和2mL苯的混合物中加入数滴水,50℃下搅拌4小时。冰冷却下向反应溶液中加入水,加入饱和碳酸氢钠水溶液使溶液呈碱性,然后用氯仿萃取。用无水硫酸钠干燥氯仿萃取液,然后减压下馏去溶剂。将所得残余物用10g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=50∶1)纯化,然后用乙醚洗涤,得到0.083g(收率:49%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.17(s,1H),8.00(d,J=5.4Hz,1H),7.54~7.45(m,4H),7.40~7.34(m,2H),7.23~7.16(m,2H),6.11(d,J=5.4Hz,1H),4.66~4.56(bs,2H),4.09(s,2H)。
Mass,m/e:423(M+),255(base)。
以下,与实施例314同样地操作,合成实施例315~317的化合物。
实施例315
4-[4-(2-氨基嘧啶基)]-5-[(2,6-二氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑
a:5-[(2,6-二氯苯基)乙酰氨基]-4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.12(s,1H),8.51(d,J=5.4Hz,1H),7.54(dd,J=5.4Hz,8.8Hz,2H),7.28~7.21(m,4H),7.13(dd,J=7.5Hz,8.8Hz,1H),6.70(d,J=5.4Hz,1H),5.94(s,2H),4.22(s,2H),2.32(s,6H)。
Mass,m/e:535(M+),94(base)。
b:4-[4-(2-氨基嘧啶基)]-5-[(2,6-二氯苯基)乙酰氨基]-3-(4-氟苯基)异噁唑
1H-NMR(CDCl3)δ:11.25~11.10(bs,1H),8.03(d,J=5.4Hz,1H),7.49(dd,J=5.2Hz,8.7Hz,2H),7.42(d,J=7.9Hz,2H),7.28(d,J=7.9Hz,1H),7.19(t,J=8.7Hz,2H),6.13(d,J=5.4Hz,1H),4.90~4.75(bs,2H),4.38(s,2H)。
Mass,m/e:457(M+),255(base)。
实施例316
4-[4-(2-氨基)嘧啶基]-3-(4-氟苯基)-5-[(2-甲氧基苯基)乙酰氨基]异噁唑
a:4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)-5-[(2-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:10.89(s,1H),8.46(d,J=5.4Hz,1H),7.51(dd,J=5.0Hz,8.9Hz,2H),7.26~7.15(m,3H),7.00(dd,J=1.5Hz,7.3Hz,1H),6.79~6.72(m,2H),6.65(d,J=5.4Hz,1H),5.97(s,2H),3.76(s,2H),3.67(s,3H),2.31(s,6H)。
Mass,m/e:497(M+),91(base)。
b:4-[4-(2-氨基)嘧啶基]-3-(4-氟苯基)-5-[(2-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.09(s,1H),7.95(d,J=5.4Hz,1H),7.48~7.36(m,4H),7.16(t,J=8.6Hz,2H),7.05(t,J=7.3Hz,1H),7.00(d,J=8.1Hz,1H),6.05(d,J=5.4Hz,1H),4.37(bs,2H),3.88(s,2H),3.84(s,3H)。
Mass,m/e:419(M+),148(base)。
实施例317
3-(4-氟苯基)-5-(2-苯基丙酰基氨基)-4-{4-(2-氨基嘧啶基)}异噁唑
a:4-(4-{2-[1-(2,5-二甲基吡咯基)]}嘧啶基)-3-(4-氟苯基)-5-(2-苯基丙酰基氨基)异噁唑
1H-NMR(CDCl3)δ:11.30(s,1H),8.46(d,J=5.4Hz,1H),7.55~7.48(m,2H),7.25~7.12(m,5H),7.02~6.97(m,2H),6.65(d,J=5.4Hz,1H),6.07(s,2H),3.66(q,J=7.0Hz,1H),2.30(s,6H),1.54(d,J=7.0Hz,3H)。
Mass,m/e:481(M+),105(base)。
b:3-(4-氟苯基)-5-(2-苯基丙酰基氨基)-4-{4-(2-氨基嘧啶基)}异噁唑
1H-NMR(CDCl3)δ:11.21(s,1H),7.96(d,J=5.4Hz,1H),7.50~7.37(m,7H),7.17(t,J=8.7Hz,2H),6.06(d,J=5.4Hz,1H),4.33(s,2H),3.95(q,J=6.9Hz,1H),1.63(d,J=6.9Hz,3H)。
Mass,m/e:403(M+),255(base)。
实施例318
4-[4-(2-氨基嘧啶基)]-3-(4-氯苯基)-5-(苯基乙酰氨基)异噁唑
a:2-(二-叔丁氧基羰基氨基)-4-甲基嘧啶的合成
向9.15g 2-氨基-4-甲基嘧啶的200mL乙腈溶液中加入40.26g二碳酸二叔丁酯、18.65g三乙胺和1.02g DMAP,室温下搅拌2小时。减压下馏去反应溶液中的溶剂。将残余物溶解于乙酸乙酯,用10%硫酸氢钾水溶液、接着用饱和盐水洗涤,然后用无水硫酸镁干燥,减压下馏去溶剂。将所得残余物用乙醚洗涤,得到15.35g(收率:59%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.59(d,J=5.1Hz,1H),7.06(d,J=5.1Hz,1H),2.54(s,3H),1.45(s,18H)。
b:4-(2-二-叔丁氧基羰基氨基嘧啶基)乙腈的合成
将15.34g 2-(二-叔丁氧基羰基氨基)-4-甲基嘧啶和25.91g叔丁氧基双二甲氨基甲烷的混合物在110℃下搅拌40分钟。将反应溶液冷却,然后减压下馏去叔丁氧基双二甲氨基甲烷。向所得残余物中加入150mL水和16.83g羟胺-O-磺酸,室温下搅拌1小时。向反应溶液中加入碳酸氢钠使溶液呈碱性,然后用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,减压下馏去溶剂。将所得残余物用120g硅胶柱层析(洗脱溶剂,氯仿∶甲醇=50∶1)纯化,得到5.27g(收率:32%)黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.80(d,J=5.1Hz,1H),7.37(d,J=5.1Hz,1H),3.92(s,2H),1.48(s,18H)。
c:5-氨基-3-(4-氯苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑的合成
向0.136g甲醇钠的10mL甲醇溶液中加入0.7g 4-[2-(二-叔丁氧基羰基氨基)嘧啶基]乙腈的10mL THF溶液,室温下搅拌45分钟。接着,冰冷却下加入0.439g 4-氯苯甲酰氯的10mL甲醇溶液,室温下搅拌2小时。减压下馏去反应溶液中的溶剂,向残余物中加水,滤取沉淀的固体。将滤取的固体水洗,然后溶解于氯仿-甲醇,用无 水硫酸镁干燥,用活性炭脱色后减压下馏去溶剂。将所得残余物用乙醚-己烷洗涤,得到0.444g(收率:43%)淡黄色结晶的标题化合物。
1H-NMR(CDCl3)δ:8.21(d,J=5.6Hz,1H),7.48(s,4H),7.07(bs,2H),6.44(d,J=5.6Hz,1H),1.53(s,18H)。
Mass,m/e:487(M+),57(base)。
d:3-(4-氯苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-5-(苯基乙酰氨基)异噁唑的合成
将0.042g咪唑和0.187g DBU溶解于5mLTHF,冰冷却搅拌下,加入0.095g苯乙酰氯,室温下搅拌40分钟。接着,加入0.1g 5-氨基-3-(4-氯苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑的5mLTHF溶液,室温下搅拌1.5小时。向反应溶液中加水,用乙酸乙酯萃取。用无水硫酸镁干燥乙酸乙酯萃取液,然后减压下馏去溶剂。将所得残余物用薄层色谱(展开溶剂,氯仿)纯化,然后用乙醚-己烷洗涤,得到0.095g(收率:77%)无色固体的标题化合物。
1H-NMR(CDCl3)δ:11.61(s,1H),8.29(d,J=5.4Hz,1H),7.50~7.24(m,9H),6.52(d,J=5.4Hz,1H),4.05(s,2H),1.57(s,18H)。
Mass,m/e:605(M+-91),57(base)。
e:4-[4-(2-氨基嘧啶基)]-3-(4-氯苯基)-5-(苯基乙酰氨基)异噁唑的合成
向0.093g 3-(4-氯苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-5-(苯基乙酰氨基)异噁唑中加入0.5mL TFA,室温下搅拌1小时。冰冷却下,向反应溶液中加入饱和碳酸氢钠水溶液,滤取沉淀的固体。将滤取的固体水洗后减压下干燥。用乙醚洗涤所得残余物,得到0.080g(收率:90%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.51(s,1H),7.97(d,J=5.4Hz,1H),7.51~7.38(m,9H),6.07(d,J=5.4Hz,1H),4.30(bs,2H),3.97(s,2H)。
Mass,m/e:405(M+),270(base)。
实施例319
4-[4-(2-氨基嘧啶基)]-3-(4-氯苯基)-5-[(2-氯苯基)乙酰氨基]异噁唑
a:3-(4-氯苯基)-5-[(2-氯苯基)乙酰氨基]-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑的合成
向0.094g 2’-氯苯基乙酸的5mL THF溶液中加入0.09g CDI,室温下搅拌1.5小时。接着,加入0.168g DBU和0.09g 5-氨基-3-(4-氯苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑的5mL THF溶液,60℃下搅拌3.5小时。减压下馏去反应溶液中的溶剂,加水用乙酸乙酯萃取。用无水硫酸镁干燥有机层,然后减压下馏去溶剂。将所得残余物用薄层色谱(展开溶剂,氯仿)纯化,得到0.088g(收率:75%)无色固体的标题化合物。
1H-NMR(CDCl3)δ:11.76(s,1H),8.30(d,J=5.4Hz,1H),7.48(dd,J=8.8Hz,12.3Hz,4H),7.41~7.35(m,2H),7.27~7.23(m,2H),6.54(d,J=5.4Hz,1H),4.22(s,2H),1.55(s,18H)。
Mass,m/e:514(M+-125),57(base)。
b:4-[4-(2-氨基嘧啶基)]-3-(4-氯苯基)-5-[(2-氯苯基)乙酰氨基]异噁唑的合成
向0.086g 3-(4-氯苯基)-5-[(2-氯苯基)乙酰氨基]-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑中加入0.5mL TFA,室温下搅拌1小时。冰冷却下向反应溶液中加入饱和碳酸氢钠水溶液,滤取沉淀的固体。将滤取的固体水洗后减压下干燥。将所得残余物用乙醚洗涤,得到0.043g(收率:73%)无色结晶的标题化合物。
1H-NMR(CDCl3)δ:11.05(s,1H),7.92(d,J=5.4Hz,1H),7.55~7.35(m,8H),6.13(d,J=5.4Hz,1H),4.08(s,2H),2.55(bs,2H)。
Mass,m/e:439(M+),271(base)
以下,与实施例318和319同样地操作,合成实施例320~326的化合物。
实施例320
4-[4-(2-氨基嘧啶基)]-3-(4-氯苯基)-5-[3-甲氧基苯基)乙酰氨基]异噁唑
a:3-(4-氯苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.61(s,1H),8.28(d,J=5.4Hz,1H),7.47(dd,J=8.7Hz,14.8Hz,4H),7.25~7.21(m,1H),7.00~6.94(m,2H),6.81(dd,J=2.3Hz,8.1Hz,1H),6.52(d,J=5.4Hz,1H),4.03(s,2H),3.79(s,3H),1.57(s,18H)。
Mass,m/e:514(M+-121),56(base)。
b:4-[4-(2-氨基嘧啶基)]-3-(4-氯苯基)-5-[3-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:10.77(s,1H),7.71(d,J=6.4Hz,1H),7.50(d,J=8.5Hz,2H),7.46~7.37(m,3H),7.02~6.94(m,3H),6.16(d,J=6.5Hz,1H),3.94(s,2H),3.84(s,3H),3.60(bs,2H)。
Mass,m/e:435(M+),271(base)。
实施例321
4-[4-(2-氨基嘧啶基)]-5-(苯基乙酰氨基)-3-(4-氟-3-甲基苯基)异噁唑
a:5-氨基-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基])-3-(4-氟-3-甲基苯基)异噁唑
1H-NMR(CDCl3)δ:8.20(d,J=5.4Hz,1H),7.39~7.34(m,1H),7.33~7.27(m,1H),7.12(t,J=8.9Hz,1H),7.03(bs,2H),6.47(d,J=5.4Hz,1H),2.33(s,3H),1.53(s,18H)。
Mass,m/e:485(M+),57(base)。
b:4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-3-(4-氟-3-甲基苯基)-5-(苯基乙酰氨基)异噁唑
1H-NMR(CDCl3)δ:11.60(s,1H),8.28(d,J=5.4Hz,1H),7.42~7.24(m,7H),7.12(t,J=8.9Hz,1H),6.54(d,J=5.4Hz,1H),4.05(s,2H),2.32(d,J=1.9Hz,3H),1.57(s,18H)。
Mass,m/e:512(M+-91),57(base)。
c:4-[4-(2-氨基嘧啶基)]-5-(苯基乙酰氨基)-3-(4-氟-3-甲基苯基)异噁唑
1H-NMR(CDCl3)δ:11.16(s,1H),7.95(d,J=5.4Hz,1H),7.51~7.38(m,5H),7.34~7.29(m,1H),7.27~7.20(m,1H),7.09(t,J=8.9Hz,1H),6.09(d,J=5.4Hz,1H),4.36(bs,2H),3.98(s,2H),2.31(d,J=1.9Hz,3H)。
Mass,m/e:403(M+),269(base)。
实施例322
4-[4-(2-氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟-3-甲基苯基)异噁唑
a:4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基])-3-(4-氟-3-甲基苯基)-5-[(2-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.74(s,1H),8.29(d,J=5.4Hz,1H),7.41~7.35(m,3H),7.31~7.21(m,3H),7.12(t,J=8.9Hz,1H),6.56(d,J=5.4Hz,1H),4.22(s,2H),2.32(s,3H),1.55(s,18H)。
Mass,m/e:512(M+-125),57(base)。
b:4-[4-(2-氨基嘧啶基)]-5-[(2-氯苯基)乙酰氨基]-3-(4-氟-3-甲基苯基)异噁唑
1H-NMR(CDCl3)δ:11.03(s,1H),7.88(d,J=5.8Hz,1H),7.55~7.46(m,2H),7.42~7.36(m,2H),7.34~7.30(m,1H),7.27~7.21(m,1H),7.12(t,J=8.9Hz,1H),6.16(d,J=5.8Hz,1H),4.09(s,2H),2.48(bs,2H),2.32(d,J=1.5Hz,3H)。
Mass,m/e:437(M+),125(base)。
实施例323
4-[4-(2-氨基嘧啶基)]-3-(4-氟-3-甲基苯基)-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
a:4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-3-(4-氟-3-甲基苯基)-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.60(s,1H),8.27(d,J=5.4Hz,1H),7.40~7.20(m,3H),7.12(t,J=8.9Hz,1H),7.02~6.94(m,2H),6.81(dd,J=1.7Hz,8.3Hz,1H),6.54(d,J=5.4Hz,1H),4.03(s,2H),3.79(s,3H),2.32(s,3H),1.57(s,18H)。
Mass,m/e:512(M+-121),57(base)。
b:4-[4-(2-氨基嘧啶基)]-3-(4-氟-3-甲基苯基)-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:10.75(s,1H),7.68(d,J=6.6Hz,1H),7.43(t,J=7.9Hz,1H),7.31~7.18(m,2H),7.14(t,J=8.7Hz,1H),7.02~6.93(m,3H),6.19(d,J=6.6Hz,1H),3.95(s,2H),3.85(s,3H),2.32(s,3H)。
Mass,m/e:433(M+),269(base)。
实施例324
4-[4-(2-氨基嘧啶基)]-3-(3-苄氧基苯基)-5-(苯基乙酰氨基)异噁唑
a:5-氨基-3-(3-苄氧基苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑
1H-NMR(CDCl3)δ:8.17(d,J=5.6Hz,1H),7.45~7.27(m,7H),7.11~7.05(m,4H),6.19(d,J=5.6Hz,1H),5.07(s,2H),1.51(s,18H)。
Mass,m/e:459(M+-1),91(base)。
b:3-(3-苄氧基苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-5-(苯基乙酰氨基)异噁唑
1H-NMR(CDCl3)δ:11.73(s,1H),8.24(d,J=5.4Hz,1H),7.44~7.30(m,12H),7.11~7.07(m,2H),6.30(d,J=5.4Hz,1H),5.07(s,2H),4.07(s,2H),1.56(s,18H)。
Mass,m/e:677(M+-175),59(base)。
c:4-[4-(2-氨基嘧啶基)]-3-(3-苄氧基苯基)-5-(苯基乙酰氨基)异噁唑
1H-NMR(CDCl3)δ:11.23(s,1H),7.90(d,J=5.4Hz,1H),7.54~7.28(m,12H),7.10~7.02(m,2H),5.87(d,J=5.4Hz,1H),5.05(s,2H),4.43(bs,2H),3.99(s,2H)。
Mass,m/e:476(M+-1),91(base)。
实施例325
4-[4-(2-氨基嘧啶基)]-3-(3-苄氧基苯基)-5-[(2-氯苯基)乙酰氨基]异噁唑
a:3-(3-苄氧基苯基)-5-[(2-氯苯基)乙酰氨基]-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}异噁唑
1H-NMR(CDCl3)δ:11.87(s,1H),8.24(d,J=5.4Hz,1H),7.43~7.20(m,11H),7.12~7.07(m,2H),6.31(d,J=5.4Hz,1H),5.08(s,2H),4.24(s,2H),1.54(s,18H)。
Mass,m/e:536(M+-175),91(base)。
b:4-[4-(2-氨基嘧啶基)]-3-(3-苄氧基苯基)-5-[(2-氯苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.26(bs,1H),7.95(d,J=5.4Hz,1H),7.54~7.48(m,2H),7.43~7.29(m,9H),7.10~7.03(m,2H),5.91(d,J=5.4Hz,1H),5.06(s,2H),4.69(bs,2H),4.10(s,2H)。
Mass,m/e:393(M+-102),91(base)。
实施例326
4-[4-(2-氨基嘧啶基)]-3-(3-苄氧基苯基)-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
a:3-(3-苄氧基苯基)-4-{4-[2-(二-叔丁氧基羰基氨基)嘧啶基]}-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.73(s,1H),8.23(d,J=5.4Hz,1H),7.44~7.20(m,8H),7.12~7.04(m,2H),7.04~6.95(m,2H),6.84~6.79(m,1H),6.30(d,J=5.4Hz,1H),5.07(s,2H),4.05(s,2H),3.79(s,3H),1.56(s,18H)。
Mass,m/e:541(M+-166),91(base)。
b:4-[4-(2-氨基嘧啶基)]-3-(3-苄氧基苯基)-5-[(3-甲氧基苯基)乙酰氨基]异噁唑
1H-NMR(CDCl3)δ:11.22(s,1H),7.93(d,J=5.4Hz,1H),7.43~7.29(m,8H),7.10~6.90(m,5H),5.87(d,J=5.4Hz,1H),5.05(s,2H),4.49(bs,2H),3.94(s,2H),3.83(s,3H)。
Mass,m/e:420(M+-87),91(base)。
制剂例1
将活性成分粉碎成70μm以下的粒度,向其中加入淀粉、乳糖和羧甲基纤维素钙并充分混合。将10%的淀粉糊加入到上述混合粉体中,搅拌混合,制造颗粒。干燥后整粒,使粒径在1000μm左右,向其中混合滑石粉和硬脂酸镁,压片。
Claims (13)
5.选自下述的异唑衍生物或它们的制药学上可接受的盐:
3-(4-氯苯基)-5-[(2-氯苯基)乙酰氨基]-4-(4-嘧啶基)异唑、
7.药物,该药物含有权利要求1~5中任一项的异唑衍生物或其制药学上可接受的盐。
8.肿瘤坏死因子-α关连疾病、白细胞介素-1关连疾病、白细胞介素-6关连疾病、白细胞介素-8关连疾病或环加氧酶-II关连疾病的处置剂,其特征在于:该处置剂含有权利要求1~5中任一项的异唑衍生物或其制药学上可接受的盐作为有效成分,其中肿瘤坏死因子-α关连疾病、白细胞介素-1关连疾病、白细胞介素-6关连疾病、白细胞介素-8关连疾病或环加氧酶-II关连疾病为急性炎症、慢性炎症、变形性膝关节症、痛风、炎症性肠疾病、胃炎、结肠息肉、哮喘、支气管炎、过敏性鼻炎、急性呼吸窘迫综合征、慢性阻塞性肺疾病、肺纤维变性、充血性心脏病、局部缺血性心脏病、心肌梗死、动脉硬化、高血压、心绞痛、早老性痴呆、再灌流损伤、血管炎、脑血管障碍、脑膜炎、多发性大脑硬化、骨质疏松症、骨硬化、贝切特氏病、骨转移、多发性骨髓瘤、急性感染、内毒素休克、败血病、毒素性休克综合征、结核、弥散性血管内凝血病、银屑病、特应性皮炎、肝硬化、肾纤维变性、恶病质、艾滋病、恶性肿瘤、自体免疫疾病、糖尿病、巨大淋巴结增生症、肾小球膜细胞增殖性肾炎、子宫内膜异位或早产。
9.权利要求8所述的处置剂,其中慢性炎症为类风湿性关节炎。
10.权利要求8所述的处置剂,其中哮喘为支气管哮喘。
11.权利要求8所述的处置剂,其中炎症性肠疾病为节段性肠炎或溃疡性大肠炎。
12.权利要求8所述的处置剂,其中恶性肿瘤为大肠癌或结肠癌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004381733 | 2004-12-28 | ||
JP381733/2004 | 2004-12-28 | ||
PCT/JP2005/024244 WO2006070927A1 (ja) | 2004-12-28 | 2005-12-27 | ピリミジニルイソオキサゾール誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101080404A CN101080404A (zh) | 2007-11-28 |
CN101080404B true CN101080404B (zh) | 2011-06-08 |
Family
ID=36615031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800435089A Expired - Fee Related CN101080404B (zh) | 2004-12-28 | 2005-12-27 | 嘧啶基异噁唑衍生物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7939536B2 (zh) |
EP (1) | EP1832584B1 (zh) |
JP (1) | JP5100126B2 (zh) |
KR (1) | KR101181692B1 (zh) |
CN (1) | CN101080404B (zh) |
AT (1) | ATE538118T1 (zh) |
AU (1) | AU2005320544B2 (zh) |
CA (1) | CA2591912C (zh) |
ES (1) | ES2375633T3 (zh) |
WO (1) | WO2006070927A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2044957A4 (en) * | 2006-06-28 | 2011-01-05 | Aska Pharm Co Ltd | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE |
EP2036905B1 (en) * | 2006-06-28 | 2012-12-12 | ASKA Pharmaceutical Co., Ltd. | Pyridylisoxazole derivative |
EP2123255B1 (en) * | 2007-02-16 | 2013-05-15 | ASKA Pharmaceutical Co., Ltd. | Pharmaceutical composition containing fine particle oil-based suspension |
WO2009000662A1 (en) * | 2007-06-22 | 2008-12-31 | F. Hoffmann-La Roche Ag | Isoxazole-imidazole derivatives |
WO2019022152A1 (ja) | 2017-07-26 | 2019-01-31 | 学校法人同志社 | TGF-βシグナルに起因する障害を治療または予防するための医薬およびその応用 |
WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
WO1996025405A1 (en) | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
GEP20033053B (en) | 1997-05-22 | 2003-08-25 | Searle & Co | Substituted Pyrazoles as P38 Kinase Inhibitors, Methods for their Production, Pharmaceutical Compositions Containing Them and Methods for Treatment |
JP4191825B2 (ja) * | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
CN1326848C (zh) * | 1998-12-25 | 2007-07-18 | 帝国脏器制药株式会社 | 氨基吡唑衍生物 |
JP2005500261A (ja) * | 2001-04-10 | 2005-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビターとしてのイソキサゾール誘導体 |
ES2271283T3 (es) * | 2001-07-03 | 2007-04-16 | Vertex Pharmaceuticals Incorporated | Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck. |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
DE10237883A1 (de) * | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
AU2003270350A1 (en) | 2002-09-06 | 2004-03-29 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use in the treatment of ischemic diseases |
-
2005
- 2005-12-27 AT AT05824638T patent/ATE538118T1/de active
- 2005-12-27 US US11/794,180 patent/US7939536B2/en active Active
- 2005-12-27 ES ES05824638T patent/ES2375633T3/es active Active
- 2005-12-27 CA CA2591912A patent/CA2591912C/en active Active
- 2005-12-27 WO PCT/JP2005/024244 patent/WO2006070927A1/ja active Application Filing
- 2005-12-27 JP JP2006550874A patent/JP5100126B2/ja not_active Expired - Fee Related
- 2005-12-27 CN CN2005800435089A patent/CN101080404B/zh not_active Expired - Fee Related
- 2005-12-27 KR KR1020077014699A patent/KR101181692B1/ko active IP Right Grant
- 2005-12-27 EP EP05824638A patent/EP1832584B1/en not_active Not-in-force
- 2005-12-27 AU AU2005320544A patent/AU2005320544B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
KR101181692B1 (ko) | 2012-09-19 |
JPWO2006070927A1 (ja) | 2008-06-12 |
CA2591912A1 (en) | 2006-07-06 |
CN101080404A (zh) | 2007-11-28 |
CA2591912C (en) | 2013-06-25 |
US7939536B2 (en) | 2011-05-10 |
AU2005320544B2 (en) | 2011-03-24 |
JP5100126B2 (ja) | 2012-12-19 |
WO2006070927A1 (ja) | 2006-07-06 |
EP1832584A4 (en) | 2010-09-08 |
ES2375633T3 (es) | 2012-03-02 |
EP1832584B1 (en) | 2011-12-21 |
KR20070089829A (ko) | 2007-09-03 |
US20080114003A1 (en) | 2008-05-15 |
EP1832584A1 (en) | 2007-09-12 |
AU2005320544A1 (en) | 2006-07-06 |
ATE538118T1 (de) | 2012-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016280717B2 (en) | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | |
CN101080404B (zh) | 嘧啶基异噁唑衍生物 | |
ES2426288T3 (es) | Novedoso derivado de imidazol | |
CN102105459B (zh) | 作为蛋白激酶抑制剂的3,4-二芳基吡唑类 | |
ES2605388T3 (es) | Compuesto inhibidor de Trk | |
JP5583694B2 (ja) | Cb2受容体を調節するピロリジン化合物 | |
MX2007000119A (es) | Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento de cancer. | |
CN101616667A (zh) | 可用作激酶抑制剂的杂环酰胺化合物 | |
CN101472914A (zh) | C-fms激酶抑制剂 | |
AU2020375720A1 (en) | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of ERK1 and ERK2 | |
CN105315285A (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
TW202304879A (zh) | Mk2抑制劑及其用途 | |
JP6559699B2 (ja) | 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用 | |
EP2036905B1 (en) | Pyridylisoxazole derivative | |
KR20110092517A (ko) | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 | |
CN108137513A (zh) | 嘧啶衍生物 | |
KR100843533B1 (ko) | 신규한 디아진 유도체, 이의 제조 및 약학적 제제로서의용도 | |
WO2014075318A1 (zh) | 嘧啶类化合物及其应用 | |
KR20230165833A (ko) | 치환된 피롤 카복스아미드, 이의 제조방법 및 이의 키나제 억제제로서의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110608 |